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ABSTRACT 
 
 
Patients suffering from lung diseases are often treated with lung transplantation, which is considered a 
definitive therapy offered for patients with end-stage lung failure. Because of this, it improves 
survival rates besides boosting the quality of life for lung transplant recipients. However, lung 
transplantation suffers from a number of flaws, mainly a scarcity of organs and tissue donors. In this 
thesis, three approaches were attempted to address these issues. These were gene therapy, 
microfluidic -device -assisted stem cell delivery and tissue engineering. 
 
MicroRNA (miRNA) is emerging as a new class of gene therapeutics with the promise of healing 
many diseases. The applications of miRNA often require miRNA to be transfected efficiently inside 
cells. Chapter 3 of this work is particularly devoted to investigating the ability of a liquid marble 
(LM) miniature bioreactor to enhance miRNA transfection. To achieve this, suspended A549 lung 
cancer spheroids were first generated using liquid marble (LM) by taking advantage of the LM non-
adhesive shell, thus promoting the cell-to-cell attachment that is essential for spheroid formation. 
Next, a tumour suppressor (miR-126) was transfected to spheroids inside LM.  It was observed that 
the resulting miR-126 expression and the subsequent down-regulation in VEGF-A expression reached 
a level that cannot be reached using conventional methods, such as transfecting miR-126 to 
monolayer cells or transfecting miR-126 to spheroids generated using liquid suspension methods. 
There are multiple possible reasons for the greater miRNA expression observed in the LM bioreactor. 
First of all, miRNA is much smaller than many chemotherapeutic drugs and thus penetrated well into 
spheroids. Secondly, the PTFE shell possesses ultra-low surface free energy and so does not absorb 
and waste any miRNA through non-specific adsorption. Lastly, the hydrophobic interface present on 
the LM shell may play a role in promoting the movement of hydrophilic miRNA towards the centre of 
the LM where spheroids resided. Overall, this study demonstrates that LM can serve not only as a 
platform that produces tumour-like spheroids, but also as an efficient microbioreactor vessel that 
enhances miRNA transfection and outperforms conventional transfection vessels. 
 xvi 
 
As part of this approach, a novel micro-centrifugation device was also developed to generate 
multicellular spheroids, as shown in Chapter 4, these spheroids are useful for lung cancer behaviour 
and drug screening studies. Intense acoustically driven micro-centrifugation flows were employed to 
enhance the assembly of multicellular spheroids in the microwells of a tissue culture plate. This 
ability to interface microfluidics with commonly used tissue culture plasticware is a significant 
advantage, mainly because it can be multiplied for high-throughput operation and allows the retention 
of existing analytical equipment designed to fit current laboratory formats.  The micro-centrifugation 
flow induced in microwells coated with a low adhesive hydrogel rapidly enhanced the concentration 
of BT-474 cells, resulting in tight aggregates within a minute. This was considerably faster than the 
conventional hanging drop and liquid overlay methods, which typically require a day to maintain their 
viability. The proposed method affords control of the spheroid dimension simply by modulating the 
input power, and is a significant improvement over other microfluidic methods that require the 
fabrication of different geometries and microstructures to generate spheroids of different sizes. The 
spheroids produced exhibited the concentric heterogeneous cell populations and tight cell-cell 
interfaces typical of in-vivo tumours. Therefore, they demonstrated the applicability of the technique 
for enhancing a broad spectrum of cancer biology and drug screening studies. 
 
Despite the promise of stem cell therapy for lung therapeutics and repair, there are very few viable 
means for directly delivering stem cells to locally target the respiratory airways via inhalation. This is 
not surprising given the significant challenges in aerosolising stem cells, particularly given their 
susceptibility to damage under the sizable stresses involved in the nebulisation process. The current 
study presents promising results using a microfluidic acoustic nebulisation platform in Chapter 5.  
This platform is not only low-cost and portable, but its high MHz order frequencies were effective in 
preserving the structural and functional integrity of mesenchymal stem cells (MSCs) during the 
nebulisation process. This was verified through an assessment of the viability, structure, metabolic 
activity, proliferation ability and genetic constitution of the nebulised MSCs using a variety of assays 
that included: cell viability staining, flow cytometry, reverse transcription, quantitative polymerase 
 xvii 
 
chain reaction and immuno-phenotyping. Given the novelty of inhaled stem cell therapy, comparisons 
with other delivery methods are difficult at present due to lack of comparable studies. More data for 
benchmarking are likely to become available in the near future due to the increasing interest in stem 
cell therapy, given the absence of viable alternative treatment régimes for respiratory ailments to date. 
Nonetheless, the results in this work provide compelling evidence that the SAW nebulisation 
platform, with its inherent benefits of low cost and portability, constitutes an attractive tool for the 
delivery of stem cells via inhalation for the treatment and repair of lung function. 
 
For lung regeneration to be successful, a 3D biodegradable and biocompatible scaffold needs to be 
synthesised. Various 3D scaffolds have been synthesised previously, ranging from natural to synthetic 
polymers. However, 3D biodegradable scaffolds for regenerated lung have not been exploited with the 
aim of regenerating new tissue in damaged lung using stem cell responses that function in a clinical 
setting. Transplantation of alveolar epithelial cells derived from murine embryonic stem cells 
(mESCs) that are encapsulated within scaffolds may provide a novel strategy to regenerate lung cells 
damaged by lung disease.  
 
In Chapter 6, a novel tissue scaffold composed of enzymatically cross-linked gelatin was developed. 
Essentially, mESCs were encapsulated in this scaffold simultaneously with the scaffold being cross-
linked.  A novel injectable hydrogel system composed of gelatin-3,4-dihydroxyhydrocinnamic acid 
(Gtn-DHHA) conjugates were cross-linked rapidly by laccase-mediated oxidation to form a hydrogel 
tissue scaffold which could simultaneously immobilise mESCs. This scaffold system supported the 
proliferation and differentiation of mESCs into lung epithelial cells in both the presence and absence 
of growth factors. The stiffness of the hydrogels was readily modulated by altering polymer precursor 
concentration.  
 
Gtn-DHHA hydrogel was maintained in air-liquid interface (ALI) conditions to mimic the lung micro- 
environment and mESC differentiation was evaluated by measuring the expression of E-cadherin and 
 xviii 
 
Foxa2, both of which are considered to be definitive endoderm markers. Furthermore, the expression 
of Pept2, Sema4F, Unc5b, and Ttf1 in hydrogel-encapsulated cells was assessed using the quantitative 
polymerase reaction (qPCR) and immunofluorescence assays. The expression of these markers was 
up-regulated in the presence and absence of growth factors, in particular under air-liquid interface by 
comparison with submerged and control cultures. This scaffold facilitated mESC differentiation into 
alveolar epithelial cells, even without growth factors, and is therefore a promising approach for lung 
repair. 
 
In summary, this thesis first presents a novel, effective method—namely liquid marble— for better 
generation of multicellular spheroids to enhance miR-126 PEI nanoparticles transfection. It then 
introduces a novel method called a SAW device, which is also used to produce multicellular 
spheroids, and to generate MSC-laden aerosols to cure small lung damage. Finally, it presents a 
novel three-dimensional (3D) biodegradable scaffold as an alternative material for an extracellular 
matrix (ECM) for improved stem cell survival, proliferation, and differentiation. This is considered to 
be a critical step for in-vitro differentiation of ESCs into lung epithelial cells for lung repair and 
regeneration.………….……………………………………
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CHAPTER ONE- INTRODUCTION 
1.1 Overview 
 
 
Lung diseases are the leading cause of morbidity and mortality worldwide. Although there is no 
curative treatment for some lung diseases, lung transplantation gives the only hope since it is the only 
current therapy available for patients with end-stage lung failure. Besides being able to improve 
survival rates, it has the capacity to improve the quality of life in lung transplant patients. However, 
lung transplantation suffers from a critical shortage of donors [1]. This has led to the development of 
regenerative medicine and tissue engineering, which target repairing and restoration of any type of 
damaged tissue due to any cause. For this reason, a combination of different approaches such as gene 
therapy, cell therapy and tissue engineering offers the best alternative to replacement therapies and 
traditional transplants [2, 3].  
 
Gene therapy is the delivery of genetic-based material (e.g. DNA or RNA) to targeted cells to alter 
their expression patterns. Cellular gene expression can be manipulated to treat different diseases such 
as lung cancer.  MiRNAs are collectively a class of noncoding RNA and consists of 20–25 
nucleotides that function as gene regulators by cleaving and/or inhibiting the translation of target 
messenger RNA (mRNA) [4] as well as simultaneously regulating a broad set of genes of interest [5]. 
Due to their ability to trigger synergistic therapeutic effect in cancer, miRNAs have recently emerged 
as a new class of cancer therapeutics. MiRNAs also play a significant role in various cellular and 
physiological processes such as organ development [6], apoptosis [7] and differentiation [8]. 
 
However, miRNA is negatively charged and may thus be interfered with while interacting with the 
cell membrane, thereby triggering poor cell uptake. Many approaches have been developed to 
improve the transfection efficiency of miRNA and prevent miRNA degradation. For example, 
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nanoparticle vesicles are often used to deliver miRNAs [5]. Gene therapy can be used to treat 
multicellular spheroids, which comprise three-dimensional (3D) spherical cell aggregates displaying 
cell-cell and cell-matrix interactions, more closely mimicking in-vivo avascular tumour structure and 
functionality than conventional monolayer cultures, in which intercellular contact is often lost [9, 10]. 
They are, therefore, of fundamental importance to studies in cancer biology, metastasis and invasion, 
in addition to therapeutic screening [11, 12]. Several methods have been used to produce these 
spheroids, all of which first involve the formation of loose cell aggregates, followed by their 
compaction into tight spheroidal clusters [10].  
 
There is increasing evidence demonstrating the efficacy of stem-cell-based therapies for 
treatment of an array of lung diseases, including: chronic obstructive pulmonary disease 
(COPD); pulmonary and cystic fibrosis; and pulmonary hypertension [13, 14]. Direct lung 
delivery via aerosol inhalation, by contrast, not only facilitates local targeting of the disease or 
injury-specific regions, but also allows easy and painless administration, has fewer side effects 
and avoids the need for anaesthesia. Nevertheless, there remain considerable challenges 
associated with stem cell aerosolisation in particular.  The likelihood that the stem cells will 
survive and retain their function during the nebulisation process is low. 
 
Tissue engineering (TE) is an interdisciplinary field that applies the principles of biology, 
medicine and engineering to manipulating various biological functions of tissues that restore 
and replace the injured tissues or organs and produce entirely functional replacements [15, 16]. 
For repair and regeneration of lung tissue to be successful, 3D scaffolds should be elastic, 
stretchable and compressible through inhalation, biocompatible, non-toxic, degradable and 
disappear from the lung post-implantation [17]. The 3D scaffolds are used as platforms for the 
culture of embryonic stem cells (ESCs) to differentiate them into lung epithelial cells that can 
replace the dying cells.  ESCs are pluripotent cells that are directly derived from the inner cell mass  
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of embryos and have a unique capability of long-term self-renewal and the ability to 
differentiate into a variety of specific cell lineages. In addition, stem cells are of paramount 
importance in regenerative tissue studies and cell-based therapies [18, 19]. 
 
1.2 Gene Therapy and Lung Cancer 
 
 
Gene therapy is broadly defined as the replacement of defective or absent genes within the cell—or 
the use of gene approaches to affect function or modulate responses—for the treatment of pulmonary 
diseases, including lung cancer. It can be classified into three categories: (a) gene addition or gene 
replacement), (b) gene reprogramming and (c) gene repair. Gene addition or replacement is the only 
approach used in clinical applications that involve adding corrected genes in order to overcome a 
genetic mutation. This method seeks to treat less complex disorders. Gene reprogramming is a second 
approach that is used for more complex disorders, in which the gene product may require controlled 
cell-specific expression or disorders with a dominant phenotype. It can be used to correct defective 
portions of endogenously encoded mutant RNA transcripts for a given gene [20]. The third approach 
is gene repair, which seeks to correct mutant sequences in the genomic DNA. However, the efficacy 
of gene repair is low, with no currently realistic clinical applications [21]. 
 
The term “gene therapy” involves a wide range of cure types that all use genetic material to modify 
cells to aid and effect a treatment [22]. Several preclinical studies have shown their efficiency by 
testing a range of gene therapy agents. Gene therapy strategies have been tested on gliomas [23] and 
cancers of the pancreas [24], liver [25] and other organs. Since the safety of gene therapy agents was 
demonstrated, many cancer patients have participated in gene therapy trials, with few or reduced side-
effects [26, 27]. Fever and colds are the most frequent side-effects compared with the more serious 
side-effects of chemotherapy. In addition, if an agent is injected into the target area, there can be 
localised swelling and inflammation at the injection site [26, 28, 29]. In lung cancer models, genes 
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have been introduced into lung cancer cells, repairing normal cellular phenotypes or causing death of 
the cancer cells [30]. 
Lung cancer is the leading cause of morbidity and mortality in Australia [31]. It is defined as the 
uncontrolled growth of abnormal cells in one or both of the lungs. The abnormal cells replicate more 
rapidly and do not grow into normal lung tissue. Cancer cells can spread from the tumour site into 
other organs via the bloodstream or lymphatic system. It is expected that approximately 1.6 million 
new cases will be diagnosed globally each year, leading to about 1.38 million deaths and accounting 
for 18.2% of all cancer-related deaths worldwide [32]. In 2014, 11,550 Australians were diagnosed 
with lung cancer (6,720 men and 4,830 women) and an estimated 13,640 people are expected to be 
diagnosed with lung cancer in 2020 [33].  
 
There are two main histological types of lung cancer that have been classified by pathologists in 
recent decades: small cell lung cancer and non-small cell lung cancer (NSCLC).  NSCLC is the most 
common and accounts for 85% of all lung cancer cases. It is further subdivided into adenocarcinoma, 
squamous cell carcinoma and large cell carcinoma (AC, SCC, and LCC, respectively) [34]. 
 
NSCLC commonly spreads to different parts of the body more slowly than does small cell lung 
cancer. Small cell lung cancer accounts for 14% of all lung cancers. It develops more quickly and is 
more likely to spread to other organs in the body than non-small cell lung cancer. Many techniques 
have limited effectiveness in lung cancer (LC) treatment [35]. The common treatment for LC is 
surgery for localised disease. However, most LC cases are diagnosed in advanced stages. As a result, 
chemo- and/or radiotherapy (CT and RT, respectively) are the major therapeutic options, which make 
the prognosis of lung cancer very poor, with a median overall survival of only about one year. The 
selection of treatment and the prognosis depend upon the specific type of tumour [36]. 
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1.3 MiRNA-based gene therapy 
 
1.3.1 MiRNA as a potential biomarker in cancer 
 
MiRNA was discovered in 1993, and was found to control the developmental timing of the nematode 
Caenorhabditis elegans [37]. MiRNAs are small, non-coding, single-stranded RNA molecules, 21–24 
nucleotides in length, that target the regulation of gene expression through either degrading the target 
mRNA or inhibiting translation of the mRNA into protein [38, 39]. The targeted genes can control 
different processes, such as stem cell division [40, 41], developmental timing [42], organ development, 
apoptosis, differentiation [43-48], disease [49, 50] and cancer [51, 52] in animals.  
 
The expression of specific miRNA has been proposed as being relevant to certain tumour types. As a 
result, miRNA signatures have been suggested as being important for the prognosis and prediction of 
cancer patient survival [53-57]. For example, miRNA was detected in the peripheral blood, making it 
an innovative biomarker for early cancer detection [58]. In addition, control of angiogenesis is the one 
mechanism by which miRNA can support tumour growth, by producing new vessels from the pre-
existing vessels.  Lewis lung carcinoma cells were injected into mice lacking the endothelial Dicer 
protein, which is important for the generation of miRNA. A deficiency of Dicer in the endothelial 
cells reduces tumour neo-angiogenesis [59].  
1.3.2 MiRNA in lung cancer 
 
Down- or up-regulation of miRNAs is an excellent strategy to study the function of miRNAs in 
cancer pathogenesis. Cancer is a complex disease characterised by abnormal cell growth and loss of 
apoptosis function. Recent studies have shown that miRNAs can regulate cell growth and apoptosis 
[45, 47]. Thus, modifications in the miRNAs’ expression levels or modification of the interaction 
between miRNAs and their mRNA targets could be the main effect of miRNAs on tumour 
development or progression.  miRNA genes were overexpressed in several cancers, such as miRNAs 
17–92 in lung and lymphoma [60]. 
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By contrast, other miRNAs (called suppressor) are decreased in some cancers. For example, miRNA 
let-7 plays a significant role in the pathogenesis of lung cancer and can control lung cancer 
development. Down-regulated let-7 levels were observed in both in vitro and in vivo lung cancer 
studies, resulting in shortened postoperative survival [61]. By contrast, the up-regulation of miRNA 
let-7 levels in A549 lung adenocarcinoma cell lines led to the inhibition of cancer cell growth [61]. In 
another example, the miRNA-200 family enhanced invasion and metastasis in lung cancer mouse 
models by regulating epithelial mesenchymal transition (EMT) [62]. In addition, the miR-17–92 
cluster enhanced tumour growth by targeting two tumour suppressor genes—PTEN and RB2—in lung 
cancer, particularly in the aggressive form of small-cell lung cancer [63].  
 
1.3.3 miR-126 in cancer 
 
 
 
Transcriptional analysis and microarrays-based assays showed that there were significant differences 
between the total expressions of miRNA in tumour cells and that of normal cells. MiRNA-126 is one 
of these miRNAs that is down-regulated in breast cancer. Restoration of levels of miRNA in primary 
breast cancer cells suppressed tumour growth and metastasis to the lung and bone in nude mice [57]. 
Importantly, patients with primary breast cancer cells characterised by a low level of miR-126 
exhibited a lower percentage survival than patients who displayed tumours with a high level of miR-
126. Therefore, this suggests that there is a clinical correlation between the loss of miR-126 and 
survival of cancer patients [57]. Down-regulation or loss activity of miR-126 has also been reported 
for other cancers versus non-cancers, such as lung [64], cervix [65], prostate [66], and colon [67] 
cancers. The miR-126 function is not yet very well known in these types of cancers. However, down-
regulation of miR-126 was correlated with an increased expression of VEGF-A in gastric cancer 
tissues [68, 69]. Sasahira et al. showed that the down-regulation of miR-126 induced angiogenesis and 
lymphangiogenesis by activation of VEGF-A.  
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This was strongly correlated with disease-free survival for oral cancer patients [70]. Volm et al. also 
explored the up-regulation of VEGF-A in non-small lung cancer; this reduced the sensitivity of lung 
cancer cells to apoptotic stimuli [71]. Liu’s group reported that VEGF-A was down-regulated by miR-
126 when lung cancer cells were transfected by lentivirus miR-126, suggesting that a down-regulation 
of VEGF-A was accompanied by cell cycle arrest and a decrease in tumour growth in vivo and in vitro 
[72].  
 
1.3.4 MiRNA therapy approaches 
 
 
A recent advance in the miRNA field has been the discovery of their role in the regulation of different 
cellular processes such as development, differentiation, proliferation and apoptosis, which are 
important in cancer formation.  MiRNAs as oncogenes or suppressors are suitable therapeutic targets 
(Figure 1.1).  
 
There are several advantages of miRNAs based therapeutics. Firstly, miRNAs can degrade the targets. 
Secondly, miRNAs can target multiple oncogenes simultaneously, which might reduce the need for 
combination therapies. If a certain miRNAs expression is reduced in the disease, miRNA mimics can 
be used for the treatment; the resulting mimics of miRNAs can minimise the effect of certain 
oncogenes as a form of replacement therapy. An example of miRNAs replacement therapy is the 
intra-tumoral introduction of the miRNA let-7 into mouse models of NSCLC, which reduced the 
tumor size [73]. In addition, an intra-tumoral injection of cholesterol-conjugated miR-99a mimics 
significantly decreased tumour growth in hepatocellular carcinoma-bearing nude mice [74].  
 
By contrast with up-regulation of miRNA resulting in disease pathology, miRNA inhibition treatment 
can be used to decrease miRNAs expression. Antagonists of miRNAs can reduce the expression level 
of oncogenic miRNAs in tumours and in turn increase the level of specific tumour-suppressor genes. 
MiRNAs-21, an antagonist, was applied in glioma cell lines and stimulated the caspase-induced 
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apoptotic pathway [75]. MiRNAs can also be introduced into the therapeutic field as indirect miRNA-
based therapy. For example some tumours have low levels of certain miRNAs compared with that of 
normal cells; thus introducing vectors that carry miRNA-regulated suicide genes into the tumour cells 
may lead to high abundance of the suicide gene in the cancer cells but not in the normal cells.  
 
 
 
     Figure 1.1:  Schematic of miRNA treatment  [76]. 
 
1.4 Synthetic materials for miRNA delivery 
 
Synthetic materials are potentially effective carriers for DNA and siRNA [77-80]. Synthetic materials 
are cationic materials that condense the negative charge of nucleic acids through electrostatic 
interactions. They have advantages over viral-based vectors because of control over their 
composition, simplified manufacturing and low immunogenicity [81]. Viral-based vectors are 
currently more efficient than synthetic materials. However, the efficiency of synthetic systems has 
been improved by adjusting particle size and surface properties to give a greater bio-distribution in 
vivo.  
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Several synthetic materials have been used to deliver miRNAs. The most common materials are 
discussed in the next section. 
1.4.1 Lipid-based delivery system 
 
Liposomes are some of the most common transfection reagents used in vitro. However, these reagents 
are not often used in vivo as a result of high toxicity, unwanted immune response and non-specific 
uptake [82]. Recently, different lipid-based delivery systems have become commercially available, 
and considerable effort has been devoted to modifying the composition and chemical structure of 
liposomes. Some studies have been successful in delivering siRNAs [83]. Although siRNA and 
miRNA share certain similarities, the subtle difference between siRNA and miRNA is the former 
typically bind perfectly to their mRNA targets, whereas the latter have multiple targets [84]. 
 
Wu et al. (2011) introduced DOTMA: cholesterol: TPGS to deliver miRNAs 133b by adding miRNAs 
133b to empty liposomes reagents. In vitro, liposomes transfected with miRNA 133b were more 
efficient in treating A549 non-small lung cancer than siPORT NeoFX. Approximately 50-fold more 
Cy5 labelled oligodeoxynucluotides lipoplexes accumulated in the lung than with the siPORT NeoFX 
reagent. Moreover, the mature miRNA level was 52% greater than that of untreated mice in lung post-
transfection [85]. However, no inhibition of tumour growth was reported. DOTMA: cholesterol: 
TPGS was also used to deliver pre-miR-107 for head and neck squamous cell cancer treatment. There 
was a 42% reduction in tumour growth by lipoplexes containing pre-miR-107 compared with controls 
[86]. However, the clearance of lipoplexes was observed; there is limited information about the 
stability of miRNA lipoplexes following injection to blood fluidics, where high salt concentrations 
and protein can change the ionic complexes. Cationic liposomes are the most common reagent used 
for lipid-based systems. However, they are limited for in vivo application due to their toxicity [82].  
 
To overcome this obstacle, a natural lipid emulsion (NLE), MaxSuppressor in vivo RNALancerII 
(BIOO Scientific, Inc.), has been developed. NLE was introduced to deliver miRNA34a and let-7 for 
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non-small lung cancer cell treatment. By contrast with the cationic liposome, NLEs accumulated in 
the lung more than in the liver. There was a decrease of tumour burden by approximately 40% in mice 
treated with miR-34a and let-7 compared with the miRNA control, and the expression of miR-34a and 
let-7 was greater than that in untreated mice [87]. Developing miRNA formulations combined with 
NLE is a novel therapy with considerable potential for lung cancer patients.  
 
While lipid-based materials constitute one of the most important candidates to deliver miRNAs, they 
are not the only option available. Several alternative materials are presented below and offer 
advantages. 
 
1.4.2 Polyethyleneimine (PEI)-based Delivery System  
 
Polyethlenimine (PEI) is one of the most common polymers used for inclusion of a gene of 
therapeutic potential.  PEI is positively charged as a protonation of amine groups. Therefore, it can be 
used to condense nucleic acids. The interaction between PEI and nucleic acids retains a net positive 
charge on their surfaces, resulting in the promotion of interactions with negatively charged 
polysaccharide on the cell surface.These interactions with the cell surface make the complexes 
undergo endocytosis. Many studies have used PEI to deliver both DNA and siRNAs in animal models 
[81, 88, 89]. However, the translation of PEI as a delivery system to clinical applications is still limited 
because of its greater activity than other polymers [90, 91]. 
 
Polyurethane-short branch polyethyleneimine (PU-PEI) has been introduced to deliver miR-145 to 
treat cancer stem cell (CSC) derived lung adenocarcinoma. The LAC-CSC did not respond to a 
combination of radiation and cisplatin during a 30-day experimental period. However, there was a 
significant reduction in tumour growth when miRNA delivery was combined with radiation and 
cisplatin [92]. In addition, when miR-145 PU-PEI was administered to orthotopic CSC-derived 
glioblastoma tumours, there was a significant tumour reduction, particularly when the miR-145 PU-
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PEI delivery system was combined with radiation and temozolomide. The synergic effect improved 
the survival rate and showed that this potential miRNA treatment could overcome tumour chemo-
radioresistance, inhibit tumour relapse and suppress cancer [93]. 
 
1.4.3 Dendrimers 
 
 
Dendrimers have received considerable attention in gene delivery because of their defined 
architecture and a high ratio of surface moieties to molecular weight. Dendrimers have successfully 
been introduced to deliver miRNAs and siRNA, but few studies have reported their applications.  
 
U251 glioblastoma cells were treated using co-delivery of anti-miR-21 and 5-fluorouracil (5-FU) by 
polyamidoamine dendrimers. This increased apoptosis and decreased the migration of tumour cells 
compared with treating with 5-FU only [94]. Anti-miR21 that was delivered by poly amidoamine 
dendrimers increased the chemo-sensitivity of glioblastoma cells to taxol [93]. Dendrimers have the 
ability to bind miRNAs, assisting in the entry of cells, but their entry is not precise. Eliciting the 
mechanism of the delivery system of cell entry has the potential to protect miRNAs by evading 
endosomal and lysosomal compartments [95]. 
 
1.4.4 Poly (lactic-co-glycolide) PLGA Particles  
 
Polylactic-co-glycolide particles are a family of water insoluble polymers that are commonly used in 
biomedical applications [96]. These particles enable the formation of micro-particles and 
nanoparticles, which entrap the biologically active molecules [97, 98]. PLGA particles can protect 
nucleic acids from degradation, and have a high loading capacity and multiple surface modifications 
that generate potentially favourable pharmacodynamics [99]. These particles have been approved by 
the USA Food and Drug Administration (FDA) as biodegradable polymers for drug and gene delivery 
[100-102]. However, the disadvantage of PLGA—which limits their application for drug or gene 
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delivery, particularly for lung cancer—is its rapid clearance from the circulatory system. To overcome 
this issue, PEG-modified PLGA was synthesised, and the inclusion of the PEG moiety effectively 
increased the blood circulation time of the carrier molecule [103]. 
1.5 Cancer cells as 3D structures (spheroids) 
 
Monolayer cultures have been commonly used in cancer research and anti-tumour drug development. 
However, they do not sufficiently reflect physiological conditions since monolayer cultures suffer 
from the loss of stroma components and the extracellular matrix. Aggregations of cells with a 3D 
structure (called “spheroids”) have been subjected to different in vitro studies for a better 
understanding of the principles of morphogenesis and tissue formation. Multicellular spheroids thus 
are of paramount importance in biomedical science since they mimic the in-vivo tumour tissue 
structure and microenvironment. Stem cells or cancer cells from malignant cell lines or fragments of 
human tumours can be used to create 3D structures [104] that have been used in studies of cell-cell 
interactions and communication, position-dependent proliferation, metabolic gradients and gene 
expression.  
 
Spheroids more effectively mimic the behaviour of tumours than do two-dimensional (2D) cell 
cultures because spheroids, very similar to tumours, usually contain both: surface-exposed and deeply 
buried cells; proliferating and non-proliferating cells; well-oxygenated and hypoxic cells [105]; and 
show a greater degree of variation in morphology [106], function [107] and differentiation than do 2D 
monolayer cell cultures.  
 
Multicellular spheroids in vitro display growth kinetics, resistance to radiotherapy, metabolic rates, 
chemotherapy, express cell signalling, and new proteins that demonstrate tissue-like structures with 
more functions than individual cells [108]. A systematic study has identified the degree of 
differentiation as an important determinant of the response of radio-therapy in various spheroid types 
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of human origin [109]. As a result, multicellular spheroids are believed to mirror the radio-sensitivity 
of differentiating tumours in vivo more precisely than do monolayer cell cultures. For example, when 
tumour cells were isolated and grown as a monolayer, they lost their drug resistance to alkylating, 
while this could be fully recaptured when cells were cultured as multicellular spheroids [110, 111]. 
Spheroids can also be used to study the adhesive properties of tumour cells [112]. Tumour-induced 
angiogenic responses can be modelled using cultures in which tumour spheroids interact with vascular 
cells generated from ESCs, which made feasible the analysis of interactions between different cell 
types in spheroids [113].  
 
Many efforts have been devoted to studying the different aspects of tumour cells since 3D 
multicellular spheroids highlighted the need for improved and more effective in-vitro system models 
that more closely resemble the in-vivo situation and the biological behaviour of the cells. 
1.6 Generation of multicellular spheroids 
 
 
1.6.1 Conventional methods 
 
 
Many techniques have been used to produce spheroids, including liquid-overlay [114], spinner flask, 
hanging drop and gyratory rotation methods [115, 116]. In the liquid-overlay technique, trypsinised 
cells are placed on dishes covered with a thin film of agar. Because the coating prevents cell 
attachment to the dish, cells grow in 3D and individual cells give rise to aggregates or spheroids. In 
the gyratory rotation and spinner flask techniques, after trypsinisation cells are located in a culture 
container with a magnetic stirrer, precluding cell attachment to the substrate and favouring cell-cell 
adhesion. In the more recently developed hanging drop technique, spheroids are grown in an inverted 
micro-plate. However, all of these techniques are limited by tedious and laborious procedures and the 
spheroids produced are usually loosely aggregated or have irregular size. Thus researchers have been 
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motivated to create novel strategies as alternative approaches for the production of uniform 
multicellular spheroids. 
 
1.4.2 Microfluidic devices  
 
Recently, several microfluidic strategies have been offered for on-chip spheroid culture, including: 
microarray devices that immobilise cells on selectively adhesive patterned structures [117]; cell 
trapping barriers [118-120]; non-adhesive microwells [121-124]; bubble- and droplet-based methods, in 
which the cells are encapsulated within bubbles [12] or gelated capsules [125-127]; cell trapping in 
microwells by ultrasonic actuation [128]; and microwells in which is induced a rotational flow [129].  
 
Microarray methods have the advantage creating uniformly sized cell aggregates, while the aggregate 
size is likely to be limited by the dimensions and geometry of the patterns. Large numbers of cells 
also need to be seeded, as any cells that are not immobilised tend to be washed away and lost [120]. 
Ultrasonic actuation needs custom-made microwells and the actuation heats up the solution in the 
microwell [128], which may damage cells that are sensitive to a temperature increase. Bubble and 
droplet methods have similar limitations, since the aggregate sizes are dependent on that of the 
capsule, which, in turn, is restricted by the surface properties and dimensions of the microfluidic 
system. In addition, a bubble method has limitations from low cell capture efficiencies. Rotational 
flow devices, on the other hand, allow cell aggregates of different sizes to be formed from microwells 
of a single dimension, thereby circumventing the need to fabricate different devices to vary aggregate 
size. However, the need for a filtration system to prevent cell clots from entering the device not only 
reduces the efficiency of the method due to loss of a large number of cells but also introduces a 
further complexity, the necessity for an additional channel shredder to break up large cell clots by 
shear [129]. In addition, the closed microfluidic device restricts practical sampling and collection of 
cell aggregates—for example, for plating the cell aggregates to stimulate cell differentiation [130].  
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1.6.3 Liquid marble bioreactor  
 
The phenomenon of liquid marbles was presented in the pioneering work of Aussillous and Quere in 
2001 [131]. Since then, extensive studies have been devoted to miniaturisation the technology [131-
133].  Due to their unique physical and structural characteristics, liquid marbles have been subjected to 
a variety of practical applications during the past decade.  
 
These applications included microfluidics [134, 135], electro-wetting [136] and water pollution [137].  
A number of studies have also been dedicated to the use of liquid marbles as miniature reactors. 
Tian’s group has reported the possibility of using liquid marbles for gas sensing [138]. Fujii et al. also 
proposed using modified liquid marbles for gas sensing. In this study, liquid marbles were made using 
PS latex particles carrying pH-sensitive PDEA hair (PDEA-PS particles). Finally, liquid marbles were 
rapidly disintegrated upon exposure to HCl gas, presumably due to desorption of the latex particles 
from the surface of the liquid marbles [139].  
 
Liquid marbles have also been created from Lycopodium spores and used to encapsulate aqueous 
solutions of 9-fluorenylmethoxycarbonyl-diphenylalanine (Fmoc-FF). Self-assembly of ribbon-like 
peptide fibrils into an ultrathin peptide membrane resulted on acidification of the Fmoc-FF solution at 
the liquid/air interface, showing the potential of liquid marbles in micro-bio-reactors applications 
[140]. In addition, a liquid marble strategy was used effectively to detected polluted water with 
contaminants such as oils, petroleum and their derivatives that minimise the surface tension of water 
[137]. Polyvinylidene fluoride (PVDF) marbles floating on the surface of contaminated water with 
silicon oil or kerosene were destroyed due to the formation of a low surface tension film on the 
surface of the water. Therefore, liquid marbles have been proposed for determination of water 
pollution from oils and petroleum [137]. Furthermore, liquid marbles are covered by graphite powder, 
have a low evaporation rate compared with that of uncovered liquid marbles and have sufficiently 
long lifetimes to retain their spherical shape, which makes them an interesting choice for industrial 
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and biological applications such as microfluidic, genetic analysis and anti-fouling uses. Hence, liquid 
marbles are also effective storage devices [141]. In addition, a gas storage system was developed in 
which methane molecules were absorbed in the water of the marbles [142, 143].  
 
Recently, liquid marbles have received considerable attention in the pharmaceutical industry. They 
have shown many advantages in drug delivery by offering the benefits of handling high drug loadings, 
production of spherical granules with excellent flow, simultaneous control of the size and structure of 
the granules, good compression properties, and fast drying periods [141, 144, 145]. Fatty acid crystals 
and triacylglycerol crystals have been used to form edible liquid marbles with useful applications in 
the food, cosmetic and medical areas [146]. Liquid marbles covered by solid particles (based on a 
copper substrate or a polystyrene latex) have been used to form capsules containing drug components 
that were stimulus-responsive [147, 148].  
 
Recently, liquid marbles with unique properties have been employed to build micro-biological 
reactors for microorganism cultivation. A liquid marble bioreactor provided a more suitable 
environment for the growth of aerobes than McCartney bottles with shaking incubation. Cell 
concentration increased more rapidly in liquid marbles [149]. Some of the significant advantages of 
liquid marble bioreactors [134, 150] are that they minimise the consumption of chemical and biological 
reagents, accurately control reaction conditions, and have much shorter reaction times. 
 
Furthermore, liquid marbles have been explored for the generation of cancer multicellular spheroids 
[151] and for immune-haematological assays [152]. Also, another important biological application for 
liquid marbles is their use to produce embryoid bodies (EBs) [153] and to differentiate cardiac tissue 
from ESCs [154]. These studies showed that liquid marbles constitute a promising approach for tissue 
engineering and biomedical applications. Studying cell behaviour becomes easier with small 
populations of cells, and small volumes significantly minimise waste when working with hazardous 
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biological materials. Since there is no direct contact between the liquid core and the underlying 
substrate bed, liquid marble bioreactors decrease the risk of contamination with biohazards.  
 
Liquid marbles (Figure 1.2) also constitute a simple and effective method that does not require 
complicated equipment (except normal cell culture). In sum, the most significant properties of liquid 
marbles are permeability of the porous shell (which allows the possibility of gas exchange between 
the medium and the surrounding environment), non-adhesiveness of hydrophobic powder particles 
(which encourages cells to suspend in the medium and generate EBs and multicellular tumour 
spheroids more effectively) and a confined liquid core volume (which supports effective contact 
between cells). This has motivated efforts to exploit these advantages for living cell applications.  
 
 
                      Figure 1.2: Preparation of Liquid Marble [152]. 
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1.7 Tissue engineering and stem cells 
 
 
Tissue engineering (TE) is a new technology that aims to produce or replace tissues and organs using 
combinations of cells, biomaterials, and biologically active molecules [155]. TE is an interdisciplinary 
field that combines biology, medicine and engineering in order to manipulate the biological functions 
of tissues in order to restore and replace injured tissues or organs and maintain normal tissue functions 
[15, 16]. The purpose of tissue engineering is also to develop novel and effective in-vitro biological 
methods and technologies that provide a better understanding of the normal function of tissues, in 
addition to functions similar to those found in vivo [156]. Therefore, the TE approach could 
revolutionise current therapies and significantly improve the quality of patients’ lives.  
 
TE started in 1933 when mouse tumour cells were transplanted into a polymer membrane and 
implanted into a pig’s abdominal cavity. The cells remained viable for a long time without any 
rejection from the immune system [157]. Collagen or collagen-glycosaminoglycan (CG) composite 
sheets were used as a 2D means to culture cells and to generate a new skin during the late 1970s and 
1980s [158, 159]. TE progressed to creating 3D structures composed of synthetic polymers to 
accommodate large cell numbers [160]. Interestingly, this discipline has only been defined in the last 
two decades, when Langer and Vacanti published an article that described how biological and 
engineering principles functioned to bring cells, biomolecules and scaffolding together to repair or 
grow new tissues [15]. The theory of construction of tissues in the laboratory seemed impossible. 
However, extensive studies have followed—for instance, the transplantation of a shaped human ear on 
to the back of a mouse opened a new way of thinking about generating new tissues [161].  
 
Although significant advances have been reported [162-164], clinical applications have progressed 
much more slowly than expected. There are several difficulties associated with current implantation 
practice. The number of organs available for transplantation is far exceeded by the number of patients 
needing such procedures. Many tissues are not stored in banks and so supply problems exist and there 
is always a possibility of organ and tissue rejection.  
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The most important elements in the success of tissue engineering are expanding the cells of interest 
that are needed for biological functions and maintaining their normal phenotype, for instance 
producing an extracellular matrix, secreting cytokines and other signalling molecules, and interacting 
with neighbouring cells/tissues (as normal cell functions are considered indispensable).  
 
In tissue engineering, biomaterials act as an artificial extracellular matrix (ECM) to replicate the 
biological and mechanical functions of native ECM. Thus, the biomaterials are designed to produce a 
microenvironment ex vivo for the generation of tissue-like constructs and regulation of cell function. 
In the promotion of tissue growth, biomaterials play important roles in producing the cell environment 
and giving mechanical support, leading to cell behaviour such as adhesion, proliferation, migration 
and differentiation. Biomaterials act as temporary mechanical supports for tissue to grow and for cells 
to undergo spatial reorganisation into tissues [15, 165].  
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1.8 Cell sources for cell therapy and tissue engineering approaches  
 
1.8.1 Primary cells 
 
Construction of an engineered tissue usually requires the use of cells to populate matrices. The source 
of donor tissue can be heterologous (such as bovine), allogeneic (same species, different individual), 
or autologous. Autologous cells are extracted from patients and then implanted into scaffolds under 
controlled culture conditions, delivering the resulting construct to the position wanted in the patient’s 
body and directing the new tissue construct into the scaffold, which can be degraded over time [166, 
167]. These cells have many advantages and are preferred over others because a biopsy can be 
obtained from the patient, expanded in vitro and then reimplanted in the same patient without any 
rejection from the immune system (avoiding side effects from immunosuppressive medications) 
[168]. Major advances have been to expand the use of several types of primary human cells to make it 
possible to use the autologous approach in clinical applications. However, the low proliferation of 
primary cells in the autologous approach limits their applications [168]. Although autologous cells are 
still used in tissue engineering as a type of primary cell, they have key drawbacks, including low yield 
and the probability of gene alterations associated with ageing. These problems have motivated 
researchers to develop or find an alternative source.  
 
Stem cells can solve the problems encountered using primary cells released from explanted tissues. 
Stem-cell-based therapies are a promising tool to address the shortfall of tissue and organs in 
medicine [169, 170]. The potential uses of stem cells in tissue engineering and stem-cell-based 
therapeutics are well established. Table 1.1 shows some of the common types of cells used in TE, 
which vary from autologous or allogeneic to differentiated to stem cell or progenitor origin, 
depending on the site where the seeding is required [171]. 
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Table 1.1: Cells used in tissue engineering and cell therapy [171]. 
 
Cell type 
 
Human cell source, 
donor immunogenicity 
 
Ex-vivo manipulation 
and immunogenicity 
 
Clinical experience 
 
Embryonic stem 
and progenitor 
cells 
 
Embryonic tissue; tight 
ethical regulation, 
allogeneic, presumably 
with low immunogenicity 
 
High expansion and 
differentiation 
capacity; potentially 
immunogenic culture 
supplements 
 
Only preclinical studies 
(potential teratoma 
formation); require 
xeno-/ pathogen-free 
culture supplements. 
 
Induced 
pluripotent stem 
cells 
 
Autologous tissue biopsy  
(e.g. skin, fat, or muscle), 
require reprogramming 
 
Limited expansion, but 
high differentiation 
capacity; epigenetic 
memory? 
 
Only experimental and 
preclinical studies 
(potential teratoma 
formation) 
 
Fetal, umbilical 
cord, and  
placenta-derived 
stem and 
progenitor cells 
 
Aborted foetal tissue 
(e.g., foetal liver or 
marrow, umbilical cord, 
amniotic fluid and 
placental tissue) 
 
High expansion 
capacity but unknown 
long-term risk of 
malignant formation; 
response to allergens? 
 
Mostly preclinical 
studies; umbilical cord 
blood cells for cartilage 
 
Adult stem and 
progenitor cells 
 
Bone marrow aspiration, 
peripheral blood, adipose, 
and other adult tissues; 
usually autologous, but 
also allogeneic sources 
 
Low to moderate risk 
of de-differentiation 
and unknown long-
term risk of malignant 
transformation; 
potential 
immunological issues 
 
Pulmonary valve and 
trachea (autologous 
EPCs/MSCs); acute 
GvHD (allogeneic 
MSCs) 
 
Lineage-
committed and 
differentiated 
adult tissue cells 
 
Commonly tissue biopsy, 
but also peripheral blood; 
selection of cell types, 
autologous vs. allogeneic 
donor? 
Limited expansion 
capacity; no 
immunogenicity 
expected but immune-
response to allergens 
Trachea; bladder; 
cartilage 
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1.8.2 Stem cells  
 
 
Stem cells are pluripotent cells that are defined by two unique properties: they have the capacity to be 
self-renewing and they can generate differentiated cells by replicating themselves many times, by 
contrast with muscle, blood or nerve cells, under controlled conditions. 
Stem cells can proliferate and produce a large number of cells in the laboratory. If these cells continue 
to be non-specific cell types with similar characters to those of parent stem cells, they are capable of 
long-term self-renewal. Stem cells are located in various areas of the human body, including the inner 
cell mass of the early embryo, some tissues of the foetus, the umbilical cord, the placenta and several 
other adult organs. The potential of stem cells was recognised in the late 1990s when pluripotent 
ESCs were isolated from early embryos and grown in the laboratory [172, 173]. One of the essential 
properties of stem cells is that they are not specialised. They can become specialised cells—including 
heart, muscle, blood and nerve cells— but they do not have any specific tissue structure with specific 
functions.  
 
Differentiation of stem cells is a process in which unspecialised stem cells give rise to specialised 
cells through several stages. The degree of differentiation of stem cells to various other tissue types 
varies with the different types of stem cells. This phenomenon is referred to as plasticity. These cells 
can also be classified, according to their differentiation capacity, into totipotent, pluripotent, 
multipotent and unipotent stem cells (Figure 1.3). 
 
Totipotent stem cells have the ability to differentiate into all specialised cell types in the body to 
generate a new embryo. These cells have the ability to develop a completely new embryo that can 
develop into a new organism. A fertilised egg is totipotent. None of the stem cells used in research 
appears to have this ability.  Stem cells that are capable of differentiating into various cell types 
within the body are called pluripotent ESCs. These cells have the ability to form three germ layers 
consisting of the mesoderm (muscle, bone, etc.), ectoderm (neurons, skin, etc.) and endoderm 
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(hepatocytes, pancreatic beta cells, etc.). Multipotent stem cells can create different types of cells. 
However, they are limited to some tissues and organs. Hematopoietic stem cells are examples of 
multipotent stem cells that can differentiate into cell blood types, but not into brain or heart cells. 
Finally, unipotent stem cells can generate only one type of cell.  
 
 
Figure 1.3: A schematic model of the origin of stem cells and reprogramming [182]. 
 
 
 
The unique properties of stem cells mentioned above mean that they offer many benefits in cell 
therapies, drug discoveries and tissue engineering [174-176]. Naturally, stem cells play a role in the 
human body by specifying the starting material for organs and tissues, as well as by their continuous 
maintenance, growth and renewal [177]. Due to their ability to generate a multitude of tissue types, 
stem cells have recently been considered as a primary cell source for tissue engineering, in which the 
focus is on developing alternative therapies for degenerative diseases and injuries by regenerating the 
damaged tissue and repairing their function in the affected individual. So far, the majority of the 
research has been carried out on two main groups of human and animal stem cells, including non-
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embryonic (adult or somatic) stem cells and ESCs for stem cell therapy and tissue engineering. This is 
discussed in more detail in the next section. 
 
1.8.2.1 Adult stem cells  
 
Adult or somatic stem cells have been used clinically since the 1950s, when stem cells in bone 
marrow stroma and blood could rescue patients suffering from bone marrow failures [178]. These 
cells are an undifferentiated type of cells, found in different areas of the human body, including the 
bone marrow, skin, brain, liver, muscle and nervous tissues, as well as in the circulation [179] (as 
shown in Figure 1.4). 
 
Figure 1.4: Locations of somatic stem cells in human body, Accessed in 2015 [180]. 
 
 
It was initially believed that stem cells were located only in the type of tissue that they generate. It 
was not expected that some components of blood were capable of developing an entirely different 
embryonic origin. For instance, the generation of muscle tissue and the development of neuron-like 
cells formed from stem cells in the bone marrow increased researchers’ expectations about the ability 
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of hematopoietic stem cells (HSCs) to give rise to multiple cell types from all three germ layers [181-
184]. For example, transplantation of hematopoietic stem cells (HSCs) into an irradiated mouse 
formed not only blood components (mesoderm layer), but also epithelial cells in the lungs, gut 
(endoderm layer) and skin (ectoderm layer) [184].  
 
Adult stem cells can generate and replace old or damaged cells when they have been located (such as 
skin stem cells to generate new skin cells). However, their ability to differentiate is more limited than 
that of ESCs. Although ESCs can give rise to multiple lineages, adult stem cells are not pluripotent, 
and are less versatile compared to ESCs. The limitations of the use of adult stem cells and primary 
cells in tissue engineering are similar because of the difficulties in accessibility, low number of cells, 
limited differentiation potential and poor growth. The isolation and expansion of adult stem cells in 
vitro has been found to be challenging. However, these cells are still a promising strategy in stem-
cell-based therapeutics to treat different diseases. By comparison with ESCs, they have not so far 
formed teratomas.  
 
1.8.2.2 Embryonic stem cells (ESCs) 
 
 
Tissue biopsy is a procedure used to extract cells from a patient’s organ, and exists in the majority of 
existing tissue engineering strategies. However, there is insufficient generation of normal cells for 
many patients through tissue biopsy and it cannot be expanded from a particular organ (such as the 
pancreas). In this regard, ESCs are an alternative source of cell sources from which the desired tissue 
can be developed. ESCs are promising tools to enhance the understanding of normal development and 
disease for cell therapy applications, and to treat incurable and damaging disorders, including spinal 
cord injury, neurological disease, blindness and type 1 diabetes [185]. 
ESCs were initially derived from mice, and then from other species, including non-human primates 
and humans [172, 186]. These cells are isolated from the inner cell mass (ICM) of pre-implantation 
embryos after generation of the blastocyst, and cultured in the laboratory [18, 187]. Blastocyst 
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formation begins by the fertilisation of an ovum by a sperm, and results in a zygote, the earliest 
embryonic stage. Thirty hours after fertilization, the zygote starts to divide. By the 16-cell stage, the 
compacted embryo is termed a morula. The morula cells start to specialise by day three (E3.0)  after 
fertilisation in the mouse and days five to six in humans, and forms a hollow sphere of cells called a 
blastocyst [188], as illustrated in Figure 1.5. 
 
The outer layer of the blastocyst is called the trophoblast, and differentiates into the placenta and other 
tissues supporting foetus growth, whereas the inner cell mass develops into a foetus [18]. Pluripotent 
cells are derived from the inner cell mass and have the potential to proliferate in vitro and to maintain 
their undifferentiated state continuously while keeping the normal karyotype [18, 187, 189].  
In addition, they have the ability to differentiate into all three somatic germ layers (mesoderm, 
ectoderm and endoderm), including cells of the hematopoietic [190, 191], cardiac [192, 193], 
endothelial [194] and neuronal tissues [195] under well-defined conditions in vitro. ESCs present 
certain advantages over somatic stem cells. They offer greater pluripotency and indefinite growth in 
culture [19, 196]. They give rise to a stable population of cells rather than a rare cell among other cell 
types, having been isolated from a relatively homogeneous population of cells within the ICM. Two 
main classes of ESCs—human and mouse embryonic stem cell—are discussed next.  
 
 
Design and Development of miRNA and stem cell based micro/nano systems as lung disease therapy            L Alhasan  
      
 
27 
 
 
          
Figure 1.5: Pre-implantation blastocyst development in human and mouse [197]. 
 
 
 
1.8.2.2.1 Human embryonic stem cells (hESCs) 
 
The first of the human ESCs derived in 1998 by Thomson and colleagues provided a tremendous 
boost to tissue engineering and stem cell biology [172]. These hESCs self-renew continuously under 
certain culture conditions. They also differentiate into cells representative of all three embryonic germ 
layers. Due to their properties, the discovery of hESCs marked the beginning of a new area of 
regenerative medicine and drug discovery. 
 
Human ESCs have several distinct differences from murine ESCs. For example, hESCs have a slower 
proliferation rate (~24 h doubling times) and a flatter morphology. Cells are derived from embryos 
discarded from in-vitro fertilisation (IVF) techniques. They are also usually easy to dissociate into 
single cells, by contrast with murine ESCs (mESCs) [198]. Another differential property of hESCs is 
their ability to proliferate for more than two years while keeping a stable and normal complement of 
chromosomes. By contrast, mESCs need careful monitoring to note genetic mutations that occur over 
time.  
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Most hESCs obtained are grown on murine embryonic fibroblasts (MEFs) as feeder cells in media 
composed of Dulbecco’s modified Eagle medium (DMEM) and serum replacement components that 
are not entirely free of animal ingredients. However, the feeder cells are inactive (i.e. they are not 
dividing and expanding) but still create the growth factors that sustain the ESCs.  
 
One of the key concerns in tissue engineering is the need to grow human ESCs without any 
contamination by other cell lines or proteins. This problem, which was reported in January 2005, 
demonstrated the expression of a non-human protein when cell lines were grown on animal feeder 
layers [199]. Subsequently, different methods have been investigated to minimise the risk of the 
feeder layer, such as: adding a basic fibroblast growth factor to the culture medium [198, 200]; 
growing the cells on matrigel or laminin in feeder cell-conditioned medium [201]; or growing the 
cells in the presence of GSK-3-specific inhibitors such as 6-bromoindirubin-3´-oxime (BIO) [202]. 
However, all of these approaches are ineffective and at present it is not entirely possible to remove 
animal products. This problem in human embryonic cell culture still limits their applications in 
regenerative medicine.  
 
More importantly, the potential use of human ESCs in regenerative medicine is at the centre of a 
cultural and religious ethical debate that varies by community. This is because different cultures and 
religious groups have their own ethical attitudes on the use of human ESC. For instance, in the UK, 
human ESC lines can only be derived legally under licence from the Human Fertilization and 
Embryology Authority, and the lines must be sited in the Medical Research Council’s Stem Cell 
Bank. This is because the derivation of hESCs from embryos that are obtained from IVF procedures is 
not autologous. Therefore, the possibility of a patient’s immune rejection is increased, which limits 
the efficacy of hESCs in clinical applications. 
 
 
Design and Development of miRNA and stem cell based micro/nano systems as lung disease therapy            L Alhasan  
      
 
29 
 
1.8.2.2.2 Mouse embryonic stem cells (mESCs) 
 
ESCs were first established from the inner cell mass (ICM) of mouse blastocysts as cell lines in 1981 
[18, 187]. Their development in mice starts with a single-cell zygote and results in a fairly complex 
structure—the blastocyst—with three distinct cell lineages. mESCs are characterized by a high 
proliferation rate and telomerase activity. It is thought that transcription factors play a key role in 
maintaining the pluripotent status of mESCs and their indefinite growth without resulting in genetic 
anomalies. For example, telomere shortening is prevented by KLF4, as the pluripotency transcription 
factor that controls telomerase reverse transcriptase (TERT) expression in mESCs [203]. 
 
The purpose of using non-human organisms as a model for human disorders is to recognise 
fundamental pathogenic mechanisms that provide a new way for developing novel therapeutic targets 
in order to evaluate the efficacy and safety of new drugs. Due to physiological, anatomical and 
genomic similarities between mice and humans, mice have historically been the most frequent model 
for the study of human diseases [204]. Mice have been used extensively as models in biological 
studies because mice and humans share approximately 99% of their genes and molecular pathways. 
Some of the other benefits of using mice are low costs, known age, known genetic background, easy 
handling and easy housing. Isolation of murine ESC lines provided biologists with a major tool. It was 
a simple model system to study the processes of early embryonic development and cellular 
differentiation.  
 
It also paved the way for tissue engineering applications if similarly totipotent cells could be extracted 
from human blastocysts. Mice and humans have the same inherited diseases, such as heart disease, 
cancer, glaucoma, anaemia, hypertension, obesity, asthma and neurological disorders. Therefore, mice 
have become a good model for experiments to understand various diseases and discover new drugs for 
humans. Other animals share diseases with humans. However, mice are still the best model to address 
and cure human diseases because of their small size and low cost.  
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ESCs have the ability to differentiate into a wide variety of cell types. They also generate embryoid 
bodies, which contain three germ layers (ectoderm, mesoderm and endoderm) that can be used in a 
variety of experiments. In vivo, the evidence of pluripotency of mESCs is their generation of 
teratomas, which contain tissues originating from all three germ layers, after being transplanted in 
immune-deficient mice.  
 
The possibility of inducing in vitro differentiation of ESCs into insulin-producing cells that can treat 
diabetes was explored. Transplantation of analogous mouse cells into mice that had diabetes resulted 
in the partial restoration of insulin regulation [205]. Furthermore, transplantation of mESCs into 
rodents with Parkinson’s disease symptoms resulted in partial relief of these symptoms [206]. mESCs 
were also transplanted into animals with spinal cord injuries and partially renewed neural function 
[207].  
 
Murine ESCs maintain their pluripotency in the presence of the cytokine Leukaemia Inhibitory Factor 
(LIF), but hESCs cannot [172]. The population doubling time of ESCs is about 12 hours, which is 
shorter than that of hESCs (24 hours). This could reflect the longer gestational period in humans than 
in mice.  
 
If in-vitro culture of ESCs causes the production of a desired cell type, these cells can be tested for 
their potential to repair damaged or degenerating tissues. The ability to produce specific lineages from 
ESCs in vitro suggests that ESC-based cell replacement therapy might be possible for treating human 
degenerative diseases. However, the differences between hESCs and mESCs are still essential in 
clinical and human applications of ESCs [208]. Theoretically, an extensive range of human disorders 
could be treated using hESCs. The evidence supporting of this essential concept has principally been 
derived from the use of mouse ES cells. 
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The investigation of stem cell properties could be facilitated using systems of mESCs, because they 
are simple to culture, have a rapid growth rate, and can differentiate into multiple cell types. In 
addition, several specific factors that affect their self-renewal have been recognised. They can grow 
clonally. This allows many biological questions to be asked at the single cell level. The simple 
method of testing their pluripotency (using blastocyst injection) and the experimental accessibility to 
their tissue of origin lead to their ready availability to provide rigorous assays of their stem cell 
activity.  
1.9 Embryonic stem cell application 
 
Regenerative medicine, tissue engineering and bioengineering are new approaches in cell therapy. 
These methods allow researchers to generate and proliferate specific cells during the culture of 
different cells and tissues, and to investigate important functions that have changed in disease 
conditions. Thanks to ESCs’ properties, ESCs have attracted considerable interest in the 
biopharmaceutical area for their use in drug discovery and cell replacement therapy. Progress in this 
area has created new potential in the studies of developmental biology, as well as in studies of gene 
functio on the level of the whole organism. All of this was accomplished after the isolation and 
identification of mESCs from mice [18, 187].  
 
ESCs were isolated first from primates and then from human blastocysts; these cells were identified as 
promising sources for regenerative medicine and tissue engineering research [172, 186]. They could 
provide functional replacements for some diseased tissues—for example, Parkinson’s disease or 
spinal cord injury [209, 210]. Adult and ESCs have provided materials for the development of 
regenerative medicine. However, ESCs exhibit many properties different from adult stem cells. An 
understanding of these properties could assist researchers in modifying adult stem cells to achieve 
better growth in culture and greater control of differentiation. 
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Due to their unlimited proliferation rate and pluripotency, ESCs have great potential in tissue 
transplantation, drug screening and cell therapy, as shown in Figure 1.6. Using ESCs in cell and 
organ transplantation has led to established treatments for a variety of diseases. ESCs are used in the 
development of the cell-based Alzheimer’s disease screening assay, as well as in compound 
identification and optimisation [211]. Derivation of liver-like cells, from bone marrow and ESCs, is 
an alternative approach to liver transplantation, which is the only successful treatment modality for 
end-stage liver failure [212]. 
 
mESCs provide a valuable source of specific neuronal and glial cells for transplantation [213, 214]. 
ESCs can be differentiated into functional islet-like cells with the potential to rescue experimentally 
induced diabetes in mouse models [215]. Pancreatic endoderm produced from ESCs generated mature 
pancreatic cell types that functioned in vivo [216]. Both adult and embryonic stem have the potential 
to differentiate into appropriate cells for repair of damaged bones, cartilage and tendons [217, 218].  
 
Using ESCs as models can improve protocols for the more successful application of ESCs in cartilage 
and bone tissue engineering. For example, mouse ESCs were used as a screening system to identify 
elements both required and sufficient for cartilage and bone generation [219, 220]. Moreover, 
differentiated ESCs were utilised for the evaluation of drug adsorption, metabolism and the toxicity of 
mutagenic, cytotoxic and embryo effects in toxicological studies [221, 222].  
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Figure 1.6: The potential use of stem cells in regenerative medicine, Accessed in 2015 [233] 
 
 
An additional important potential of ESCs is their ability to differentiate into lung lineages, thus 
demonstrating a promising source for lung regenerative therapy because of their self-renewal 
capability. mESCs can also provide a novel approach for generation of infinite quantities of lung 
epithelial cells for lung repair. 
1.10 Stem cell therapy 
 
1.10.1 Mesenchymal stem cells for lung repair 
 
Several studies have reported the feasibility of using mesenchymal stem cells (MSCs) cells to cure 
lung diseases. For example, mice were exposed to bleomycin followed by systemic MSCs 
administration, resulting in a major reduction in lung inflammation [223].  MSCs that were 
administered to animal models with acute lung injury/sepsis resulted in the animals having 
significantly greater survival, with less damage to the lung and less inflammation [224, 225].  The 
Design and Development of miRNA and stem cell based micro/nano systems as lung disease therapy            L Alhasan  
      
 
34 
 
administration of MSCs into damaged lung led to the discovery that some growth factors, such as 
keratinocyte growth factor and angiopoietin, can stimulate repair of the lung from injury.  Moreover, 
delivering MSCs to animal models improved their survival and function in some sepsis-damaged 
organs such as kidney by producing circulating pro-inflammatory cytokines and chemokine levels , 
which has led to decrease bacterial inflammation [226, 227]. 
 
MSCs were also administrated to patients with moderate-severe COPD disease in the United States of 
America in 2008. The aim of the trial was to assess the safety of MSCs and to evaluate their 
efficiency in reducing the inflammation associated with disease. The outcomes were major reductions 
in the inflammatory marker C- reactive protein and improved quality of life for patients [228].  
 
MSCs also produce anticancer agent(s), resulting reduced lung cancer [229, 230]. Airway and 
alveolar lung markers have been identified from embryonic and mesenchymal stem cells derived from 
umbilical cord or bone marrow [231-234]. For instance, when isolated MSCs from cystic fibrosis 
patients were co-cultured with those from airway CF patients, these cells give a rise to wild type CF 
trans-membrane conductance regulator (CFTR) and partly corrected defective CFTR-mediated 
chloride conductance, thus repairing the damaged CF cells,. This provided evidence for the potential 
of MSCs for therapeutic use [235]. In addition, mouse MSCs derived from bone marrow were 
pinpointed in the lung, provided a rise of airway and alveolar cell markers [236, 237]. Taken together, 
these studies suggest a bright future for the potential of MSC therapy for lung disease. 
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1.10.2 Embryonic stem cells for lung repair  
 
Pluripotent ESCs (ESCs)—or induced pluripotent stem cells (iPS)—and endogenous pulmonary stem 
cells have been utilised in lung regeneration [238, 239]. iPS can be induced into forming definitive 
endoderm, and then, critically, airway and alveolar epithelium in vitro [240]. 
 
Growth factors, such as epidermal growth factor, retinoic acid and triiodothyronine, play a role in the 
differentiation of ESCs into lung epithelial cells [241]. Activin A induced ESCs to form lung 
epithelial cells [231]. ESCs have also been induced to form lung lineages by treatment with extracts of 
differentiated mature lung cells [242]. Rodents with acute lung injury (lipopolysaccharide injury) 
were treated by systemic injection with purified murine SPC-positive cells, but there was no resulting 
engraftment in the lung. Unpurified, differentiated ESCs showed only transient engraftment [243]. 
However, pulmonary epithelial cell delivery may be realistic, as shown in recent work using human 
ESC-derived AT2 cells in a bleomycin-induced lung injury model, in which hESC-AT2 cells 
engrafted in the lung after intra-tracheal delivery. They were then induced to differentiate into an AT1 
phenotype, resulting in improved survival, reduced lung inflammation, fibrosis, and the generation of 
pulmonary epithelium—such as AT2 cells and airway epithelium—by several protocols [244]. ESC 
results can also be affected by the surrounding environment. For instance, ESCs can differentiate into 
lung epithelial when embryoid bodies are co-cultured with lung mesenchyma [245].  
 
Differentiated human ESCs have several advantages for human health, including producing lung 
epithelial cells for treatment of pulmonary diseases and neurons for patients with Parkinson’s disease. 
Furthermore, the potential of ESCs to differentiate into mature cells of all three germ layers makes 
them a promising tool for treatment of different diseases by controlling the differentiation of stem 
cells into linages of choice. For instance, if ESCs can be induced to differentiate into lung epithelial 
cells, they will assist in the therapy and treatment of patients with pulmonary diseases. 
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A schematic model showing endogenous, embryonic and adult stem cells that can contribute to lung 
development and repair [246] is illustrated in Figure 2.7. 
 
 
Figure 1.7: A schematic model showing the roles of endogenous, embryonic and adult stem cells in 
lung development, injury, repair and regeneration [246]. 
1.11 Stem cell delivery for pulmonary disease 
 
Physical and life scientists have recently collaborated to discover novel routes for direct handling of 
living cells for precision placing or disposition in order to produce a viable microenvironment. A 
multicellular environment has many different applications in tissue engineering and regenerative 
medicine.  
The tissues developed have been used, for example, for rapid wound healing. Several approaches have 
been used to deliver the cells, including ink jet printing [247], laser-guided cell writing [248], bio-
electrospraying [249] and aerodynamically assisted bio-jetting [250]. Primary/immortalised 
embryonic and mesenchyme stem cells have been used in these processes. A jet-based technique was 
employed to process cell suspensions. This technique has received considerable attention due to its 
ability to direct cells in 3D architectures to generate functional tissue. Despite offering great promise, 
ink-jet printing and laser guided cell writing have some restrictions that prohibit their exploration. 
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These restrictions preclude the processing of concentrated multicellular suspensions and producing 
fine cell-bearing residues to the time taken for forming complex microenvironments [251]. Novel 
microfluidic technologies have been designed to overcome the drawbacks associated with these 
conventional techniques. Some of these technologies are discussed next. 
 
1.11.1 Electrospraying 
 
Bio-electrospraying function generates a monodispersed distribution of aerosol drops in the optimal 
size range. DC electrospraying has been used to produce aerosols of methylparahydroxybenzoate, 
which is an antibacterial and antifungal agent, as a preservative in pharmaceutical preparations, and of 
beclomethasone dipropionate, which is a glucocorticoid steroid used to treat allergies and asthma 
[252].  
 
The procedure for electro-spraying is simply designed and consists of a liquid reservoir feeding into a 
capillary nozzle that is connected to a high-voltage source. This facilitates miniaturisation of the 
technology into a cheap and portable consumer device that has so far avoided the common problems 
of conventional nebulisation technologies. 
 
Electrospraying or electrohydodynamic jetting is jet-based technology; the liquid suspension is 
charged using 1000 V and passed through a large-bore needle to be fragmented into drops [253]. 
Pioneering research has shown that suspensions of living cells can form micro-droplets with no 
effects on cell viability or phenotype, and electrospraying can generate finer droplets than others such 
as ink-jet printing and aerosol [249, 254]. Bio-electrospraying has been used to process mature cell 
types such as smooth muscle cells [255], kidney cells [256], lymphocytes [257] and neuronal cells 
[253] with more than 70% viability after one week of culture [255]. A few studies have attempted to 
electrospray stem cells [258]. A disadvantage is that, although bio-electrospraying forms fine cell-
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bearing droplets and residues, the flow rate is low (approximately 6 mL/h). The advantage of this 
technique, however, is that it is an alternative and novel approach for cell handling. 
 
1.11.2 Surface acoustic waves (SAW) 
 
 
A surface acoustic wave is an acoustic wave that travels along a surface; the use of surface acoustic 
waves is an efficient approach for the generation of aerosol droplets [259, 260]. By contrast with 
electrospraying, SAW requires large voltages, similar to those of conventional ultrasonic atomisation, 
which requires bulky and cumbersome transducers necessitating tens of watts of power [261]. 
However, efficient fluid-structural coupling of SAW allow atomisation to be carried out with only      
1 W of power, which is sufficiently small to be powered by small camera or watch batteries. Thus, an 
SAW nebuliser can be packaged into a low-cost compact portable format. An SAW device was used 
in an in vitro lung model by British Pharmacopeia; the SAW device yielded 70–80% lung dose 
efficiency for pulmonary delivery of the short-acting 2-agonist salbutamol
®
, an important 
improvement over the 20–30% efficiency obtained with currently available off-the-shelf inhalers 
[262].  
 
The high frequency and low power of SAW play a significant role in minimising shear damage of 
drug molecules, both of which are serious concerns associated with the use of conventional ultrasonic 
transducers [263, 264]. SAW atomisation has also been employed to generate nanoparticles [265]. In 
this, the advantages of SAW devices is their ability to generate a large number of nanoparticles 
directly from the interfacial destabilisation and atomisation process, simultaneous particle generation 
and pulmonary delivery using the same micro-device can be carried out.  
 
Protein particles of 50–100 nm can likewise be generated in this manner [266]. As this gives a one-
step synthesis of nanoparticles and a device for direct pulmonary administration, it is a more attractive 
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method than other delivery pathways for protein and peptide delivery, given the low protolithic 
activity in the lung. 
1.12 Tissue engineering for lung repair 
 
 
Patients suffering from lung diseases are commonly treated using transplanted lung organs. However, 
the limited number of donors means that lung patients requiring organs die while waiting for 
transplants. Even if organs are available for transplants, the patients need lifelong use of 
immunosuppressive medications and these medications can interact with others, leading to 
complications. These problems focused attention on finding alternatives to organ transplantation, and 
thus tissue engineering was begun. Tissue engineering is the use of combinations of cells, scaffolds 
and other signals to construct living, functioning 3D tissues or organs [267].  
 
The scaffolds for lung tissue need to be elastic, stretchable and compressible through inhalation. 
Ultimately, once new lung tissue has been generated, the scaffold should be degraded and the 
degraded scaffolds should not be toxic and disappear from the lung site. Many strategies have been 
developed to engineer lung tissue by utilising both natural and artificial polymeric scaffolds, including 
polyglycolic acid (PGA) polymer, Pluronic F-127 hydrogels [268], Matrigel [269] and Gelfoam [270].  
 
Porous scaffolds with polyglycolic acid or pluronic (PF-127) were seeded with ovine somatic lung 
progenitor cells; once these had grown in vitro, they were implanted in the back of a nude mouse or 
into an ovine lung wedge resection site. PF-127 scaffolds implanted with somatic lung progenitor 
cells resulted in similar morphology to lung alveolar tissue but there was an inflammatory reaction as 
a response to the scaffold polymer. Despite this, these results hold promise for engineering distal lung 
tissue [268]. Alveolar-like structures were also achieved by using simple porous scaffolds [270]. In 
brief, foetal rat pneumocytes were seeded into gelfoam sponges and then injected into the healthy 
lung of a rat. Angiogenesis produced vascular structures in the sponges and these communicated with 
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native lung vessels; these results confirmed previous studies suggesting that native lung cells could 
generate a morphogenic lung structure [271]. 
Chen and co-workers obtained evidence of organised, ciliated, pseudo-stratified epithelium as well as 
presumptive developing alveoli by growing foetal rat pneumocytes on a collagen-glycosaminoglycan 
scaffold and seeded in vitro for up to 2 weeks [272]. Seeding foetal mouse pneumocytes on Matrigel 
for one week in vitro permitted the construction of alveolar structures, though these were not detected 
on poly-L-lactic acid (PLLA) or poly-lactic-co-glycolic acid (PLGA) matrices [273]. This indicated 
that stem cell culture in a 3D scaffold in medium conducive to lung epithelial development could 
provide an excellent environment for lung regeneration, much better than that accomplished with 
routine tissue culturing [273]. 
 
Coraux et al. in 2005 showed that ESCs seeded on different substrates such as collagen type I, 
collagen type IV, collagen type VI and gelatin in submerged cultures and air-liquid interface produced 
fully differentiated airway epithelium. At day 8, Clara cells were derived from cells grown on 
collagen type I with or without keratinocyte growth factor and retinoic acid; ciliated cells were 
obtained from ESCs grown on collagen type I after air-liquid interface culture. At day 15, Clara cells 
were obtained in other substrates [274]. This suggested that the structure and composition of the 
extracellular matrix were physiological requirements for these tissues [275].  
 
In previous studies, the lung environment supported cell survival, and oxygen diffused through both 
natural and synthetic materials [276, 277].  Therefore the best matrix that can be used to support 
engineered lung tissue is decellularised matrix. Some limitations should be considered before 
selecting between natural matrix and decellularised matrix, though decellularised matrix may be 
degraded in the decellularisation process. Results obtained using decellularized tracheal matrix 
suggest that it may be the best matrix for lung regeneration in the future [278]. 
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1.12.1 Hydrogels as extracellular matrix mimics for 3D cell culture 
 
Although most knowledge in modern biology has been provided from classical 2D cell culture, cells 
reside, proliferate and differentiate in complex 3D microenvironments. Using 3D biodegradable 
scaffolds offers an alternative approach to finding an extracellular matrix (ECM) conducive to 
restructuring the cells, considered an important area of study in current tissue engineering.  
 
Stem cells have unique functions; thus these cells need to reside in the specialised, 3D 
microenvironment that surrounds them in native tissues. The microenvironment components need to 
be positioned in their correct physiological and functional locations, since the interactions between 
those components are essential for the control of stem cell functions [279]. 
 
Several studies have demonstrated a role of the extracellular microenvironment (ECM) in controlling 
cellular behaviour [280-282]. A preferred scaffold with appropriate biochemical and biophysical 
signals can offer structural stability for developing tissues’ cellular behaviour and  function as well as 
providing a temporary platform for cell activities [283]. Because of the major role of matrix 
composition in ESC proliferation, differentiation and behaviour into specific lineages, extensive 
efforts have been devoted to producing biomaterials that behave more like natural extracellular matrix 
(ECM).  
 
The similarities between hydrogels and natural ECM suggested that hydrogels would provide a 3D 
environment to cells in culture similar to that inside the body, and so is an attractive area for tissue 
engineering. Additionally, hydrogels have the best potential for allowing the proper diffusion of 
nutrients and waste to and from tissues due to their high water contents and so providing an ideal 3D 
platform for cell-cell and cell-material communications [284]. Hydrogels are defined as 3D stable 
networks of macroscopic dimensions formed from cross-linked hydrophilic polymers to form 
insoluble polymeric materials that have the ability to swell and retain large amounts of water [285].  
Design and Development of miRNA and stem cell based micro/nano systems as lung disease therapy            L Alhasan  
      
 
42 
 
Various special characteristics of hydrogels have been shown to guide and affect stem cell fate; these 
are their tuneable physical and chemical properties and spatially controlled distribution of bio-stimuli 
[286, 287]. As a result of offering highly hydrated 3D networks of polymers in which cells can attach, 
grow, proliferate and differentiate, hydrogel scaffolds offer interesting opportunities for cell delivery 
and tissue development. It is relatively easy to manipulate the mechanical properties of the hydrogel 
and so provide chemical signals to the cells through a combination of growth factors and mechanical 
signals. Currently, hydrogel scaffolds are being used in attempts to engineer a wide range of tissues 
such as cartilage, bone, muscle, fat, liver and neurons [288]. 
 
1.12.2 Biomaterials for synthesising hydrogels 
 
Polymers are the most frequently used materials for tissue construction because of the ability to 
control their chemical and structural properties, and can be in general categorised into synthetically 
derived and naturally occurring polymers [289]. 
 
Greater understanding of the composition of the ECM in different stem cell niches has stimulated the 
production of synthetic materials and they are produced by the polymeriation of monomers with a 
wide range of properties. These materials offer advantages over natural ones but they also have 
limitations. Synthetic materials are inherently less bioactive but are mechanically strong and can be 
engineered with the desired macro- (shape) and micro-structure (pore size and porosity), as well as 
being modified to possess the desired bioactive properties that facilitate cellular growth and 
organogenesis in a biomimetic manner [290, 291]. The surface properties of synthetic polymers can 
also be engineered to suit specific functions and hence be more beneficial for tissue engineering 
applications. Moreover, degradation rate and mechanical strength are known for many synthetic 
polymers; hence degradation time should not change significantly between hosts.  
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The most popular synthetic polymer in the biomedical field is polyethylene glycol (PEG) due to its 
properties, which include biocompatibility, low immunogenic polymers, protein-resistance and good 
solubility in various solvents [292, 293]. Three dimensional degradable polyethylene glycol (PEG) 
and poly (lactic co-glycolic acid)/poly(l-lactic acid)-based hydrogels have been used in many studies 
for the maintenance and support of complex tissue structures, and for the formation of structures with 
the characteristics of neural tissues, cartilage and liver, in addition to a network of blood vessel-like 
tubules, and for the cultivation and differentiation of stem cells [294]. Moutos et al. in 2006 designed 
a 3D woven scaffold prepared from PGA to mimic the mechanical properties of a native articular 
cartilage [295].  In general, synthetic polymers are hydrophobic and mechanically strong and have 
slower degradation rates than natural polymers [283].  
 
Polyacrylamide/acrylic acid copolymers and polyurethanes (PU) are examples of synthetic 
biomaterials with properties that can be highly modified to affect the behaviour of stem cells. 
Significantly, proteolytic sensitivity can be conferred in these materials by using small peptides with 
enzyme-specific cleavage sequences as cross-linkers in polymer synthesis [296]. Poly (acrylic amide) 
(PAAm), poly (acrylic acid) (PAA) and its derivatives, and poly (vinyl alcohol) (PVA) are synthetic 
polymers used for scaffold construction and have been approved by the USA Food and Drug 
Administration (FDA). PVA has been utilised in pharmaceutical and biomedical applications and 
controlled drug release tests, regeneration of artificial articular cartilage and for a hybrid artificial 
pancreas [297-299]. As implied by the term “synthetic”, they are deficient in the biological 
components of the native extracellular matrix (ECM) [300, 301]. Moreover, during degradation of 
these polymers, weak acids could possibly be produced that could be toxic and cause an adverse 
reaction if they accumulate locally [302]. 
 
Biomaterials derived from natural sources are commonly applied materials in the earliest recorded 
cases of modern tissue engineering [303]. Collagen, fibrinogen, agarose, alginate, hyaluronic acid,  
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glycosaminoglycans (GAGs), hydroxyapatite (HA) etc. are examples of natural biomaterials being 
used in scaffold fabrication. These commonly consist of ECM components and therefore have the 
advantage of being bioactive, biocompatible and with mechanical properties similar to native tissue. 
The similarity between natural biomaterials and native extracellular matrix (ECM), permits the cells 
to interact with these polymers in a natural manner through receptors and signals, and to support the 
correct functioning of cells in attachment, growth, proliferation and differentiation. Agarose, alginate, 
chitosan, hyaluronic acid, gelatin, fibrin glue, collagen derivatives, and acellular tissue matrices are all 
natural materials that have supported ESC differentiation. 
 
 
Polysaccharide and proteins are naturally derived polymers, are potentially recognised by the cells 
and support cell development. The use of polysaccharides for the fabrication of hydrogels is valuable 
not only from a biomimetic prospective but also from a scaffold-processing perspective. These 
polysaccharides have hydroxyl groups and carboxylic acid groups as abundant functional groups, and 
so are amenable to various types of chemical modifications. This composition offers the possibility of 
introducing cross-linkable, cell-specific ligands, or extracellular signalling molecules, such as peptides 
and oligosaccharides, into the polysaccharide precursors of hydrogels that accelerate tissue 
reorganisation. Collagen, hyaluronic acid (HA) and alginate are natural polymers being used for tissue 
engineering to improve surface chemistry and to support cell growth and differentiation of 
embryonic/adult stem cells as a natural polymers [284]. Fibrinogen, fibrin and hyaluronic acid (HA) 
are other examples of derived natural materials introduced for producing 3D scaffolds, mESCs 
differentiation, cellular behaviour and cell signalling [304, 305]. Hyaluronic acid hydrogels have been 
employed to maintain the pluripotency and undifferentiated state of hESCs, after which these cells 
could be differentiated into specific lineages by adding soluble factors into the scaffold [306].  
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HA has also been applied in a nano-structured self-assembling peptide scaffold to stimulate 
osteogenic differentiation of mESCs [307]. However, although fibrinogen, fibrin and HA are available 
commercially, they are usually very costly.  
 
Alginate is a natural polysaccharide that has been used in a wide range of applications, including cell 
encapsulation and drug, antibody and growth factor delivery, due to its biocompatibility and low 
toxicity [308, 309]. Alginate has been used for cell encapsulation and differentiation of both hESCs 
and mESCs [310]. For example, after encapsulation of mESCs in alginate polyl-lysine (PLL), cells 
retained their ability to proliferate [311]. Porous alginates as 3D matrices have also been associated 
with enhanced proliferation of embryonic, mesenchymal and neural stem cells [284]. Indeed, alginate 
is considered to have the simplest as well as the most biocompatible gelling process; however, its lack 
of bio-active moieties and lack of diverse modifications limit its practical applications [312]. 
Furthermore, degradation of alginate causes loss of divalent ions into the surrounding medium, 
discourages protein adsorption and is uncontrollable and unpredictable, and so it is not the best 
biomaterial option [288].  
 
Cellulose is a natural polysaccharide, consisting of glucose repeating units. Because cellulose and its 
derivatives can be degraded by microbial or fungal enzymes in nature, it is regarded as an 
environmentally friendly component. Cellulose is biocompatible and inexpensive [313, 314]. An early 
result with liver cells demonstrated superior adhesive properties of cellulose-based materials 
compared to most polymer surfaces [315]. Several studies have reported the applicability of cellulose-
based materials for culturing cells and for implantation, such as for bone regeneration [316], 
hepatocyte culturing for an artificial liver [317], and expansion of progenitor hematopoietic cells in 
culture [318]. 
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Cellulosic materials are desirable materials for tissue engineering applications because they are 
renewable, inexpensive, biodegradable, photo-cross-linkable, easy to functionalise, biocompatible to 
most stem cells, and have mechanical properties similar to those of soft tissues and organs. Moreover, 
cellulose-based materials have very low water solubility, therefore allowing for better control over 
scaffold design in pharmaceutical and biomaterials applications. These materials can be degraded and 
the products are water-soluble in the body and so disappear from the site where they have been 
implanted. Hydrogen bonds from the hydroxyl groups hold the cellulose chains together, and account 
for the high degree of crystallinity, low solubility and poor cellulose degradation in vivo [314].  
 
Hydroxypropylcellulose (HPC), carboxymethycellulose (CMC) and hydroxypropylmethyl cellulose 
(HPMC) are commonly used cellulose derivatives [319]. HPC has been approved by the US Food and 
Drug Administration (FDA) as an agent for drug delivery. It is soluble in water and many organic 
solvents, and available abundantly at low cost, and this partly contributed to its use in biomedical and 
pharmaceutical applications. In addition, HPC has desirable properties such as biocompatibility, 
biodegradability and cell-responsiveness, which leads to its use as a hydrogel for tissue engineering 
applications.  
 
Generally, materials derived from natural sources are advantageous due to their inherent properties of 
biological recognition, including presentation of receptor-binding ligands and susceptibility to cell-
triggered proteolytic degradation and remodelling. By contrast, common disadvantages of natural 
polymers include variations in degradation rate, batch-to-batch inconsistency and poor mechanical 
strength [300, 302, 320]. Biomaterials play a significant role in cell behaviour. Most important, the 
scaffold must be biodegradable. Biodegradability of polymers is one of the most important factors in 
pharmaceutical and biomaterials, and is needed for functional clinical applications, because after 
implantation the scaffolds must be degradable by the body and changed by native tissue to replace the 
dying cells and so restore the original function. Therefore, scaffolds should support cell growth and 
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differentiation. Furthermore, they must be degraded into metabolites that do not have any toxicity 
effects or immunogenic responses. 
 
Three dimensional scaffolds could collectively play an important role as in-vitro models to expand 
our knowledge about fundamental aspects of tissue biology or to generate systems for drug and 
cosmetics screening [321]. In this regard, the most common compositions of extracellular matrix in 
vivo include collagen, non-collagenous glycoprotein, amino-polysaccharides and proteoglycans, and 
elastin. For synthetic scaffolds to replace these, their biocompatibility has to be raised. 
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1.13 Outline of Thesis  
 
This thesis is presented in a “thesis by chapters” format. Each chapter contains a brief introduction, 
relevant methods, results, and discussion. The outline of the present PhD thesis is as follows: 
Chapter 1 gives a general introduction, an introduction to gene therapy, miRNAs and their 
therapeutics for cancers, information about stem cell types, stem-cell-based tissue engineering and 
their applications for different diseases, including lung tissue ailments and this thesis outline.  
 
Chapter 2 provides a summary of the general materials and experimental methods used in this thesis.  
 
Chapter 3 describes the potentially therapeutic use of miR-126 PEI nanoparticles for lung cancer 
spheroids. In addition, this chapter describes a novel application of liquid marbles in the formation of 
3D structures inside liquid marbles made of polytetrafluoroethylene powder and cell culture medium. 
Liquid marbles are shown to be capable of accommodating A549 cells in a convenient growth 
condition. A case study is then conducted and includes an investigation of miRNA-126 PEI 
nanoparticle treatment for those spheroids. 
 
Chapter 4 describes the rapid enhancement of multi-cellular spheroid assembly by acoustically 
driven micro-centrifugation. In this chapter, the ability of surface acoustic devices to generate multi-
cellular spheroids that can be used in in-vitro experiments is examined. The advantages of this method 
over existing technologies are mentioned. The high efficiency of the method is highlighted. Finally, 
the potential of spheroids that are formed using SAW microfluidic devices for further applications is 
explored.  
 
Chapter 5 describes SAW nebulised delivery of stem cells for the potential treatment of lung disease. 
In this chapter, a novel device constitutes an attractive tool for the delivery of stem cells via inhalation 
for treatment and repair of lung function.  
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Chapter 6 describes stem cell differentiation in hydrogel for lung tissue regeneration. In this chapter, 
a novel 3D scaffold is developed as an extracellular matrix, and used for the immobilisation of ESCs 
to allow them to differentiate into lung epithelial cells in air-liquid interface (ALI) conditions, for 
eventual injection into damaged lung to replace dying cells.  
 
Chapter 7 discusses the major findings and recommends the scope for further exploration of these 
approaches to repair other organs.…………………………………………………………………….
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CHAPTER TWO-General Materials & Methods 
 
This chapter describes general methods used in this study. Specific methods are described in the 
relevant chapters. All materials used in this study are also listed in the appendixes. 
2.1 General Procedures 
All of the glassware used to store solutions was washed using Pyroneg® detergent and rinsed in tap 
water, with a final rinse in deionised water (dH2O). All of the glassware, micropipettes, solutions, 
pipette tips and Eppendorf tubes were sterilised by autoclaving at standard conditions (121°C for 20 
min) before being used. Solutions were prepared in dH2O filtered through a Millipore Milli-Q® water 
system (Liquipure), unless otherwise specified. Small volumes of the solutions were dispensed with 
micropipettes from Finnpipette (Eppendorf Pty Ltd., Australia), using pipettes with ranges of the 
following volumes: 200 μL–1 mL, 20 μL–200 μL, 2.0 μL-20 μL, 0.1 μL–10 μL, and 0.1 μL–2.5 μL. 
Sodium hydroxide (NaOH) and hydrochloric acid (HCl) used to adjust pH were AnalaR grade or 
higher. Chemicals, consumables, software, reagents, commercial kits, antibodie, and common 
equipment’used during this study are itemised in the appendixes. 
2.2 Solution Preparation 
 
2.2.1 Phosphate-Buffered Saline (PBS) 
One tablet of PBS was dissolved in 100 mL of dH2O and sterilised by autoclaving under standard 
conditions. 
 
2.2.2 Ethanol 70%  
Ethanol 96% (74% v/v) was diluted with sterile dH2O. 
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2.2.3 Tris-Acetic Acid-EDTA (TAE) Buffer (50X) 
TAE buffer was prepared by dissolving a mixture of glacial acetic acid (5.17%, w/v), EDTA (1.86%, 
w/v) and Tris-base (24.2%, w/v) in sterile dH2O, and diluting to 1X before use. 
 
2.2.4 Agarose Gel Electrophoresis 
 
2.2.4.1 Preparing Agarose Gel  
For RNA or DNA gel electrophoresis, agarose powder (1.5%, w/v) was dissolved in 1X TAE buffer 
and boiled until completely liquefied. The prepared boiled agarose was allowed to cool on a shaker to 
reach approximately 55°C. It was then poured into a casting tray and allowed to solidify for 30 min 
before use. 
 
2.2.4.2 DNA Loading Preparation 
One volume of 11X loading dye was added to 10 volumes of cDNA sample and mixed with gel 
electrophoresis.  
 
2.2.4.3 Electrophoresis 
The mixture of RNA or cDNA samples and loading dye were loaded into the prepared gel wells. 
Electrophoresis was at 80 V for an appropriate time period. 
 
2.2.4.4 Agarose Gel Staining 
The RNA or DNA gel was stained in ethidium bromide solution with a concentration of 1 mg/mL for 
10 min. The gel was then rinsed with tap water for at least 15 min before viewing. 
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2.2.4.5 Visualisation of RNA & DNA 
RNA or DNA bands in the gel were visualised using ultraviolet (UV) light, and photographed using 
the Gel-Doc System (Biorad). 
2.3 PEI Stock Solution Preparation (10 mg/mL)  
The polyethyleneimine powder was dissolved in sterilised dH2O. The pH of PEI solution was adjusted 
to 7.0 with HCl. The solution was then sterilized using 0.22 µm membrane, and stored at 4°C. 
2.4 Preparation of Buffers for Mouse Embryonic Stem Cells (mESCs) 
 
2.4.1 Gelatin Preparation (0.1%) 
Gelatin (0.1%) was prepared by diluting 5 mL of 2% gelatin stock in 95 mL of sterilised phosphate 
buffer solution (PBS), filtered through a 0.22 µm membrane, aliquoted and stored at 4°C. 
 
2.4.2 Collagenase Type I Solution (100 U/µl) 
Collagenase type I was prepared by dissolving 1 g of collagenase powder in 1 mL Hank’s salt solution 
(HSS). The solution was sterilised by filtration through a 0.22 µm filter, aliquoted and stored at -20°C. 
 
2.4.3 Human/Mouse Activin A Stock Solution (50 µg/mL) 
Activin A was prepared by dissolving 50 µg in 1 mL of 0.1% BSA/PBS, filtered through a 0.22 µm 
membrane, aliquoted into sterile Eppendorf tubes and stored at -20°C. 
 
2.4.4 Mouse Wnt3a Stock Solution (40 µg/mL) 
Wnt3a solution was prepared by dissolving 40 µg in 1 mL of 0.1% BSA/PBS, filtered through a     
0.22 µm filter, aliquoted and stored at -20°C. 
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2.4.5 L-Ascorbic Acid Stock Solution (5mg/mL)  
The L-ascorbic acid solution was prepared by dissolving 5 mg in 1 mL cold TC-H2O and vortexing 
periodically until completely dissolved. The solution was sterilised by filtration, aliquoted and stored 
at 4°C. 
 
2.4.6 Mono-Thioglycerol Stock Solution 
Mono-thioglycerol was prepared by diluting 32 µL of 1-thioglycerol in 100 mL sterilised phosphate 
buffered solution (PBS). The stock solution was diluted immediately to the final working 
concentrations before use. 
 
2.4.7 Heparin Sulphate Salt Solution (1 µg/mL) 
Heparin sulphate salt powder (1 µg) was dissolved in 1 mL sterile dH2O and filtered, aliquoted and 
stored at 4°C. 
 
2.4.7 Preparation of Growth Factor (F0291) 
Growth factor F0291 was reconstituted by dissolving 25 µg in 1 mL filtered 20 mM Tris, pH 7.0, 
aliquoted into sterile Eppendorf tubes and stored at -20°C. The stock solution was diluted 
immediately before use to the final working concentration. 
2.5 Preparation of Buffer Solutions for Immunofluorescence Assays 
 
3.5.1 Bovine Serum Albumin (BSA) solution (1%) 
BSA was prepared by dissolving 1 g of BSA in 100 mL sterile phosphate buffer solution (PBS) and 
stored at 4°C. 
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2.5.2 Tween-20 (0.05%) 
Tween-20 solution was prepared by diluting 50 µL Tween-20 in 100 mL sterilised phosphate buffer 
solution and stored at room temperature.  
 
2.5.3 Triton -100X (0.5%) 
Triton-100X was prepared by diluting 0.5 mL in 100 mL sterilised phosphate buffer solutions (PBS) 
and stored at room temperature. 
 
2.5.4 DAPI Solution (1µg/mL) 
DAPI powder (1 µg) was dissolved in 1 mL sterilised dH2O, protected from the light, and stored at  
-20°C.  
2.6 Inactivation of Foetal Bovine Serum (FBS) 
The following procedure was performed to extinguish heat-labile complement prior to using FBS in a 
tissue culture cell line medium. An FBS (500 mL) bottle at -80°C was thawed at 4°C overnight. The 
following day, the FBS bottle was incubated in a water bath at 37°C until it thawed completely. The 
bottle was aliquoted into conical 50 mL tubes, which were incubated in a water bath at 56°C for 30 
min. The tubes were removed from the water bath and allowed to cool down at room temperature for 
one hour. The FBS tubes were stored at -20°C and FBS was through a 0.22 µm membrane before use. 
2.7 Cell Culture Techniques 
All procedures for tissue culture were performed in a biological safety cabinet Class II to reduce the 
risk of contamination. All solutions and buffers were sterilised twice by autoclaving. All materials 
were wiped with 70% ethanol and sterilised with ultraviolet light for 20 min before use in the 
experiments. 
 
Design and Development of miRNA and stem cell based micro/nano systems as lung disease therapy            L Alhasan 
 
55 
 
All tissue culture media, non-essential amino acids, and TrypLE select enzyme were stored at 
4°C.  Foetal bovine serum (FBS), 0.05% trypsin-EDTA, growth factor supplements and penicillin-
streptomycin were stored at -20°C unless specified otherwise. 
 
2.7.1 Cell Culture Growth Conditions 
All tissue culture protocols were performed carefully using sterile techniques with clean, detergent-
free, sterile glassware. Before use, media and solutions were pre-warmed at 37°C in a water bath. All 
cell lines were routinely seeded in 25 cm
3
 or 75 cm
3
 tissue culture flasks, six-well microtitre plates or 
in 35 cm
2
 area Petri dishes containing the appropriate medium.  
 
Cell cultures were incubated at 37°C with 5% CO2 overnight before being used in an experiment. The 
cell cultures were regularly tested and confirmed to be mycoplasma-free using a Mycofluor Detection 
Kit. No mycoplasma infection was identified in any of the cell cultures during the work in this thesis. 
 
2.7.2 Cell Lines 
Cell lines used in this project were lung cancer cells (A549), breast cancer cells (BT474), rat 
mesenchymal stem cells and mouse embryonic stem cells (E14TG2A). Cell cultures were monitored 
visually with an inverted phase-contrast microscope and each cell line was cultured as described in the 
relevant chapter. 
 
2.7.2.1 Cell Counting 
Cells were quantified using a Countess® Automated Cell Counter (Invitrogen, Australia) according to 
the manufacturer’s protocol to determine the total number of cells and their viability. In brief, 10 μL 
of cells in suspension was added to 10 μL of 0.4% Trypan blue dye and 10 μL of this mixture was 
loaded into a counting chamber. 
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2.7.2.2 Cryopreservation of Cell Lines 
Lung cancer cells A549, breast cancer cells BT474, rat mesenchymal stem cells (MSCs) and murine 
embryonic stem cell (E14TG2A) pellets were resuspended to a concentration of 2×10
6
 cells/mL in 
freezing medium containing 30 % (v/v) FBS and 1% (v/v) penicillin/streptomycin or gentamicin and 
10% (v/v) dimethyl sulfoxide (DMSO). Cells were aliquoted to polypropylene cryovials, stored at  
-80°C overnight in an isopropanol chamber and then placed in liquid nitrogen (-196ºC) for long-term 
storage. 
 
2.7.2.3 Thawing Cell Lines 
Frozen cells were removed from liquid nitrogen, sprayed with 70% ethanol and transferred to 10 mL 
tube containing complete medium. Cells were centrifuged for five minutes. The supernatants were 
aspirated and each cell pellet was resuspended in 1 mL of growth medium and then reseeded into 75 
cm
2
 tissue culture flasks. 
…………
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                                            CHAPTER THREE 
Liquid marble micro-bioreactor for miRNA transfection 
3.1 Introduction 
 
 
Liquid marble (LM) is a soft solid-like droplet made from encapsulating aqueous liquid droplet with 
hydrophobic powder [322]. The flexible powder shell of LM allows the droplet to be split and 
merged, as well as allowing liquid to be introduced into or extracted from the LM. The unique 
properties of LM can be utilised to control chemical and biochemical reactions that occur within LM, 
making LM an attractive reactor vessel [154]. LM can act as a miniature bioreactor; with its non-
adhesive shell promoting cell-to-cell interaction, thereby facilitating the formation of spheroids from 
cancer cells as well as the formation of embryoid bodies from ESCs [151, 153, 154]. Cancer spheroids 
are well regarded as in-vitro models for the evaluation of drugs, as the cell-cell and cell-extracellular 
matrix (ECM) interactions within three-dimensional (3D) spheroids better represent the in-vivo 
microenvironment than in conventional monolayer cultures. Compared with monolayer cultures,      
3D spheroids allow longer observations periods, which is advantageous for studying time-dependent 
gene expression resulting from non-viral gene delivery vectors. In particular, this applies to polymeric 
gene delivery systems, which release genes slowly after their delivery inside cells or tissues [323]. 
 
MiRNAs are collectively a class of non-coding RNA; they consist of 20 – 25 nucleotides that function 
as gene regulators by cleaving and/or inhibiting the translation of target messenger RNA (mRNA) [4], 
as well as simultaneously regulating a broad set of genes of interest [5]. Due to their ability to trigger 
synergistic therapeutic effects in cancer, miRNAs have recently emerged as a new class of cancer 
therapeutic. MiRNAs are also involved in many cellular and physiological processes, including 
differentiation, proliferation and the maintenance of metabolic homeostasis [324-326]. 
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Many applications of miRNA require miRNA to be transfected into cells. However, the use of 
miRNAs is limited due to their poor stability and integrity. Naked miRNAs are susceptible to 
nucleases and are often degraded in serum prior to transfection. In addition, miRNAs are expensive 
and are usually present in only small quantities. Many strategies have been devised to improve the 
transfection efficiency of miRNAs; for example, nanoparticle carriers are often used to deliver 
miRNAs [5]. However, little attention has been paid to developing and improving the vessel or 
‘reactor’ where the transfection ‘reaction’ occurs.  
 
In this study, the use of LM as a miniature reactor to generate an in-vitro tumour model, namely a 
cancer spheroid, was investigated, and its use as a miniature reactor to enhance miRNA transfection 
was evaluated. 
3.2 Methods  
 
 
3.2.1 Cell culture 
 
The human non-small cell lung cancer line A549 was obtained from cryostored stocks in the School 
of Medical Sciences, RMIT University, and routinely cultured in RPMI 1640 medium containing 10% 
fetal bovine serum (Gibco, Australia) at 37°C in a humidified atmosphere containing 5% CO2. 
3.2.2 Generation of lung multicellular spheroids  
 
LM micro-bioreactors containing human lung carcinoma cells (A549) were prepared according to 
previous protocols [151, 153]. In brief, a 300 l drop of cell suspension was placed on a 
polytetrafluoroethylene (PTFE) powder bed and was swirled gently until a marble was formed 
(Figure 3.1). Cells were allowed to further incubate inside LM for another 7 days to obtain cancer 
spheroids. As a control, cancer spheroids were prepared using a liquid suspension (LS) method, in 
which A549 cells were allowed to aggregate to form spheroids in ultra-low attachment 96-well plates 
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(Corning Costar). In addition, an LM array was generated for use in different assays, as shown in 
Figure 3.2. Samples were taken from the LM at different times and compared with the control.  
 
 
 
Figure 3.1: Preparation of lung spheroids using liquid marble. The liquid containing the suspended 
A549 cells in the growth medium was placed on the hydrophobic powder bed where the liquid beads 
up due to the high hydrophobicity of the powder. The drop was then rolled on the powder bed to 
cover it with the hydrophobic powder. The Petri dish containing the resulting liquid marble was then 
placed inside a second Petri dish that was half filled with sterile water and incubated at 37ºC for 7 
days.  
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  Figure 3.2: Liquid marble array for different assays. 
 
3.2.3 Spheroid viability and morphology 
 
 
A Live/Dead cytotoxicity kit (Life Technologies) containing Calcein-AM and propidium iodide (PI) 
was used to evaluate the viability of lung multicellular spheroids [327]. Liquid marble containing  
10
5
 cells/ ml was formed and incubated by adding 50 µl fresh medium every 2-3 days; liquid 
suspension cultures served as controls. Seven days later, spheroids were collected from the liquid 
marble and placed in a new Petri dish with a diameter 35 mm, and stained with Calcein and PI. Dead 
cells were imaged by the inclusion of the PI fluorophore in the medium. Images of live (green) and 
dead (red) cells were acquired by laser confocal fluorescence microscopy (Nikon A1R) using a Nikon 
Eclipse Ti Fluorescence Microscope. 
The diameter of the spheroids was measured using ImageJ (National Institutes of Health, Bethesda, 
MD). The irregularity parameter IP, defined as the ratio of the diameter of the minimum 
circumscribed circle D to that of the maximum inscribed circle d, i.e. IP  D/d [328], was used as an 
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indicator to evaluate the circularity of a spheroid; an IP with a value of 1 indicates a perfect circle, 
whereas a larger IP value indicates that the spheroid exhibits irregular morphology [328].  
3.2.4 Complexation of PEI and miR-126  
 
 
MiR-126 with the sequences 5’ UCGUACCGUGAGUAAUAAUGCG ’3 and  
5’ CAUUAUUACUUUUGGUACGCG ’3 [329] was employed as a model drug. To protect the   
miR-126 from nuclease degradation in serum, anionic charge miR-126 was complexed with either 
cationic charge Lipofectamine RNAiMAX transfection reagent or cationic charge linear 
polyethylenimine (PEI, MW 25,000) at a Nitrogen/Phosphate (N/P) ratio of 33:1 to form 
nanoparticles via polyelectrolyte interaction. PEI and lipofectamine both served as delivery vehicles 
to protect miRNA against degradation by nucleases in serum.   
 
PEI/miR-126 complexes were prepared essentially as described previously for siRNAs [330, 331].   In 
brief, 1 µg miRNA was dissolved in 75 µL 10 mol/L HEPES/150 mmol/L NaCl, pH 7.4, and 
incubated for 30 minutes on ice. Ten microliters of PEI (4.3 µg/µL) was dissolved in 75 µL of the 
same buffer, and after 10 minutes, pipetted into the miRNA solution. This resulted in an N/P ratio = 
33, which was previously determined as optimal for siRNAs [330].  
3.2.5 Measurement of size and charge of particles 
 
 
Size and charge of miR-126 containing PEI were measured using a Zetasizer Nano ZS (Malvern 
Instruments, Malvern, UK). The samples for testing were prepared in triplicate and measured at 20°C. 
The surface charge of miR-126 containing PEI nanoparticles was measured using its Zeta potential in 
triplicate. Malvern software was used to calculate the Zeta potential and the mean ± standard 
deviation was calculated. 
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3.2.6 Transfection of mature miR-126 containing PEI nanoparticles 
 
 
Lung cancer spheroids were formed using liquid marble and liquid suspension methods in RPMI 1640 
medium supplemented with 10% FBS. The monolayer cells and multicellular spheroids were 
incubated at 37°C in a humidified incubator atmosphere containing 5% CO2 overnight. The next day, 
Opti-MEM® I reduced serum medium was added along with miR-126 nanoparticles and 
lipofectamine and incubated for 24 hours; miR-126 delivered by Lipofectamine® RNAiMAX 
Transfection Reagent was used as a positive control. Transfection of miR-126 via Lipofectamine® 
RNAiMAX Transfection Reagent was performed according to the manufacturer’s protocol. In brief, 
4.5 µl of lipofectamine was mixed with 75 µl Opti-MEM medium and incubated for 10 min. Then 1 
µg of miR-126 was mixed with 75 µl Opti-MEM medium. Diluted lipofectamine was added to diluted 
miR-126 and incubated for 5 min at room temperature. Ten microlitres of mature miR-126 
lipofectamine 2000 complex was added to 100 µl of monolayer and spheroid cultures by following the 
same procedure as for miR-126 PEI nanoparticles. Untreated cells treated with scrambled miRNA 
precursor with no target transfected with PEI and lipofectamine 2000 served as a negative control. 
 
3.2.7 Measurement of VEGF-A protein expression  
 
 
Immunofluorescence staining was performed on monolayer and spheroid A549 cells to detect total 
VEGF-A. Spheroids were collected from liquid marble by pipetting into Eppendorf tubes and washed 
with PBS (2 x 5 min) by centrifugation to avoid losing the spheroids.  The collected spheroids were 
fixed with 4% paraformaldehyde solution at room temperature for 30 min and subsequently washed 
twice by soaking the sample in washing buffer comprising 0.05% Tween-20 in PBS for 10 min each. 
The spheroids were next permeabilised using 0.5% Triton X-100 in PBS for 20 min at room 
temperature, followed by blocking in a solution containing 1% BSA in PBS for 1 hour at room 
temperature. The samples were then washed three times with washing buffer for 10 min each, 
followed by incubation for 1 hour at room temperature with vascular endothelial growth factor 
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(VEGF-A) primary antibody diluted in blocking solution (1:100). The samples were again washed 
three times with washing buffer for 10 min each. The samples were incubated with secondary 
antibodies (1:1000) for 1 hour at room temperature, followed by washing three times with washing 
buffer for 10 min each. The cell nuclei were then counterstained with 4’,6-diamidino-2-phenylindole 
dihydrochloride (DAPI, blue)(1:2000) for 5 min. Finally, the sample was again washed three times 
with washing buffer for 10 min each time prior to analysis using laser scanning confocal microscopy 
(LSCM). Monolayer A549 cells served as the control, and were similarly stained using the 
immunofluorescence staining protocol. During imaging using laser scanning confocal microscopy 
(LSCM), PBS was replenished periodically to prevent drying of the spheroids. 
 
3.2.8 Quantification of mature miR-126 and VEGF-A expression by TaqMan-qPCR 
assay 
 
 
After transfection (24 hours), cells were washed with 1 X PBS and RNA was extracted using an 
RNeasy Mini Kit (Qiagen, Australia) according to the manufacturer’s protocol. To determine miR-
126 expression, total RNA was transcribed into cDNA using a TaqMan MicroRNA Reverse 
Transcription Kit (Applied Biosystems, 433596). The qPCR amplifications of cDNA were measured 
by TaqMan miRNA assay (Applied Biosystems, assay ID 000451). Mature miR-126 expression was 
measured by ∆∆CT and normalised to RNU44 (Applied Biosystems, assay ID 001094) as an 
endogenous control in the tested samples, relative to the untreated samples. To determine VEGF-A 
expression at the miRNA level, RNA was transcribed into cDNA by the QuantiTect reverse 
transcription kit (Qiagen, Australia). qPCR (Rotor-Gene, Qiagen Pty Ltd, Australia) with default 
settings was performed using an activation start cycle for 10 min at 95°C, followed by 40 cycles of 15 
seconds at 95°C and 60 seconds at 60°C and 30 seconds at 72°C . The VEGF-A expression (Applied 
Biosystems, assay ID Hs00900055_m1) was normalised to GAPDH (Applied Biosystems, assay ID 
Hs02758991_g1) and the experiment was conducted in triplicate. Relative gene expression values 
were determined by the ∆∆CT method [332]. 
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3.2.9 Cellular uptake of miR-126 PEI nanoparticles in A549 cells 
 
 
The cellular uptake of mature miR-126 PEI nanoparticles was measured using LSCM. A549 cells, as 
a monolayer or spheroids, were transfected with fluorescently labelled miRNA (Dharmacon Miridian 
miRNA-Dy547) containing PEI for 24 hours to measure cell uptake efficiency. Monolayer cells were 
fixed with 4% paraformaldehyde, washed twice with washing buffer and permeabilised using 0.5% 
Triton X-100 in PBS for 2 min at room temperature, followed by blocking in a solution containing 1% 
BSA in PBS for 30 min at room temperature. Cells were then washed three times with washing buffer 
for 5 min each, followed by incubation for 1 hour at room temperature with Vinculin primary 
antibody (Millipore), diluted in blocking solution (1:100) and again washed three times with washing 
buffer for 5 min each. Cells were incubated with mouse secondary antibodies (1:1000) for 30 min at 
room temperature, followed by washing three times with washing buffer for 5 min each. The cell 
nuclei were then counterstained by DAPI (1:2000) for 5 min. Finally, cells were again washed three 
times with washing buffer for 5 min each prior to analysis using LSCM. Monolayer A549 cells served 
as a control. Calcein-AM was added to spheroids generated using liquid marble (LM) and liquid 
suspension (LS), incubated for 20 min and observed by LSCM.  
3.2.10 Statistical analysis 
 
 
The differences between the treatments were analysed for significance using one-way analysis of 
variance with post-hoc Duncan’s multiple range tests at specific times and doses. A Student’s t-test 
was used to analyse differences between two groups, using GraphPad Prism version 6.01 (GraphPad 
Prism software Inc., La Jolla, CA, USA). Experiments were performed independently at least three 
times. All values are expressed as mean ± standard deviation. Differences between treatments were 
considered significant at p< 0.05. 
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3.3 Results and Discussion  
 
 
3.3.1 Cell culture, generation of spheroids and spheroid viability and morphology 
 
Both liquid marble (LM) and liquid suspension (LS) methods resulted in cells aggregating to form 
spheroids. Consistent with a previous study [153], spheroids generated from LM were a spherical 
shape (Figure 3.3A), whereas spheroids generated from LS were more irregular shapes (Figure 
3.3B).  The irregular parameter (IP) value of LM spheroids was approximately half that of LS 
spheroids and the difference increased with period of culture (Figure 3.3C). 
 
 
 
Figure 3.3: Generation of lung cancer A549 spheroids at 2×104/100 µl
 
cell seeding density
 
by liquid 
marble (A) and liquid suspension (B) methods after 7 days incubation. Scale bar represents 100 µm. 
C. Irregular parameter (IP) values for liquid marble and liquid suspension cells over time. 
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In both LM and LS generated spheroids, the periphery of the spheroids was populated by viable cells 
(stained green) in a viability assay using Calcein AM and propidium iodide (PI). PI is impermeable to 
live cells (hence they stain green), but penetrates through dead cells’ leaky membranes and stains the 
nuclei red [333]. There was an absence of color in the spheroid core, whereas red staining was 
expected from previous research showing necrotic cores in spheroids [11, 323, 334]. Such necrotic 
cores are a typical feature of cancer tumors and spheroids, especially older and larger spheroids in 
which oxygen and nutrient transport is limited by diffusion, resulting in a core populated by dead cells 
[11, 334]. The anomalous absence of central spheroid staining found here is possibly because PI 
penetration into the spheroid core was blocked by tight cohesion of the live cells around the spheroid 
surface. 
 
3.3.2 Complexation of PEI and miR-126 and measurement of size and charge of 
particles 
 
MicroRNA-126 (miR-126) is a microRNA that is highly expressed in vascular endothelial cells [335]. 
A reduction in miR-126 was associated with increased capillary density in lung cancer, whereas the 
restoration of miR-126 suppressed lung cancer though down-regulating vascular endothelial growth 
factor A (VEGF-A) expression and microvessel density (MVD) [336].  
 
The hydrodynamic size of PEI-miR-126 complexes was 234.7  3.8 nm, and the Zeta potential was 
14.2  1.1 mV (Figure 3.4). By contrast, the Zeta potential of free miR-126 complexes was negative. 
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Figure 3.4: Mean size (nm) and Zeta potential (mV) of miR-126 PEI complexes (NP33) prepared 
using phosphate-buffered saline (PBS). A. Size of miR-126 PEI nanoparticles, B. Charge of free miR-
126 and miR-126 PEI-nanoparticle complexes. The difference between treatments was analysed by 
Student’s t-test and considered significant at p <0.05. 
 
3.3.3 Transfection and Quantification of mature miR-126 containing PEI nanoparticles 
 
To evaluate the performance of LM as a bioreactor, nanoparticles containing 1 g of miR-126 were 
transfected to four groups of cells for comparison. The four groups were (1) spheroids generated using 
LM and transfected inside LM, (2) spheroids generated using LM and transferred to ultra-low 
attachment plates for transfection, (3) monolayer cells cultured on tissue culture plates (TCP), and (4) 
spheroids generated using the LS method and then transfected in ultra-low attachment plates. For 
miR-126 transfection in LM (1), the nanoparticles were introduced into the LM by simple injection 
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using a pipette. At 24 hours post-transfection, the miR-126 expression of cells inside spheroids was 
quantified using real-time polymerase chain reaction (qPCR). The VEGF-A expression from 
spheroids was also quantified using qPCR. 
 
In general, spheroids treated with PEI nanoparticles showed greater miR-126 expression than in those 
treated with lipofectamine nanoparticles, indicating that PEI had greater transfection efficiency 
(Figure 3.5).  
 
 
Figure 3.5: Mature miR-126 expression 24 hours after transfection with miR-126 PEI and 
lipofectamine. Data are mean ± standard deviation (n=3) and were analysed by unpaired Student’s t-
test (one-tailed). (A) Control cells, (B) Spheroids (LS), (C) Spheroids (LM), (D) Spheroids generated 
using liquid marble and then transferred into low adhesion 96-well plates for transfection. 
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In micro-bioreactor performance, LM-generated and transfected spheroids showed the greatest miR-
126 expression, followed in turn by spheroids generated in LM but transfected in ultra-low attachment 
plates, cells in monolayers and lastly LS spheroids, with the least miR-126 expression. 
 
To evaluate if the up-regulated miR-126 expression in LM was specific to nanoparticle-miR-126 
delivery or is an artifact, spheroids were transfected separately with nanoparticles containing pre-
miR (negative control). Pre-miR contains miRNA precursor with a scrambled sequence that does 
not target any human gene products specifically. As a second negative control, the miR-126 
expression in untreated spheroids was also assessed.  
 
There was negligible miR-126 expression from the two negative controls, namely untreated spheroids 
and spheroids that received scrambled miRNA, thus confirming that the miR-126 expression observed 
was specific to nanoparticlemiR-126 transfection. Cells in monolayers showed greater miR-126 
expression than those in spheroids generated using LS.  
 
Interestingly, miR-126 was highly expressed in spheroids generated using LM, and especially more 
highly in spheroids that were transfected inside LM. Yet spheroids are often reported to be more 
resistant to chemotherapeutic drug uptake than monolayer cells, due to a variety of reasons including 
differences in cell-cell communication, cell shape and/or ability of spheroid to repair damage [337].  
A study by Saleh et al. reported that spheroids showed less plasmid DNA uptake than monolayer cells 
and suggested that the major barrier for DNA transfection was limited DNA penetration into deep 
regions of the spheroids [338]. By contrast, while most drugs are less effective in killing cancer cells 
in spheroids than in monolayers, some studies have reported that drugs such as Thiotepa (MW 189) 
and Bortezomib (PS341, MW 384.2) are equally or more effective against cells in spheroids than in 
monolayers [339, 340]. The effectiveness of such drugs is thought to be associated with their small 
molecular weight, and so these drugs penetrate better into spheroids [339]. 
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The spheroid generation method may affect transfection efficiency. In these experiments, miR-126 
was much smaller than plasmid DNA and many conventional drug systems. One would expect miR-
126 to be able to penetrate deeply into spheroids and show equal or higher transfection than in 
monolayers. Interestingly, spheroids showed greater miR-126 expression than did monolayer cells 
(Figure 3.5), but only in spheroids generated using the LM method and not in spheroids generated 
using the LS method. These results indicate that small molecular weight is not the only factor that 
influences miRNA transection  the method used to generate spheroids also influences the subsequent 
transfection.  
 
Spheroid shape may also affect miRNA uptake. The shape of LM-generated spheroids was more 
regular and spherical, and cell viability was greater, than in LS-generated spheroids. After 
transplantation, hepatocytes in the spheroid form showed longer survival and a greater survival rate 
than those with the conventional shape [341]. A previous study on embryoid bodies (EBs) - spheroids 
formed by aggregating ESCs  also observed that LM-generated EBs, which are homogeneous in size 
and shape, contained greater numbers of viable cells than LS-generated EBs, which were often 
irregular in size and shape [153], probably because regularly shaped spheroids have even nutrient 
diffusion, gas diffusion and waste removal. Therefore, the differences in miR-126 expression between 
LM spheroids and LS spheroids could be because cells in LM spheroids have greater viability, and 
only viable cells expressed miRNA after transfection. 
 
For LM-generated spheroids, the miR-126 expression in those transfected in LM was greater than in 
those transfected in the ultra-low attachment plate, especially when the delivery vehicle being used 
was PEI (p < 0.0098). This suggests that the properties of transfection vessels also play a role in 
influencing miRNA transfection.  
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3.3.4 Cellular uptake 
 
 
To better understand the reasons for the high miRNA transfection in LM-generated and transfected 
spheroids, fluorescently labelled miRNA (Dharmacon Miridian miRNA-Dy547) was used for 
transfection. Cellular uptake of PEI-miRNA-Dy547 was monitored at 24 hours post-transfection. 
Monolayer cells and LS spheroids were used as controls; both of these stained with Calcein AM 
(green) for visualisation. 
 
Representative confocal microscopy images in Figure 3.6 show that very little miRNA-Dy547s (red) 
had internalised into LS spheroids, and it was found only near the periphery of LS spheroids. By 
contrast, more miRNA-Dy547 internalised into LM-generated but ultra-low attachment plate-
transfected spheroids; however, the internalized miRNA-Dy547 was again only localised at the 
periphery of the spheroids. As explained earlier, the high transfection in LM spheroids may be due to 
a more regular shape and thus greater viability than LS spheroids. Compared with the controls (LS 
spheroids and monolayer cells) and spheroids generated in LM but transfected in ultra-low attachment 
plates, more miRNA-Dy547 was taken up in LM-generated and transfected spheroids, both at the 
periphery and penetrating deeply into the core. These results revealed that the high miR-126 
expression found in LM-generated and transfected spheroids was due to high miRNA uptake. The 
high miRNA uptake was only observed in LM-transfected spheroids and not in LM-generated but 
ultra-low attachment plate-transfected spheroids, indicating that LM, as a vessel, also plays a key role 
in transfection. Many studies have reported that PTFE, the materials that made up liquid marble 
shell, is non-adhesive. It is likely that such non-adhesive properties contribute to high miRNA 
transfection by not absorbing any miRNA, whereas ultra-low attachment plate comparatively 
absorbs more miRNA as shown in Figure 3.6, thus lead to lower miRNA uptake as less 
miRNA is available to the spheroid [151, 153, 342]. 
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Figure 3.6: Confocal microscopy analysis of cellular uptake of miRNA-Dy547 containing PEI 
nanoparticles. Left side: A: Monolayer cells, B: Cells from liquid suspension method, C: Cells from 
liquid marble method transfected with miRNA-Dy547, D: spheroids formed using liquid marble and 
transferred to 96-well plate to be transfected. Right side: well plate only. Scale bar represent 100 µm. 
 
PTFE, which constitutes the LM shell, resists protein adhesion due to its ultra-low surface free energy 
and high hydrophobicity, with a water contact angle of 108[343, 344]. The anti-adhesive LM shell 
therefore inhibits non-specific absorption of miRNA into the shell and does not waste any miRNA in 
surface binding. The hydrophobic PTFE/water interface is negatively charged [345]. A statistical 
model proposed by England and Pande suggested that a hydrophobic and charged surface drives the 
surrounding water to reorganise; such forces may play a vital role in protein folding in vivo [346]. 
 The PTFE interface of the LM, which presents as a 3D sphere, may drive reorganisation of its 
confined water molecules in a way that promotes movement of hydrophilic miRNA towards the LM 
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core where spheroids are located, and subsequently enhances spheroids’ miRNA uptake. This can be 
demonstrated by the fact that more miRNA-Dy547 aggregated at the periphery of LM-generated and 
transfected spheroids than in LM-generated but ultra-low attachment plate-transfected spheroids, 
indicating that LM was a better transfection vessel than ultra-low attachment plates. 
 
In addition, the spent medium collected at the end of the transfection experiment from the LM 
bioreactor had the least amount of un-transfected miRNA-Dy547, indicating that most of the miRNA-
Dy547 had internalized into the spheroids; this explained why LM-generated and transfected 
spheroids showed the greatest miRNA expression. The spent medium from LS spheroids had the 
greatest amount of un-transfected miRNA-Dy547, as expected from the LS spheroids showing the 
least miRNA expression. Monolayer cells and LM-generated but low ultra-low attachment plate-
transfected spheroids had similar amounts of un-transfected miRNA-Dy547 in their spent medium. 
 
These results confirmed that LM performed better as a transfection vessel than ultra-low attachment 
plates. Ultra-low attachment plates have commonly been used for various gene transfection studies 
[347, 348] due to their biological inertness. The ultra-low attachment plates are covalently bonded 
with hydrophilic and neutrally charged hydrogel layers that inhibit cellular attachment and protein 
adsorption. Unlike the LM PTFE interface, which confines aqueous transfection reagents in a 3D 
context, the hydrogel layers on ultra-low attachment plates are only present at the bottoms and sides 
of the wells; these hydrogel layers are abundant in hydrogen bonds that do not distort the orientation 
of water molecules, unlike the hydrophobic PTFE interface. 
 
3.3.5 Measurement of VEGF-A protein expression 
 
Representative images of immunostaining in Figure 3.7 show that after miR-126 transfection, the 
level of VEGF-A (green) was low in A549 cells, regardless of whether cells were cultured in 
monolayers or in spheroids. These results are similar to those of others, in which it was reported that 
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miR-126 transfection led to down-regulation of VEGF-A in A549 cells [349]. The greater the miR-
126 transfection, the less was the resulting VEGF-A protein expression. 
 
Figure 3.7: Immunostaining of VEGF-A expression 24 hours post-transfection. Monolayers (A) and 
spheroids (B) in the liquid marble method were transfected with miR-126 PEI complexes at NP=33 
ratio, miR-Lipofectamine. Scale bar represents 100 µm. 
 
 
3.3.6 Quantification of VEGF-A expression by TaqMan-qPCR assay 
 
Quantitative qPCR analysis in Figure 3.8  demonstrated that LM-generated and transfected spheroids 
showed the least VEGF-A expression, followed in turn by spheroids generated in LM but transfected 
in ultra-low attachment plates, cells in monolayers and then LS spheroids, in order of increasing 
VEGF-A expression. These results agree with the earlier miR-126 transfection results, where LM-
generated and transfected spheroids showed the greatest miRNA transfection and expressed the least 
level of VEGF-A, compared with the controls.  
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Some studies suggested that miRNA and protein expression does not always correlated with each 
other. An increase in miRNA levels may not lead to increase protein levels because of various levels 
of post-transcriptional and post-translational regulation, the amount of transcript does not always 
correlate with the amount of protein produces. In addition, there is a huge variability in this 
correlation for different genes, where some correlate better than others. This may be the reason why 
the expression levels of VEGF-A and miR-126 do not correlate with each other [350-352]. 
This suggests again that LM is an ideal bioreactor vessel for miRNA transfection.  
 
In addition, cells transfected by PEI-miR-126 expressed less VEGF-A level than those transfected by 
lipofectamine, confirming that PEI was more efficient in transfecting miR-126, thus leading to lower 
VEGF-A expression.  Cells or spheroids that received scrambled miRNA showed negligible change in 
VEGF-A expression from the control. 
 
 
Figure 3.8: VEGF-A expression at 24 hours of A549 cells. Cells were transfected with miR-126 PEI 
complexes at N/P=33, miRNA-Lipofectamine, Negative Control polyethylenimine (NC-PEI), 
Negative Control Lipofectamine (NC-Lipofectamine), Data are shown as mean (n =3) ± standard 
error of the mean and were compared by Student’s t-test with controls. A Monolayer cells, B 
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Spheroids (liquid suspension), C Spheroids (liquid marble), D Spheroids generated by liquid marble 
method and then transferred into well plates for transfection. 
 
3.4 Conclusion 
 
 
In summary, A549 lung cancer spheroids were generated by a LM microbioreactor and the spheroids 
were subjected to miR-126 transfection inside the LM. The miR-126 expression and the subsequent 
VEGF-A down-regulation in LM transfected spheroids reached a greater level than in various 
controls: monolayer cells, spheroids generated using the LS method, and LM-generated spheroids that 
were transfected in a conventional ultra-low attachment plate. There are multiple possible reasons for 
the greater miRNA expression observed in the LM bioreactor. First of all, miRNA is much smaller 
than many chemotherapeutic drugs and thus penetrated well into spheroids. Secondly, the PTFE shell 
possesses ultra-low surface free energy and so does not absorb and waste any miRNA through non-
specific adsorption. Lastly, the hydrophobic interface present on the LM shell may play a role in 
promoting the movement of hydrophilic miRNA towards the centre of the LM where spheroids 
resided. Overall, this study demonstrates that LM can serve not only as a platform that produces 
tumour-like spheroids, but also as an efficient microbioreactor vessel that enhances miRNA 
transfection and outperforms conventional transfection vessels. 
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                                                              CHAPTER FOUR 
Rapid Enhancement of Multicellular Spheroid Assembly by Acoustically-Driven 
Microcentrifugation 
4.1   Introduction 
 
Multicellular spheroids, comprising three-dimensional spherical cell aggregates displaying cell–cell 
and cell–matrix interactions, more closely mimic in vivo avascular tumor structure and functionality 
than conventional monolayer cultures, in which intercellular contact is often lost [9, 10]. They are 
therefore of fundamental importance to studies in cancer biology, metastasis and invasion, in addition 
to therapeutic screening [11, 12, 353]. Multicellular spheroids have also been shown to play a role in 
improving the differentiation efficiency of mesenchymal stem cells [354, 355].  
 
Various techniques have been used to produce these spheroids, all of which involve first the formation 
of loose cell aggregates followed by their compaction into a tight spheroidal cluster [10]; the different 
approaches vary primarily in the way the cells are driven to aggregate, and the method by which 
intercellular adhesion is promoted by preventing cell adhesion to the surface of a tissue culture dish 
[153]. The most widely used spheroidal culture technique to date is the hanging drop method [116] in 
which cell suspensions are first dispensed onto the lid of a Petri dish followed by inversion of the lid 
to form a hanging drop, each of which leads to the formation of a single cell aggregate. This method, 
however, requires a careful balance between capillary and gravitational forces, is not practically 
amenable to medium exchange [356], and is difficult to translate to large-scale production since the 
maximum permissible drop size is limited to 50 l [151]. Rotational bioreactors such as spinner 
flasks, on the other hand, have been employed for large-scale spheroid production and allow for 
medium exchange and cell sampling, although costly specialised culture equipment is required and 
the large shear stresses exerted lead to a tendency to fragment cells [153].  
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Liquid overlay methods; by contrast, involve culturing a cell suspension on a weakly adhesive surface 
such as a thin agarose layer, agar gel or temperature-responsive methylcellulose coating atop a tissue 
culture dish [114, 357]. Whilst simple, inexpensive and amenable to scale-up, these methods suffer 
from large variations in spheroidal quality [10]. Furthermore, agar performs poorly as a non-adhesive 
substrate [114]. Additionally, agarose preparation requires the reagent to be autoclaved for dissolution 
and sterilisation, followed by a long cooling period for the sol-gel transition. Temperature-responsive 
methylcellulose hydrogels, on the other hand, make medium exchange difficult due to their high 
viscosity and stringent temperature requirements [357].  
 
More recently, various microfluidic strategies have been proposed for on-chip spheroid culture. These 
include microarray devices that immobilise cells on selectively-adhesive patterned structures [117], 
cell trapping barriers [118-120] or non-adhesive microwells [121-124]; bubble and droplet-based 
methods in which the cells are encapsulated within bubble [12] or gelated capsules [125-127]; cell 
trapping in microwells by ultrasonic actuation [358]; and microwells in which rotational flow of a cell 
suspension is induced [129, 359].  Microarray methods possess the advantage of large-scale 
production of uniformly sized cell aggregates, although the aggregate size tends to be limited by the 
dimensions and the geometry of the patterns. Large numbers of cells also need to be seeded, as any 
cells that are not immobilised tend to be washed away and lost [120]. Bulk ultrasonic actuation, on the 
other hand, typically requires large transducers and custom-made microwells that facilitate the 
transmission of sound energy into the wells, and the necessity for relatively high power is associated 
with considerable heating as well as long stabilisation times (typically 15 minutes), which can be 
detrimental to the cells [358]. Bubble and droplet methods possess similar limitations as the aggregate 
sizes are dependent on that of the capsule, which, in turn, is restricted by the surface properties and 
dimensions of the microfluidic system. In addition, bubble methods suffer from low cell capture 
efficiencies. The rotational flow device, on the other hand, allows cell aggregates of different sizes to 
be produced from microwells of a single dimension, therefore circumventing the need to fabricate 
different devices to obtain aggregate size variation.  However, the requirement of a filtration system to 
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prevent cell clots from entering the device not only reduces the efficiency of the method due to loss of 
a large number of cells but also introduces further complexity embodied in the necessity for an 
additional channel shredder to break up large cell clots by shear [129].  In addition, the closed 
microfluidic device restricts practical sampling and collection of cell aggregates, for example, for 
plating the cell aggregates to stimulate cell differentiation [130].  
 
Whichever approach is chosen, the low adoption of microfluidic technology at the bench has 
primarily been due to the inertia of practitioners such as laboratory technicians in adopting new and 
sophisticated technology, preferring instead to continue using familiar equipment and protocols even 
if these are inefficient and not cost-effective [360].  Another reason for their preference for existing 
laboratory formats in lieu of new technology is  the existing compatibility of these methods to a vast 
array of ancillary laboratory technology, e.g. microscope stages, microplate readers, etc. that are 
already available without needing to invest in costly new equipment to accommodate the new format. 
 
In this chapter, it is  therefore proposed to interface a novel surface acoustic wave (SAW) 
microcentrifugation tool for rapid spheroid generation with a laboratory format with which 
practitioners are already intimately familiar and that has already been customised to fit a vast array of 
existing ancillary equipment for laboratory analysis, with the aim of exploiting the advantage of 
process improvement through new technology whilst allowing the user the benefit of retaining an 
existing format to which they are accustomed: the tissue culture microplate (Figure 4.1). 
Microcentrifugation driven by SAWs nanometer amplitude electromechanical waves localised on a 
chip-scale piezoelectric substrate [361] has already been demonstrated for a variety of purposes, e.g. 
chaotic micromixing [362], rapid particle concentration [363]  and sorting [364], as well as driving the 
rotation of small disks on which microchannels for a wide range of microfluidic operations can be 
patternedthe so-called Miniaturized Lab-on-a-Disc [365]; this is in addition to the vast array of 
other microfluidic manipulations enabled by the SAW [366-371]. Unlike high-shear rotational 
bioreactors or other bulk ultrasonic devices which typically operate below 1 MHz, the 10–100 MHz 
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order frequency SAWs, which operate at very low (< 1 W) power given the efficiency of the device, 
have significantly less tendency to denature large biomolecules and cells, as there is insufficient time 
between the field reversal at these frequencies compared with the shear relaxation time of molecules 
or cells. Furthermore, cavitationa common cause of biomolecular or cellular damage in ultrasonic 
devicesis also suppressed at these high frequencies and low powers [372]. 
 
 
Figure 4.1: (A) Schematic depiction of the setup used for rapid spheroid generation in a microwell on 
a well plate. The surface acoustic wave (SAW) device is interfaced from beneath using a fluid 
coupling layer.  (A) Representative images of (B) the SAW device and (C) the arrangement used. For 
clarity, a 12-well plate is shown in (C), although the SAW micro-centrifugation technique was 
demonstrated in a 96-well plate. 
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The aggregation of cells using the microcentrifugation flow induced in the microwells by the SAW 
device is complemented by a low-adhesive coating in the well plate using fast-gelling carboxymethyl 
cellulose (CMC)-based hydrogel, namely carboxylmethyl cellulose tyramine (CMC-TYR). CMC is a 
cellulose derivative approved by the Food and Drug Administration (FDA) and has been commonly 
used as a degradable pharmaceutical material; it is commercially available at low cost, and is non-
fouling in addition to possessing low cell-adhesive properties [373].  Another advantage of the use of 
CMC-TYR is its fast gelation rate, which minimises the preparation time for coating the tissue culture 
surface. Altogether, the fast (1–10 s) SAW-driven microcentrifugation together with the use of the 
CMC-TYR coating facilitates rapid production of uniform tumour cell spheroidshere demonstrated 
with BT-474 cellsusing standard tissue culture plasticware and allowing easy access for medium 
exchange and sampling, thus constituting a promising platform for studies in cancer biology and drug 
screening. Although SAWs have previously been coupled into superstrates on which sessile drops are 
manipulated [374-376], the use of SAWs to drive micro-centrifugation in a standard tissue culture 
well plate has yet to be demonstrated. Moreover, spheroid dimension can potentially be simply 
controlled by modulating the power input to the SAW, therefore removing the need, for example, for 
elaborate fabrication of different microstructures.  
4.2   Methods 
 
4.2.1   SAW Device Fabrication 
 
 
The electrodes of the SAW device were fabricated using standard UV photolithography according to a 
method modified from Qi et al. [377].  Briefly, a 5 nm thick layer of chromium, followed by a 1.5 m 
thick layer comprising 99% aluminium and 1% copper, were sputtered on a 127.68 Y-axis rotated, X-
axis propagating lithium niobate wafer (Roditi Ltd., London, UK). A thin (~3 m) layer of AZ4562 
photoresist (Microchemicals GmBH, Ulm, Germany) was then spun coated onto the wafer, followed 
by UV exposure through a glass mask, development of the photoresistant layer and wet etching for 
Design and Development of miRNA and stem cell based micro/nano systems as lung disease therapy            L Alhasan 
 
82 
 
electrode pattern generation, using a commercially available aluminium etchant (ANPE 5-5-80-10, 
Microchemicals GmBH, Ulm, Germany). Here, elliptical single-phase unidirectional transducers 
(SPUDT) [363] were used for the Rayleigh SAW generation with an electrode finger width and 
spacing corresponding to a resonance frequency of ~30 MHz. The substrate wafer containing the 
SPUDT was then diced into chips approximately 180 mm long and 120 mm wide. 
 
4.2.2 Hydrogel Synthesis and Preparation  
 
 
CMC-TYR was synthesized according to Al-Abboodi et al. [130].  In brief, 5 g CMC and 0.864 g 
TYR were first dissolved in 250 ml of Milli-Q

 water (Millipore; Merck Pty. Ltd., Kilsyth, VIC, 
Australia), followed by the addition of 0.573 g NHS and 0.955 g EDC, and overnight agitation at 
room temperature and pH 4.7. For purification, the mixture was then transferred to dialysis tubing and 
dialysed against 100 mM NaCl, 25% ethanol, and Milli-Q

 water in sequence for 2 days each. The 
product was then lyophilised for storage.  
 
CMC-TYR hydrogel was used as a low-adhesion coating of the tissue culture well plate. The 
lyophilized CMC-TYR was first dissolved in PBS at a final concentration of 5% (v/v) and filter-
sterilised using a 0.22 m sterile syringe filter. Filter-sterilised HRP and dilute H2O2 were added to 
this solution at final concentrations of 224 units/l and 2.88 mM, respectively. Next, 125 l/cm2 of this 
solution was vortex-mixed for 4 s and immediately transferred to the inner walls of each well in the 
well plate and allowed to cross-link enzymatically to form the coating. 
4.2.3 Hydrogel Characterisation  
 
 
The conjugation of TYR on CMC was assessed in deuterium oxide (D2O) using NMR operating at 
300 MHz (ACF300, Bruker Pty. Ltd., Alexandria, NSW, Australia). The gelation time of CMC-TYR 
was estimated using an inverted tube test method according to Gupta et al. [378]. Briefly, HRP and 
H2O2 at final concentrations of 224 units/l and 2.88 mM, respectively, were added to a 2 ml 
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microcentrifuge tube (Axygen Scientific, VWR International Pty. Ltd., Murarrie, QLD, Australia) 
containing 5% (v/v) CMC-TYR in PBS. The mixture was vortex-mixed for 4 s with the tube reverted 
in 30 s intervals to observe for flow. The gelation time was recorded as the time when the gel ceased 
to flow. 
 
The swelling ratio of the CMC-TYR hydrogel was measured using a conventional gravimetric method 
according to Hoo et al. [379]. In brief, sterilised hydrogels were prepared from 5% (v/v) CMC and 
HRP at a final concentration of 245 units/l with varying amounts of H2O2 to give final concentrations 
of 3.2, 12.8, and 28.8 mM.  
 
The hydrogels were subsequently cut into round disks using a sterile circular mould that was then 
swollen by immersion in sterile PBS for 3 days at 37°C. Excess liquid was wiped off by gently 
blotting the hydrogel with laboratory wipes. The swollen weight Ws of the hydrogel disks was then 
measured, followed by lyophilisation, after which the dry weight Wd was measured. The swelling ratio 
was calculated as (Ws – Wd)/Wd  100% [380]. 
 
4.2.4 Cell Culture 
 
 
The human mammary gland carcinoma BT-474 cell line was used as a model cancer cell line and was 
obtained from the School of Health Sciences, RMIT University (Bundoora, VIC, Australia).  
Cells were maintained in a cell culture medium consisting of DMEM supplemented with 10% (v/v) 
FBS and 100 g/ml penicillin-streptomycin at 37C in a 5% CO2 humidified incubator. Cells were 
trypsinised using 0.25% trypsin–EDTA after reaching 80–90% confluence. 
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4.2.5 Spheroid Generation 
 
 
A cell suspension was first prepared by suspending BT-474 cells with the desired cell density (2  
10
3
, 4  103, 5  103, or 6  103 cells/ml) in cell culture medium, followed by the addition of 1% 
gelatin to the cell culture medium as an intercellular linker to assist cell aggregation. The feasibility of 
generating spheroids using SAW microcentrifugation was investigated in both 12-well and 96 well-
plates. Specifically, the microwells of the microplate were coated with a thin layer of CMC-TYR (167 
l/cm2) that functioned as a low-adhesive coating and were subsequently filled with 20 l of cell 
suspension. Acoustic energy was then transmitted into the microwell to induce the 
microcentrifugation flow within it for the purpose of driving the cells to aggregate. This was achieved 
by placing the SAW device beneath the microwell, sandwiching a thin layer of fluid couplant 
consisting of KY Jelly (Chemists Warehouse, Virginia, QLD, Australia) in between. This technique 
for acoustic energy coupling from the SAW device into a superstrate layer was first demonstrated by 
Hodgson et al. [374] and later employed for a variety of acoustomicrofluidic operations on 
superstrates [375, 376]. 
 
The microcentrifugation flow was generated by introducing asymmetry in the delivery of the acoustic 
wave with respect to the geometry of the drop or microwell [381], achieved most easily here by 
simply offsetting the drop or microwell with respect to the SPUDT. The SAW device was activated 
by supplying an oscillating electrical signal at a resonance frequency of 30 MHz to the SPUDT for 1 
min using a multifunction synthesiser (Wave Factory WF1966 2CH, NF Corporation, Yokohama, 
Japan) and coaxial amplifier (Mini-Circuits ZHL-1-2W, RS Components Pty. Ltd., Sunshine West, 
VIC, Australia) to induce the microcentrifugation flow within the well in order to drive the cell 
aggregation.  Once the cell aggregate was formed, 100 l of medium was carefully added to the well. 
The position of the SAW device beneath the well plate was then moved under other wells in order to 
repeat the same spheroid generation process as required, although multiple SAW devices, one under 
each well, can also be employed in order to parallelise the process for high throughput operation.  
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Spheroids were also produced using a liquid overlay method for comparison. In brief, 20 l of cell 
suspension containing the intercellular linker was prepared in the same manner and with the same 
seeding density as those used for the SAW microcentrifugation. The cell suspension was further 
mixed with 100 l of medium and added to microwells that were pre-coated with a thin layer of 
CMC-TYR (167 l/cm2). In both cases, the microwell plates were then transferred to a 5% CO2 
humidified incubator for further spheroid cultivation at 37C. Wells that were not subjected to the 
acoustic irradiation were used as controls. 
4.2.6 Characterization of Spheroid Viability, Morphology and Proliferation 
 
 
After the SAW irradiation, cells were incubated for 2 hours. Cell viability was then evaluated using a 
LIVE/DEAD

 Cell Viability Assay (Life Technologies, Mulgrave, VIC, Australia) according to the 
manufacturer’s protocol.  
 
To investigate the cell distribution within the spheroid, the spheroids produced were cultured for 10 
days and then collected by centrifuging at 300 rpm. The collected spheroids were subsequently fixed 
with 4% paraformaldehyde followed by rinsing in PBS, and finally subjected to Tissue Tex

 O.C.T. 
embedding. Histochemical analysis was performed on 5 m sections of the spheroid. The sections 
were further stained by hematoxylin and eosin (H&E) using standard procedures [382]. The 
morphology of the H&E, calcein AM and propidium iodide (PI)-stained spheroids was visualised 
using optical microscopy (CKX41, Olympus Pty. Ltd., Notting Hill, VIC, Australia) and laser 
scanning confocal microscopy (LSCM; Eclipse Ti Confocal Microscope, Nikon Instruments Inc., 
Melville, NY), respectively. The diameter, cross-sectional area, and perimeter of the spheroids were 
measured using ImageJ (National Institutes of Health, Bethesda, MD). The irregularity parameter IP, 
defined as the ratio of the diameter of the minimum circumscribed circle D to that of the maximum 
inscribed circle d, i.e. IP  D/d [328], was used as an indicator to evaluate the circularity of a 
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spheroid; an IP with a value of 1 indicates a perfect circle, whereas a large IP value indicates that the 
spheroid exhibits irregular morphology [328].  
 
For the spheroid proliferation studies, the spheroids were cultured and subsequently monitored for a 
period of 10 days after being exposed to the SAW. The same viability and morphology 
characterisation studies were employed as that detailed above. The spheroids were collected for 
trypsinisation at different time intervals, and the number of cells proliferating within spheroids was 
determined by measuring the DNA content using a Quanti-iT PicoGreen dsDNA Assay (Life 
Technologies, Mulgrave, VIC, Australia) according to Hoo et al. [383]. For the control, cells were 
allowed to aggregate using the conventional liquid overlay method on a CMC-TYR coated well plate 
and monitored in the same way. 
4.2.7 F-actin Organisation 
 
The F-actin organisation in the spheroids was examined using an Actin Cytoskeleton and Focal 
Adhesion Staining Kit (Merck Millipore, Bayswater, VIC, Australia).  Firstly, 20-day-old spheroids 
were removed from the CMC-TYR coated well plate by pipetting and were subsequently centrifuged 
for 3 min at 500 rpm in order to concentrate the spheroids at the bottom of a centrifuge tube, with the 
supernatant then decanted to remove most of the medium. The spheroids were next embedded 
according to a method modified from Al-Abboodi et al. [384] to prepare the spheroids for staining.  
Finally, a small drop of sample containing the spheroids was pipetted from the centrifuge tube onto a 
separate well plate. CMC-TYR was employed as the embedding substrate, the high water content of 
the hydrogel allowing the stain to penetrate through the hydrogel. Briefly, freshly prepared hydrogel 
precursor solution (100 l) containing 5% (v/v) CMC-TYR, 245 units/l HRP and 3.2 mM H2O2 were 
immediately added into the wells of the well plate containing the spheroids to form a thin liquid layer. 
The spheroids were embedded simultaneously with the precursor crosslinking to form a hydrogel 
layer. The embedded spheroids were further fixed with 4% formaldehyde solution at room 
temperature for 1 hour and subsequently washed twice by soaking the sample in wash buffer 
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comprising 0.05% Tween-20 in PBS for 10 min each. The spheroids were next permeabilised using 
0.5% Triton X-100 in PBS for 20 min at room temperature, followed by blocking in a solution 
containing 1% BSA in PBS for 1 hour at room temperature. The samples were then washed three 
times with wash buffer for 10 min each, followed by incubation with anti-vinculin primary antibody 
diluted in blocking solution (1:100) for 1 hour at room temperature and a similar washing step in the 
buffer solution.  
 
For double labelling, the sample was incubated with FITC-conjugated secondary antibodies (1:1000) 
and tetramethylrhodamine isothiocyanate (TRITC)-conjugated phalloidin (1:200) for 1 hour at room 
temperature, followed by washing three times with wash buffer for 10 min each. The cell nuclei were 
then counterstained by DAPI (1:2000) for 5 min. Finally, the sample was again washed three times 
with buffer solution for 10 min each time prior to analysis using LSCM. Monolayer BT-474 cells 
were employed as the control, and were stained using the Actin Cytoskeleton and Focal Adhesion 
Staining Kit according to the manufacturer’s protocol. During imaging with LSCM, ten representative 
cells were selected from each specimen and the mean fluorescence intensity (MFI) of FITC was 
quantified using ImageJ; PBS was replenished periodically to prevent drying of the sample.  
4.2.8 Statistical Analysis 
 
All experiments were performed with at least three replicates and results reported as the average value 
 standard deviation. Multiple groups of data were compared using One-Way Analysis of Variance 
(ANOVA). Two groups of data were compared using the Student’s t-test. Differences were 
considered statistically significant when p < 0.05. 
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4.3 Results and Discussion 
 
4.3.1 Hydrogel Characterisation 
 
CMC-TYR conjugate synthesis via mediated coupling according to the scheme illustrated in     
Figure 4.2 was confirmed by 
1
H NMR spectroscopy. Figure 4.3 shows the typical spectrum of CMC-
TYR; the signal of aromatic protons of tyramine appeared at  = 6.8 and 7.2. CMC-TYR conjugates 
were enzymatically cross-linked with HRP to form an irreversible hydrogel in approximately 3 min; 
HRP-mediated oxidative coupling of phenol derivatives gives rise to a C–O linkage between the 
ortho–carbon and the phenolic oxygen groups or a C–C linkage between the ortho-carbons of the 
aromatic ring [130, 385], thereby cross-linking CMC-TYR conjugates to form a hydrogel. The 
hydrogel obtained was clear and insoluble in aqueous solution. The fast gelation time of CMC-TYR, 
which can be modulated via the enzyme concentration [130, 386], also contributes to a significant 
reduction in the preparation time of the non-adhesive coating compared to the conventional methods 
in which agarose gel is used, which requires at least 20 min to gel [387].  
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Figure 4.2: Synthesis scheme for (A) CMC-TYR, and (B) CMC-TYR hydrogel cross-linking.  
 
Design and Development of miRNA and stem cell based micro/nano systems as lung disease therapy            L Alhasan 
 
90 
 
 
 
Figure 4.3: 1H NMR spectra of CMC and CMC-TYR  
 
Figure 4.4 summarises the swelling ratios of the CMC-TYR hydrogel at different H2O2 
concentrations. The swelling ratio is a measure of the material wettability; hydrogels with high 
swelling ratios are highly hydrophilic and highly permeable, which facilitates the transport of water-
soluble molecules through the pores [379, 388] and minimises cell adhesion, whereas long-range non-
covalent interactions between cells and the hydrophobic surface promotes cell surface adhesion [380].  
As expected, the swelling ratio decreased with increasing H2O2 concentration (p < 0.0001, n = 3), 
from 85.5%  1.1% to 70.4%  1.5% and 47.5%  3.2% for hydrogels prepared from 3.2, 12.8 and 
28.8 mM H2O2, respectively. The increasing H2O2 concentration led to a greater number of cross-
linking bonds per unit volume (cross-linking density) within the hydrogel, which reduces the 
infiltration of water molecules into the densely cross-linked network, thereby resulting in a lesser 
swelling ratio [389]. The high swelling ratios exhibited by the CMC-TYR hydrogels thus revealed 
that these hydrogels were highly hydrophilic due to the presence of numerous hydroxyl groups on the 
CMC backbone, therefore constituting the required low-adhesive surface coating. 
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Figure 4.4: Swelling ratio of CMC-TYR, prepared from 5% (v/v) CMC-TYR and HRP at a final 
concentration of 245 units/l and various concentrations of H2O2. The error bars represent the standard 
deviation (n = 3). 
 
4.3.2 SAW Microcentrifugation Driven Cell Aggregation as a Precursor to Spheroid Formation 
 
Figure 4.5 shows representative images of the spheroids generated using the SAW device compared 
with those from the control experiment, in which acoustic irradiation and hence microcentrifugation 
flow were absent.  Also shown are representative results when the hydrogel low-adhesive coating was 
absent. In the uncoated microwells (top row of images in Figure 4.5), cells were more concentrated as 
a result of the microcentrifugation flow in the well from the acoustic irradiation than in the control 
experiment, in which no external force was applied and the cells simply sedimented under gravity. 
The relationship between the numbers of cells in the aggregate and the input power is discussed 
below. Nevertheless, a large number of cells remained in a spoke-like pattern instead of being 
concentrated into a tight pallet at the centre of each well. This pattern is due to standing waves that 
arise as a consequence of the reflection of sound waves from the walls of the well; in other words, the 
well forms an effective acoustic cavity. Particles and cells with densities greater than the surrounding 
fluid are easily trapped at the nodes of standing waves, where the acoustic radiation pressure is at its 
minimum [390]. In addition, the absence of a weakly adhesive coating meant that the cells tended to 
adhere to the bottom of the well.  
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It can, however, be seen from the bottom row of images in Figure 4.5 that these difficulties in 
attempting to drive the cells into a tightly-packed aggregate were circumvented by coating the 
microwell with the hydrogel, which had a direct effect on the quality of the spheroids formed . In the 
presence of the coating, the cells were concentrated into a tight central aggregate in each well; a larger 
aggregate cell density was achieved when the cells were concentrated by the SAW-driven 
microcentrifugation flow. The disappearance of the spoke-like cell patterns with the use of the 
hydrogel coating suggests that the hydrogel plays a two-fold role in not only preventing cell adhesion 
along surfaces but also in absorbing the sound wave and thus preventing its reflection and hence the 
generation of standing waves in the well. 
 
 
Figure 4.5: Representative microscopy images showing the cells in a microwell of a 96-well plate in 
both the presence (right) and absence (left) of the microcentrifugation flow induced by the acoustic 
radiation. The effect of the hydrogel low-adhesive coating in the well is also shown in the bottom row. 
The solution in each well contained BT-474 cells at a seeding density of 5 x10
3
cells/ml. The scale bar 
represents a length of 0.5 mm. 
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The effect of the SAW power applied, which has a direct effect on the velocity of the induced 
microcentrifugation flow in the well, is shown in Figure 4.6. The cells all remained viable (stained 
green with Calcein AM); no PI stained cells (dead cells) were observed. This was consistent with 
previous findings on the lack of effect of SAW irradiation on cell viability [372]. 
 
The morphology of the cell aggregates and hence the subsequent spheroid formation, however, 
depends intimately on the power applied as well as the cell seeding densities (2  103 – 6  103 
cells/mL) employed. In order to obtain quantitative morphometric characterization, both the spheroid 
cross-sectional area and irregularity parameter IP were examined as a function of these system 
parameters. The former is a measure of the compactness of the spheroid formed, whereas the latter is 
a measure of the circularity of the spheroid (IP values close to 1 correspond to more circular 
spheroids).  
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Figure 4.6: Effect of applied SAW power on the morphology of the cell aggregates prepared from a 
seeding density of 5 x 10
3
cells/ml. These representative confocal microscopy images were obtained 2 
hours after the SAW was applied to drive the microcentrifugation flow. The cells were then stained 
using a live/dead cell viability assay. Live cells are stained by Calcein AM and appear green; no cell  
is stained by propidium iodide (PI). Scale bars represent 50 µm in length 
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Figure 4.7 shows that the smallest spheroid cross-sectional area, i.e. the most compact spheroids, and 
the most circular spheroids were obtained at intermediate powers of about 1 W. This was consistent 
with previous findings on SAW microcentrifugation-driven particle concentration, which found that 
the tendency for particles to concentrate increased with the power applied and hence the intensity of 
the microcentrifugation flow up to a point beyond which the increasingly rapid convective flow 
overcame the diffusion-driven particle concentration dynamics, thereby leading to re-dispersion of the 
particles [381]. The existence of an optimum at intermediate applied powers is also true for the 
formation of spherical spheroids with IP values close to 1, given that excessive convective dispersion 
at high microcentrifugation velocities leads to increasingly chaotic flow [362] that promotes 
increasing irregularity in the cell aggregates.  Furthermore, the optimum for spheroid shape shifted 
slightly to higher powers for larger cell seeding densities. This suggests that greater 
microcentrifugation velocity thresholds are necessary to concentrate and also to disperse larger 
numbers of cells, given the increase in the intrinsic viscosity with greater cell concentrations [391]. 
 
The ability to achieve some degree of control over spheroid uniformity for different cell densities 
using the SAW device is a significant advantage because of  importance of spheroid uniformity, 
especially for many cell-based assays [118]. Non-uniform spheroids commonly lead to non-
uniformities in the exposure and diffusion of reagents to the cells, thus resulting in large variations in 
the observed cell behaviour [392]. In addition, image analysis in these studies is also complicated by 
irregularity in spheroid morphology. By contrast, other microfluidic techniques such as the 
microarray- and microcapsule-based approaches only yield spheroids of a fixed size range for a given 
system geometry, therefore requiring expensive and laborious steps in tailoring different photomasks 
for the fabrication of different microstructures for each cell seeding density and desired size range. 
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Figure 4.7: Effect of the SAW applied on the spheroid (A) cross-sectional area, and (B) irregularity 
parameter IP. The spheroids were obtained 2 hours after the SAW was applied to drive the 
microcentrifugation flow. The error bars represent the standard deviation (n = 3). 
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4.3.3 Spheroid Proliferation 
 
The representative confocal microscopy images in Figure 4.8 show that the size of the spheroids 
generated by both the SAW microcentrifugation method and the liquid overlay method (control) 
increased over time, indicating the proliferation of cells. The vast majority of cells on the periphery of 
the spheroids remained viable (stained green by Calcein AM) and formed a shell around a poorly 
stained core, but there was little evidence of necrotic or dead cells (stained red by PI). This lack of 
central staining may be because PI is impermeable to live cells and did not penetrate through the outer 
viable cell layer to reach the cells at the centres of the spheroids, as discussed earlier as other studies 
on tumor spheroid also observe similar phenomenon [11, 323]. Necrotic cores are common in 
spheroids, especially in older and larger spheroids, in which the cells in the centre of the spheroid are 
deprived of oxygen and nutrients due to diffusion limitations [11, 334]. 
 
Figure 4.8: Representative confocal microscopy images showing the viability of spheroids cultured 
using both the liquid overlay (LO, top panel) and SAW microcentrifugation (SAW, bottom panel) 
methods over a period of 10 days. In both cases, the spheroids were prepared from a seeding density 
of 5 x 10
3
cells/ml and stained using a live/dead cell viability assay. Live cells, which appear green, are 
stained by Calcein AM; dead cells, which appear red, are stained by propidium iodide. Scale bars 
represent 100 µm in length. 
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Proliferation of the cells forming the spheroids was assessed by determining the DNA content, given 
that DNA is a cellular component that accurately reflects the cell number. Figure 4.9 shows that the 
number of cells in the spheroids cultured using both the SAW microcentrifugation method (p = 0.01, 
n =3) and liquid overlay method (p < 0.001) increased gradually over a 7 day period, indicating that 
the cells proliferated within the spheroids.  
 
 
Figure 4.9: Gradual increase in the proliferation of BT-474 cells in spheroids cultured using both the 
liquid overlay and SAW microcentrifugation methods over a period of 7 days, as assessed by increase 
in DNA content. In both cases, the spheroids were prepared from a seeding density of 5 x 10
3
cells/ml. 
The error bars represent the standard deviation (n = 3). 
 
This proliferation was also by the quantitative data in Figure 4.10 showing that the mean diameter for 
spheroids produced from the SAW microcentrifugation method (p < 0.0001, n = 5) increased over 
time, although spheroid shape became more irregular. Spheroids produced using the liquid overlay 
method exhibited relatively large variation in diameter within the same treatment due to their more 
irregular shapes. Spheroids produced using the SAW microcentrifugation method had a smaller size 
and a lesser irregularity parameter (IP) (closer to a value of 1) than did spheroids obtained with the 
liquid overlay method, suggesting the possibility of using the SAW microcentrifugation method to 
synthesise more uniform and compact spheroids, allowing them to be potentially more useful for cell-
based assays.  
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Figure 4.10: (A) Diameter and (B) irregularity parameter (IP) of spheroids obtained using both the 
conventional liquid overlay (LO) and SAW microcentrifugation (SAW) methods with a seeding 
density of 5 x 10
3
cells/ml. The error bars represent the standard deviation (n = 3). 
 
Figure 4.11 is a representative histological section of a spheroid produced with the SAW 
microcentrifugation method showing the distribution of cells; nuclei appear in violet from the H&E 
staining. A large number of cells are tightly packed within the spheroid, typical of tumor morphology 
[11].  It is this tight packing that limits nutrient and oxygen diffusion into the spheroid interior, thus 
resulting in the necrotic cores observed in Figure 4.8 and may explain the lack of stain penetration in 
live/dead staining. Indeed, such concentric heterogeneous cell populations of spheroids mimic the 
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avascular stage of tumours in vivo [393], making the in-vitro spheroid model a useful tool for cancer 
biology studies. 
 
The spheroids produced by both methods exhibited heterogeneous cell subpopulations that contained 
viable cells at their periphery and non-viable cells in their core. Such necrotic cores are common in 
spheroids, especially in older and larger spheroids, in which the cells in the centre of the spheroid are 
deprived of oxygen and nutrients due to limitations on diffusion [11, 334]. 
 
 
Figure 4.11: Representative image showing the histological section of a spheroid generated using the 
SAW microcentrifugation device with a seeding density of 5 x 10
3
cells/ml. The 20-day old spheroid 
was stained by H&E and visualized using light microscopy. 
 
 
4.3.4 F-actin Organisation 
 
 
The cytoskeletal organisation and focal adhesion of the spheroids generated using the SAW 
microcentrifugation method compared with those of monolayer cells are shown by the representative 
images in Figure 4.12. Actin filaments in the cytoskeleton of the spheroids were stained red by 
TRITC-conjugated phalloidin, while the focal adhesion marker vinculin was stained green by 
fluorescently labeled anti-vinculin monoclonal antibody. Monolayer cells exhibited the usual spindle 
morphology and displayed more well-spread actin filaments and typical cell–substrate adhesion. By 
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contrast, in the spheroids the organisation of the actin filaments was more irregular whereas the 
vinculin appears more aggregated, especially at the centre of the spheroids. As shown in Figure 4.13, 
compared with monolayer cells, the mean flourscent intensity (MFI) of vinculin expressed by the 
spheroids produced using the SAW microcentrifugation method was significantly greater (p < 0.0001, 
n = 20), again indicating that the vinculin in spheroids was more aggregated than that in monolayer 
cells. Together, these suggest the formation of tight cell–cell interfaces in the spheroid, thus 
suggesting again the possibility of the production of tumour-like spheroids by the SAW 
microcentrifugation method. 
 
 
Figure 4.12: Representative confocal microscopy images revealing the focal adhesion points and 
nuclei of monolayer BT-474 cells (top panel, control) and that of a 20-day old BT-474 spheroids 
generated using the SAW microcentrifugation device (bottom panel). Nuclei were stained blue by 
DAPI, focal contacts were stained green by anti-vinculin antibody, and F-actin was stained red by 
TRITC-conjugated phalloidin. Images were overlaid in the last column. The scale bars represent 100 
µm in length.   
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Figure 4.13: The mean fluorescence intensity (MFI) of vinculin expressed in monolayer BT474 cells 
(control) and 20-day old BT-474 spheroids generated using the SAW microcentrifugation device. The 
error bars represent the standard deviation (n = 20). 
 
4.4 Conclusion 
 
In summary, this chapter has presented evidence of the feasibility of interfacing a SAW microfluidic 
device with a superstrate, such as a tissue culture dish or a microarray well plate, for the controlled 
generation of uniform multicellular spheroids. This has considerable advantages over other 
microfluidic devices for spheroid production, as it uses existing laboratory formats already highly 
familiar to biologists and laboratory technicians and for which ancillary equipment such as 
microscopes and plate readers have been designed to fit are retained, without requiring further 
investment into new analytical equipment. Furthermore, the chip-scale dimensions of the SAW 
device, as well as its low cost, by exploiting the economies of scale associated with large volume 
nanofabrication, facilitate scale-out (i.e. numbering up) for high-throughput operation. Whilst this 
study has demonstrated the use of a SAW device to enhance spheroid production in a single 
microwell on a standard tissue culture microplate, it is equally feasible to envisage the use of multiple 
SAW devices in parallel, for example one under each well. 
 
The acoustic irradiation was coupled into the microwell through a fluid couplant layer sandwiched in 
between. Through symmetry breaking of the sound waves in the liquid, an intense microcentrifugation 
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flow was induced in the microwell, which drove the cells into a tight aggregate. This was aided by the 
use of a low-adhesive hydrogel coating on the microwell walls, which prevented cell adhesion to the 
wall and suppressed standing sound waves, which trap cells at nodal positions away from the centre. 
This study has shown the generation of compact and circular spheroids, the size of which was 
controlled by modulating the input power of the SAW; the most compact and uniform (in terms of 
circularity) spheroids were obtained at intermediate powers, since a trade-off existed between the 
increasing concentration and aggregation of cells with more intense microcentrifugation flow as the 
power was increased and the increasingly dispersive nature of the intense chaotic flow at high power. 
This optimum power depended on the cell seeding density. The ability to control spheroid size simply 
through the input power represents a distinct improvement on current processes, since it circumvents 
the need for the fabrication of multiple devices with various geometric designs. Moreover, the cell 
concentration process was rapid, requiring only a minute, compared with conventional methods such 
as liquid overlay methods, which require at least a day. The fast gelation rate of the CMC-TYR 
hydrogel also considerably reduced the preparation time for coating of the tissue culture surface. 
Compared with the conventional hanging drop method, the SAW microcentrifugation method had the 
advantage of being able to handle larger fluid volumes. Furthermore, the resulting spheroids exhibited 
a concentric heterogeneous cell population arrangement and the tight cell-to-cell interfaces typically 
observed in solid tumors in vivo, thus demonstrating the usefulness of the platform for improving 
investigations of cancer biology and drug screening. 
…………………
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CHAPTER FIVE 
Assessment of the Potential of a High Frequency Acoustomicrofluidic Nebulisation 
Platform for Inhaled Stem Cell Therapy 
 
5.1   Introduction 
 
 
There is growing evidence that demonstrates the efficacy of stem cell-based therapies for the 
treatment of a variety of lung diseases, including: chronic obstructive pulmonary disease 
(COPD); pulmonary and cystic fibrosis; and pulmonary hypertension [13, 14]. This is 
especially timely given the recognition of the urgency for new approaches to treat lung 
diseases in light of its increasing prevalence, in particular of COPD, which is anticipated to be 
among the leading causes of global mortality in the next 5 years. Motivated by the shortage of 
donor lungs and the extremely high mortality rate (almost 50%) following lung 
transplantation, there is an increasing number of studies examining the potential of stem cell 
administration to injured lungs, for both an immodulatory role to attenuate inflammation and a 
regenerative role for injury repair [394].  
 
There are, however, far fewer studies on the development of methods to administer stem cells 
to the lung. While there have been investigations that show recruitment of stem cells to the 
lung following systemic (e.g. intravenous) administration, recruitment depends on many 
critical factors [395]. Direct lung delivery via aerosol inhalation, on the other hand, not only 
facilitates local targeting of the disease- or injury-specific region, but also allows easy and 
painless administration, involves fewer side effects and avoids the need for anaesthesia. 
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Nevertheless, there remain considerable challenges associated with stem cell aerosolisation, in 
particular the stem cell survival and retention of function during the nebulisation process. 
Their fragility rules out the use of a wide number of commonly-used nebulisation techniques, 
particularly those that subject the aerosols to intense stresses (e.g. shear, cavitation and heat) 
such as jet (compressed air) and conventional ultrasonic nebulisers [396-398]. By contrast, 
electrohydrodynamic atomisation is a viable method for stem cell delivery [399-402], although 
the necessity for large (kV) DC potentials typically renders electrospray impractical as a 
portable consumer inhalation device from a safety viewpoint. 
 
MSCs possess multi-lineage potential to differentiate into a number of cell types including 
osteocytes, adipocytes and chondrocytes. They express surface markers CD29, CD44 and 
CD106, these markers often being considered indicators for MSC isolation as well as 
differentiation [403-406], and therefore used to assess the pluripotent phenotype and integrity 
of the MSCs prior to and after nebulisation at different time intervals.  
 
In this chapter, the aim was to develop and evaluate a novel high frequency acoustic 
nebulisation platform as an effective aerosolisation technique for inhaled mesenchymal stem 
cell (MSC) therapy. This is the first study that has investigated the viability of stem cells under 
surface acoustic wave (SAW) nebulisation. SAWs [366, 368] operate at much higher 
frequencies (10–100 MHz) [407] than conventional bulk ultrasonic nebulisers                       
(10  kHz – 1 MHz) [408] and so the vibrational excitation to which the cells are subjected 
occurs over a much shorter period than their hydrodynamic shear relaxation time scales, thus 
eliminating the risk of cell lysis [264, 409]. Additionally, the low power (about 1 W) is one to 
two orders of magnitude less than that required by conventional ultrasonic nebulisers and so 
not only eliminates the possibility of cavitation but also makes feasible the development of 
miniaturised options, such as battery-powered portable handheld devices [410]. While the 
efficacy of the SAW nebulisation has been demonstrated for proteins, e.g. monoclonal 
Design and Development of miRNA and stem cell based micro/nano systems as lung disease therapy            L Alhasan 
 
106 
 
antibodies for lung tumour inhibition [411] and nucleic acids, e.g. plasmid DNA for influenza 
vaccination [412], as well as for microfluidic mass spectrometry interfacing [413-415] and 
protein substrate patterning [416], there has yet to be a demonstration of the efficacy of the 
SAW nebulisation platform for pulmonary stem cell delivery. Stem cells did retain their 
viability and functionality under SAW excitation, but the intensity of the vibration to which 
the cells were subjected (typically 100 mW) were far below the critical levels required for 
nebulisation [417].  
5.2   Methods 
5.2.1   Cell culture 
 
GIBCO rat (SD) MSCs from the bone marrow of Sprague Dawley rats (Life Technologies, 
Mulgrave, VIC, Australia) were maintained in cell culture medium comprising D-MEM with 
GlutaMAX supplemented with 10% MSC qualified FBS and 5 g/ml gentamicin at 37C in 
a humidified 5% CO2 incubator. Cells were rinsed with DPBS, followed by trypsinisation with 
TrypLE after reaching 80% confluence. The harvested cells were rinsed with cell culture 
medium and reconstituted to a cell suspension solution containing 2  106 cells/ml. 
 
5.2.2 SAW nebuliser device fabrication and setup 
 
A 0.5 mm thick 127.68 Y-axis rotated, X-axis propagating lithium niobate wafer (Roditi Ltd, 
London, UK), which constituted the piezoelectric substrate on which the SAWs were 
generated, was first cleaned according to standard procedures [365]. The electrodes were then 
fabricated on the wafer using standard UV photolithography according to a protocol modified 
from Qi et al. [377].  In brief, the clean wafer was sputtered with a 5 nm thick layer of 
chromium followed by a 1.5 m thick layer comprising 99% aluminium and 1% copper using 
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an electron beam evaporator (Nanochrome II, Intlvac Corp., Niagara Falls, NY, USA). The 
wafer was then spun-coated with a thin layer (approximately 3 m thick) of AZ4562 
photoresist (Microchemicals GmBH, Ulm, Germany) followed by exposure to UV through a 
glass mask. The next step comprised the development of the photoresist layer and wet etching 
using an aluminium etchant, ANPE 5-5-80-10 (Microchemicals GmBH, Ulm, Germany) to 
generate the IDT patterns, which consisted of elliptical single-phase unidirectional transducers 
(SPUDT) [363] with an electrode finger width and spacing corresponding to a resonance 
frequency of approximately 30 MHz. The wafer containing the SPUDT was subsequently diced 
into microchips, each of approximately 18 mm length and 12 mm width. 
 
A two-dimensional spatial distribution of the surface displacement amplitude near the focal 
point of the elliptical SPUDT was measured with a laser Doppler vibrometer (LDV) (UHF-
120, Polytec GmBH, Waldbronn, Germany); an in-depth analysis of the surface displacement 
patterns produced by various IDT designs can be found in Shilton et al.[363]  
 
To affect the nebulisation process in order to generate the aerosol-laden MSCs, the edge of a 
SAW microchip was partially immersed into the MSC suspension contained in a Petri dish, as 
depicted in Figure 5.1. Rayleigh SAWs were then generated by applying an input oscillating 
electrical signal to the SPUDT at the resonant frequency using a signal generator (SML01, 
Rhode & Schwarz, Munich, Germany) and amplifier (10W1000C, Amplifier Research, 
Souderton, PA, USA). Above a critical power of 1.5 W, nebulisation ensued and the resultant 
aerosol mist containing the MSCs was collected for further characterisation. 
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Figure 5.1: Schematic depiction of the SAW nebulisation setup for rapid aerosolisation of MSCs (not 
to scale). Power is supplied as an oscillating electrical signal to the SPUDT electrodes 
photolithographically patterned onto a lithium niobate (LN) substrate. This causes the generation of a 
SAW, which, when in contact with the MSC suspension in the Petri dish, nebulises the fluid to form 
an aerosol mist, each droplet of which contains MSCs. 
 
5.2.3   Aerosol characterisation 
 
The SAW device was characterised to determine its nebulisation rate and the aerosol sizes 
under ambient conditions. The nebulisation flow rate of the SAW nebuliser device was first 
modulated by adjusting the input power (1.5–3 W) and the time for a fixed volume of solution 
to completely nebulise was subsequently measured. Aerosol droplet sizes were determined 
using laser diffraction (Spraytec, Malvern Instruments, Malvern, UK), specified as a median 
diameter from a volume-based size distribution; a mean value across five replicates was 
calculated. 
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5.2.4   Characterisation of cell morphology, viability and proliferation 
 
For preliminary testing, the nebulised MSCs were first collected and stained with trypan blue 
to assess their viability. Cells were counted immediately to quantify the stained and unstained 
cells using an automated cell counter (Countess, Life Technologies Pty. Ltd., Mulgrave, 
VIC, Australia). 
 
The nebulised MSCs were transferred to a new tissue culture well-plate at a seeding density of 
5  103 cells/ml for re-culturing for 2 and 24 hours in order to determine their viability, 
metabolic activity and proliferation ability. The morphology of the cells was monitored using 
phase contrast microscopy and images were captured at various time points. The viability of 
the re-cultured MSCs was examined by staining the cells with Calcein AM and PI according 
to the manufacturer’s instructions; viable cells stained green, while inviable cells stained red. 
The stained MSCs were re-cultured for 2 hours and visualised using laser scanning confocal 
microscopy (LSCM) (Eclipse Ti, Nikon Instruments Inc., Melville, NY, USA) without further 
rinsing. The stained MSCs that were re-cultured for 24 hrs were rinsed using phosphate 
buffered saline (PBS) before LSCM visualisation. 
 
For quantification, in a separate experiment MSCs were nebulised as described above and 
collected. Some of these MSCs were immediately stained with Calcein AM and PI according 
to the manufacturer’s instructions while others were transferred to a new tissue culture well-
plate at a seeding density of 5  103 cells/ml and re-cultured for 24 hours. The recultured cells 
were then trypsinised and stained with Calcein AM and PI. The stained cells were analysed 
using flow cytometry (FACSCanto II, BD Biosciences, North Ryde, NSW, Australia). As a 
positive control, MSCs were treated with 0.1% Triton X-100 for 2-3 min prior to staining. 
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The metabolic activity of the re-cultured MSCs was quantified using an AlamarBlue assay 
according to Hoo et al. [380]. In brief, spent medium was removed from each well prior to 
rinsing with Dulbecco's Phosphate-Buffered Saline (DPBS). AlamarBlue dye (10%) diluted 
with cell culture medium was added into each well and incubated at 37C in humidified 5% 
CO2 for 4 h. Fluorescence was visualised using a multi-mode microplate reader with an 
excitation wavelength of 570 nm and an emission wavelength of 600 nm  (SpectraMax 
Paradigm, Molecular Devices LLC, Sunnyvale, CA, USA). 
 
The ability of the nebulised MSCs to proliferate was determined by quantifying the 
deoxyribonucleic acid (DNA) content using a Picogreen assay according to Hoo et al. [380]. 
In brief, the MSCs were trypsinised after re-culturing for 1, 3, 5 and 7 days. The cells were 
then washed twice using cold DPBS, followed by centrifugation for 5 min at 152 g The 
resultant cell pellet was subsequently collected for lysis using a NP40 cell lysis buffer for 30 
min on ice and vortexed every 10 min; the cell lysates were subjected to a freeze-thaw cycle 
prior to centrifugation at 13000 rpm for 10 min at 4C. Each 100 l of clear lysate was 
aliquoted to a new 96-well plate and incubated for 5 min with 100 l of PicoGreen reagent. 
Fluorescence was subsequently analysed using a multi-mode microplate reader at an excitation 
wavelength of 480 nm and an emission wavelength of 520 nm. The number of cells in each 
sample was determined by correlating the DNA content with a standard curve, obtained using 
cell lysates containing a known number of MSCs. Non-nebulised cells were used as control 
for all of the experiments. 
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5.2.5 Reverse-transcription polymerase chain reaction (RT-PCR) and real-time polymerase 
chain reaction (qPCR) 
 
The gene expression of nebulised MSCs and control MSCs were determined qualitatively 
using RT-PCR and quantitatively using qPCR with CD29, CD44, and CD106 as markers. 
Ribonucleic acid (RNA) was isolated from the MSCs using an RNAeasy Mini Kit (Qiagen, 
Chadstone, VIC, Australia) according to the manufacturer’s instructions. The RNA quality and 
concentration were examined using a spectrophotometer (ND-1000, NanoDrop Technologies, 
Thermo Fisher Scientific Inc., Waltham, MA, USA). To eliminate any contaminating genomic 
DNA, the isolated RNA was treated with a DNA-free kit (Life technologists, Australia) 
according to the manufacturer’s protocol. Complementary DNA (cDNA) was generated using 
a QuantiTect Reverse Transcription kit (Qiagen, Chadstone, VIC, Australia) according to the 
manufacturer’s instructions and subjected to PCR amplification using primers obtained from 
Geneworks Pty. Ltd. (Thebarton, SA, Australia); the primer sequences are listed in Table 5.1. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the housekeeping gene. 
For RT-PCR, the PCR products were size-fractionated using 1.5% agarose gel electrophoresis. 
 
The qPCR analysis was performed on a Rotor-Gene Q (Qiagen, Chadstone, VIC, Australia) 
using a QuantiTect SYBR Green PCR kit (Qiagen, Chadstone, VIC, Australia). After 10 min 
of denaturation at 95C, 40 PCR cycles were carried out: 95C for 15 s, 60C for 30 s, and 
72C for 15 s. The relative mRNA levels were calculated using the CT method according to 
Sarvi et al. [418]. The results were reported as fold change values compared with the non-
nebulised cells. 
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Table 5.1: PCR primer sequences: 
 
Gene Forward/reverse (5’ 3’)  Ref. 
ITGB 
(CD29 
protein) 
AATGGAGTGAATGGGACAGG / 
TCTGTGAAGCCCAGAGGTTT  
[419] 
CD44 TTGGCATCCCTCCTGGCGCTGG / 
AAGGAGGAACTGGAAGAGACCC 
[420] 
CD106 CCTCACTTGCAGCACTACGGGCT / 
TTTTCCAATATCCTCAATGACGGG- 
[421] 
GAPDH CAAGGTCATCCATGACAACTTTG / 
GTCCACCACCCTGTTGCTGTAG 
[422] 
 
5.2.6   Immunophenotyping 
 
MSCs possess multi-lineage potential to differentiate into a number of cell types including 
osteocytes, adipocytes and chondrocytes. They are known to express surface markers CD29, 
CD44, and CD106 positively, these markers often being considered indicators for MSC 
isolation as well as differentiation [403-406], and therefore used to assess the pluripotent 
phenotype and integrity of the MSCs prior to and after nebulisation at different time intervals.  
MSCs were nebulised as described previously and collected for further cultivation. After 24 h 
of cultivation, the cells were harvested and aliquoted at a concentration of 1  106 cells per 
sample. The cells were washed with PBS and centrifuged at 1500 rpm three times and 
subsequently re-suspended in buffer [0.1% bovine serum albumin (BSA) in PBS] containing 
antibodies and incubated on ice for 25–30 min. The MSCs were labelled with one of        
Alexa Fluor 488-conjugated integrin beta-1/CD29 antibody (Life Technologies, Mulgrave, 
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VIC, Australia), FITC-conjugated anti-CD44 antibody (Merck Millipore, Bayswater, VIC, 
Australia) or PE mouse-conjugated anti-rat CD106 antibody (BioLegend, San Diego, CA, 
USA), followed by labelling with FITC-conjugated goat anti-mouse IgG secondary antibodies 
(Merck Millipore, Mulgrave, VIC, Australia); the antibodies were diluted according to the 
manufacturer’s protocols. The labelled MSCs were then washed twice in buffer (3% BSA in 
PBS), followed by resuspension in 500 l of buffer (3% BSA in PBS) and analysed by flow 
cytometry; 10,000 events were acquired from each sample and the results were plotted using 
flow cytometry data analysis software (Flowing Software, v2.5.1, 
www.flowingsoftware.com). The surface marker expression of the nebulised cells was 
compared with that of the non-nebulised cells (control). 
5.2.7   Statistical analysis 
 
All experiments were performed with at least three replicates. Unless otherwise stated, the 
results were reported as the average value ± standard deviation. Multiple groups of data were 
compared using One-Way Analysis of Variance (ANOVA), while two groups of data were 
compared using Student’s t-test; differences were considered statistically significant when  
p < 0.05. 
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5.3 Results and Discussion 
5.3.1 Aerosol characterisation 
 
As shown in Figure 5.2, the applied SAW power had a direct influence on the nebulisation 
rate, which increased as the power was ramped to approximately 350 L/min at 3 W  
(p < 0.0001, n = 3). 
 
 
Figure 5.2: SAW nebulisation rate (µL/min) as a function of the power applied to the device. 
The data are represented as mean value (n = 3) ± standard error. 
 
The corresponding surface displacement amplitude of the SAW is plotted in Figure 5.3, which 
shows a linear response in the magnitude of the surface displacement with an increase in the 
power input, indicating that the device has not reached its power saturation limit. These 
observations are consistent with previous findings that as more acoustic energy is transmitted 
into the fluid to drive both streaming and destabilisation of its interface, this, in turn, leads to 
its disintegration into aerosol droplets that constitute the nebulised mist [410]. 
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Figure 5.3: (A) Representative two-dimensional spatial distribution of the surface displacement 
at the focal region of the SPUDT, obtained using laser doppler vibrometry at an input power 
of 2.5 W, (B) Average surface displacement as a function of the input power to the device that 
corresponds to the nebulisation rates.  
 
Table 5.2 shows that the mean aerosol size across all input powers was about 13 m, which is 
similar to the size of a single MSC, thus indicating that most of the droplets contained a single 
cell. Aerosols with droplet sizes >5 m would be expected to deposit due to inertial impaction 
in the upper respiratory tract [357, 423]. Therefore there is potential for the use of the SAW 
device in inhaled stem cell delivery for tissue repair and regeneration within the extra-thoracic 
(pharyngeal and laryngeal) regions. 
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Table 5.2: Median aerosol drop size as a function of the input power to the SAW device 
measured using laser diffraction. 
 
Applied power (W) Median droplet size (m) 
1.5 13.17  0.29 
2.0 13.33  0.29 
2.5 13.50  0.50 
3.0 13.50  0.50 
 
5.3.2 Cell morphology and viability 
 
In a preliminary study to optimise the SAW nebulisation (in terms of maximising retention of 
the cell viability post-nebulisation). Cell viability was judged by Trypan blue assay and (cells 
were examined using Trypan blue immediately after being nebulised and cell viability were 
calculated by normalising the number of viable cells in the nebulised samples against the 
viable cells in the untreated samples). Cell viability decreased with increasing applied power 
(Figure 5.4), possibly due to the increase in the stresses to which the cells are subjected with 
increasing levels of acoustic radiation pressure. This observation is consistent with a previous 
study using SAW radiation to drive osteoblast perfusion into tissue scaffolds (although not via 
nebulisation), in which cell viability decreased as the power applied increased [372]. Cell 
viability (normalised by that of the control cells) remained relatively high—close to 90% even 
at 1.5 W, which, together with the 100 L/min delivery at this power (Figure 5.2), is adequate 
for most stem cell therapeutic applications and demonstrates the potential efficacy of the 
device as a platform for pulmonary stem cell delivery. To minimise the loss in stem cell 
viability, the device was henceforth operated at the optimum applied power of 1.5 W.  
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The minimum power need to drive microcentrifugation is 1.5 W, below this power, no 
microcentrifugation was observed.  
 
 
Figure 5.4: Post-nebulisation MSC viability as a function of the power applied to the SAW 
device, measured immediately after nebulisation using a trypan blue assay. The data are 
represented as mean value (n = 3) ± standard error.  
 
Figure 5.5 shows representative LSCM images of the cells stained with Calcein AM and PI 
after being seeded on a new well-plate and incubated for 2 and 24 hours. At 2 hours post-
nebulisation, most of the MSCs were stained by Calcein AM (green), indicating that they 
remained viable after nebulisation. These MSCs had started to attach on to the well-plate. At 
24 hours post-nebulisation, the nebulised MSCs exhibited spindle-like morphology similar to 
that of untreated cells, indicating the retention of their structural integrity post-nebulisation. 
Furthermore, most of the cells were viable (stained green with Calcein AM) and there were 
relatively few inviable cells (stained red with PI).  
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Figure 5.5: Viability of unexposed and nebulised MSCs, as indicated by Calcein AM and PI 
staining. The cells were examined 2 hours and 24 hours post-nebulisation. Live cells stained 
by Calcein AM appear green and dead cells stained by PI appeared red. For the positive 
control, cells were treated with 0.1% Trition X-100 prior to staining. The scale bars represent a 
length of 50 µm. 
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The high cell viability was confirmed by flow cytometry, in which representative dot plots of 
Calcein AM intensity against PI intensity (Figure 5.6) showed that the majority of nebulised 
cells was stained with Calcein AM. MSCs nebulised at 1.5 W exhibited a viability of 86.0  
4.2% immediately after nebulisation. Nonetheless, MSC growth recovered after re-culturing 
for another 24 hours, to the extent that there was no significant difference in cell viability 
between nebulised MSCs and untreated MSCs (p = 0.026, n = 4). Thus, SAW nebulisation did 
not change MSC viability. 
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Figure 5.6: Flow cytometry analysis indicating the viability in the population of unexposed and 
nebulised MSCs stained with Calcein AM and PI immediately after nebulisation and at 24 
hours after nebulisation. For the positive control, cells were treated with 0.1% Trition X-100 
prior to staining. 
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5.3.3 Cell metabolic activity and proliferation 
 
When MSCs were seeded into a well-plate and cultured over 7 days, as shown in the 
representative phase-contrast optical microscope images in Figure 5.7, both nebulised and 
untreated MSCs expanded and occupied more of the substrate area over time. In addition, the 
morphology of nebulised MSCs remained similar to that of untreated MSCs. 
 
Figure 5.7: Phase contrast images of unexposed (left column) and nebulised (right column) MSCs 
acquired at different incubation times. The majority of cells exhibited a spindle-like morphology. 
Scale bars represent a length of 100 µm. 
 
 
Unexposed cells  Nebulised cells 
Day 1 
Day 3 
Day 5 
Day 7 
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Figure 5.8 shows the metabolic activity of the nebulised MSCs over a period of 7 days, 
calculated by normalising the extent of AlamarBlue reduced by the nebulised cells compared 
with that reduced by the untreated cells. The metabolic activity of the nebulised MSCs 
increased over time, regardless of the power at which the cells were nebulised, but decreased 
as the power applied increased. The metabolic activity of MSCs nebulised at 1.5 W was the 
greatest amongst the range of applied power that was tested. This observation is not surprising, 
given the decrease in cell viability with increasing power (Figure 6.3) which was expected to 
influence the metabolic rate proportionally.  
 
Figure 5.8: Metabolic activity of nebulised MSCs at day 1, 3, 5, and 7 days, determined using an 
AlamarBlue assay, the results of which were normalised against the activity of the control, 
i.e. the unexposed cells (100% activity). The data are represented as mean (n = 3) ± standard 
error. 
 
The strong correlation between the number of cells and DNA content allowed the cellular 
proliferation rate to be determined with high accuracy by measuring the DNA content of the 
MSCs over time using a Quant-iT PicoGreen dsDNA assay. Figure 5.9 shows that the 
number of MSCs increased gradually over a 7 day period in both the nebulised (p < 0.0001,  
n = 3) and untreated (p < 0.0001, n = 3) samples. This study note though that the nebulised 
Design and Development of miRNA and stem cell based micro/nano systems as lung disease therapy            L Alhasan 
 
123 
 
cells proliferated slightly slower from day 5 (p = 0.16, n = 3); nonetheless, the nebulised cells 
were observed to maintain their proliferation ability throughout the entire test duration. 
 
 
Figure 5.9: MSC proliferation after nebulisation at 1.5 W. Cell proliferation was determined by 
quantifying the DNA content using a Quant-iT PicoGreen dsDNA assay. The data are 
represented as mean (n = 3) ± standard error. 
 
5.3.4 Gene and protein expression 
 
MSCs possess multi-lineage potential to differentiate into a number of cell types including 
osteocytes, adipocytes and chondrocytes. They express the surface markers CD29, CD44 and 
CD106. RT-PCR analysis of the expression of these three genes showed no significant 
different between control and nebulised MSCs at either 24 or 72 hours, and no significant 
trend with time, suggesting that nebulised cells were phenotypically similar to control cells 
(Figure 5.10A).  
 
Gene expression of the nebulised MSCs was further quantified using qPCR at different time 
points as shown in Figure 5.10B. Compared to the control, the nebulised MSCs continued to 
express similar levels of CD29, CD44 and CD106 after 24 hours (p = 0.92, n = 4; p = 0.6, n = 
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4 and p = 0.49, n = 4, respectively) and 72 hours (p = 0.5, n = 4; p = 0.65, n = 4; p = 0.98, n = 
4, respectively), suggesting that SAW nebulisation did not alter the expression of these genes 
in the MSCs. 
 
 
Figure 5.10: (A) RT-PCR and (B) qPCR analysis of nebulised MSCs, showing the lack of 
change in expression of three genes relative to unexposed MSCs after 24 and 72 hours. The 
error bars indicate the standard deviation (n = 3). In (A), lanes 1 and 3 are from unexposed 
cells (control) whereas lanes 2 and 4 are from nebulised cells. 
 
This lack of change in gene expression was further verified by flow cytometry analysis, used 
to determine the expression of these proteins in cells.  Figure 5.11 shows that the nebulised 
MSCs had similar CD29, CD44 and CD106 positive cell counts to their their controls after 24 
hours (p = 0.30, n =3; p = 0.69, n = 3 and p = 0.16, n =3, respectively) and 72 hours (p = 0.72, 
n =3; p = 0.32, n = 3 and p = 0.83, n = 3, respectively). Taken together, these results suggest 
that SAW nebulisation caused no detrimental effect to the phenotype and integrity of the 
MSCs, even after taking into account the longer culture period post-nebulisation. The SAW 
device is therefore a promising platform for stem cell nebulisation.  
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Figure 5.11: Immunophenotypic profile of unexposed (control) and nebulised MSCs after 
incubation periods of 24 and 72 hours. 
 
5.4 Conclusions 
 
This study demonstrates the feasibility of generating MSC-laden aerosols using a SAW 
nebulisation platform without deleterious effects on the cells. An optimum power level of 1.5 
W yielded a balance between maximising cell viability at an acceptable level of approximately 
90% after re-culturing for 24 hours whilst maintaining a practically useable delivery rate of 
100 µL/min for inhalation. This was verified by post-nebulisation assessment of the structure, 
metabolic activity, proliferation and genetic makeup of the MSCs, which indicated that the SAW 
nebulisation process did not have any significant adverse effects on the cell metabolic rate, 
proliferation ability, or genotypic and phenotypic characteristics compared with their non-nebulised 
counterparts. Given the novelty of inhaled stem cell therapy, comparisons with other delivery methods 
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are difficult at present due to lack of comparable studies. More data for benchmarking are likely to 
become available in the near future due to the increasing interest in stem cell therapy, given the 
absence of viable alternative treatment regimes for respiratory ailments to date. Nonetheless, the 
results in this work provide compelling evidence that the SAW nebulisation platform, with its inherent 
benefits of low cost and portability, constitutes an attractive tool for the delivery of stem cells via 
inhalation for the treatment and repair of lung function. 
………………………………
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CHAPTER SIX 
 
 
Stem cell differentiation in hydrogel for lung tissue regeneration 
 
6.1 Introduction 
 
 
Lung diseases are major causes of morbidity and mortality worldwide. Currently, there is no effective 
therapy for many lung diseases including chronic obstructive pulmonary disease (COPD), idiopathic 
pulmonary fibrosis (IPF) and cystic fibrosis. Lung transplantation is the only option for patients with 
end-stage lung diseases however; there are limited donor lungs available for transplantation. 
Typically, transplantation recipients have suffered immune response problems, resulting in only 50% 
survival.  
Currently, there is increasing interest in using hydrogels as either a drug- or protein-delivery system 
along with cell therapies and this may offer new treatment options for a wide range of diseases. The 
use of injectable and biodegradable hydrogels encapsulated with desired cells for implantation is 
attractive, as the implantation can be administrated by simple needle injection. Nevertheless, there is a 
need to develop new injectable hydrogels as well as optimising hydrogel performance. Such injectable 
hydrogels can be used to regenerate lung tissues as well as many other tissue types.  Many chemical 
cross-linking processes have been utilised to cross-link hydrogel tissue scaffolds. However; many of 
these processes involve the use of toxic reagents or can cause unwanted side effects, making them not 
suitable for biomedical applications [424]. It is therefore very important to identify biocompatible 
cross-linking mechanisms using non-toxic catalysts such as enzymes that can occur under mild 
conditions [425]. Laccases are enzymes produced by fungi, higher plants, bacteria and insects. They 
are multi-copper oxidases that have the ability to catalyse the oxidation of several phenol-like 
compounds, aromatic amines and some inorganic compounds [426]. Due to their ability to catalyse 
the oxidation of an aromatic substrate in the presence of molecular oxygen, which is then reduced to 
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water after the reaction, laccases are widely used in various applications such as pulp delignification, 
bio-bleaching, treatment of industrial plant wastewater, fibre modifications, fruit juice processing and 
biosensor and biofuel cell construction [427, 428]. Kato et al. have reported the encapsulation of 
laccase in an aluminium silicate nanotube hydrogel as a new technology for stable biocatalysis [429]. 
Mano’s group has reported the synthesis and characterisation of a laccase-mediated redox hydrogel 
for efficient catalysis of O2 electroreduction [430]. 
 Also, for tissue regeneration, Bletchley et al. have developed a hybrid hydrogel system comprised of 
two polymer backbones, gelatin and dextran, for functional vascular morphogenesis in vitro. The 
polymer precursors in this system were cross-linked through a laccase-mediated reaction [431]. 
Rocasalbas et al. developed a bioactive hydrogel dressing for chronic wound treatment containing 
plant polyphenols, chitosan and gelatin, that were cross-linked by laccase [432]. Park and Gerecht 
have reported a new hypoxia-inducible (HI) hydrogel containing gelatin and ferulic acid that forms 
hydrogel networks through a laccase-mediated reaction. Laccase successfully cross-linked gelatin 
polymers to form hydrogels that promote the formation of vascular networks and establish 
neovasculature that is functional and anastomoses with the host network during subcutaneous wound 
healing [433].  
Cell-based tissue engineering using hydrogel scaffolds offers great promise for repairing lung tissue. 
Embryonic stem cells (ESCs) are a promising cell source for cell therapy applications and the 
treatment of incurable and damaging disorders, including spinal cord injury, neurological disease, 
blindness and Type 1 diabetes [185]. ESCs are isolated from the inner mass of the blastocyst during 
embryological development. These cells have a pluripotent nature and differentiate into three germ 
layers: endoderm, mesoderm and ectoderm, and they can also renew themselves while maintaining an 
undifferentiated state [434]. They have received great attention due to their ability to provide the 
biomedical community with an unlimited source of all cell types for tissue replacement [435].  
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A review of the literature suggests that an air-liquid interface closely mimics the lung 
microenvironment that cells experience in vivo for lung tissue engineering. Airway epithelial cells de-
differentiate as a flat non-ciliated morphology in routine culture conditions: however, when the 
cultures are exposed to an air–liquid interface that mimics the in vivo conditions, the cells differentiate 
into pseudo-stratified columnar epithelium that creates high-resistance barriers [436, 437]. Rippon and 
co-workers have shown that induced pluripotent stem cells (iPSCs) differentiated into definitive 
endoderm and then fully differentiated into airway epithelia when raised in an air-liquid interface 
medium by culturing in transwell inserts coated with a combination of fibronectin, laminin and 
collagen or in six-well plates coated using Matrigel [243]. Wong et al. developed a protocol to induce 
the differentiation of stem cells into definitive endoderm and then into airway epithelium cells by 
culturing ESC and iPSC cells in transwell inserts pre-coated with human placental collagen Type IV 
with the addition of Activin-A and WNT3A to drive their differentiation into definitive endoderm and 
then promote polarisation in apical expression for CFTR in bronchial-air liquid interface (B-ALI, 
Lonza) medium in the presence of a growth factor (FGF18)  [438]. Firth et al. have also developed a 
step-wise differentiation protocol ending in an air–liquid interface to generate a pseudo-stratified 
polarized layer of endodermal-derived epithelial cells from human induced pluripotent stem cells by 
culturing iPSCs cells in transwell inserts coated with a combination of fibronectin, laminin and 
collagen or six-well plates coated Matrigel [439].  
Growing stem cells in tissue engineering constructs in air-liquid interface conditions instead of in 
tissue culture plasticware may offer a better solution for lung tissue regeneration, since the whole 
tissue engineering construct can be transplanted into the patient directly as a piece of 3D tissue instead 
of needing to retrieve differentiated cells from tissue culture wells, which often results in distortion of 
the cell-cell bonding. For example, Shojaie et al. demonstrated the differentiation of pluripotent cells 
cultured in a decellularized mouse and rat lung scaffold under air-liquid interface conditions into 
mature airway epithelia, complete with ciliated cells, club cells and basal cells with morphological 
and functional similarities to native airways, with specific lung epithelia markers and compared them 
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with 2D culture [440]. They showed the development of 3D scaffolds that mimicked the 3D 
architecture of lung tissues synthesized from DHHA and gelatin; such synthetic scaffolds are more 
economical than decellularized tissue scaffolds, which need expensive enzymes to remove cells.  
The overall aim of the current study was to develop an injectable tissue scaffold capable of improving 
the differentiation of embryonic stem cells in air-liquid interface culture conditions. Cytotoxicity 
studies using murine embryonic stem cells were carried out to examine the biocompatibility of the 
scaffold. The hydrogel was investigated as a support for the proliferation and differentiation of 
mESCs into lung epithelial cells at air-liquid interface culture (ALI). 
6.2 Methods  
 
6.2.1 Synthesis and characterisation of Gtn-DHHA 
 
 
Gelatin and 3,4-dihydroxyhydrocinnamic acid (Gtn-DHHA) conjugates (Figure 6.1) were synthesized 
using a general carbodiimide ester-mediated coupling reaction. In brief, DHHA (1.66 g) and NHS (1.6 
g) were dissolved in 75 mL MilliQ water and 50 mL dimethylformamide (DMF); the solution was 
purged with N2 gas for 20 min. To this solution, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
hydrochloride (EDC) (1.91 g) was added immediately. The reaction was stirred at room temperature 
for 5 hours at pH 4.7 and N2 gas was purged in the solution during the synthesis. Then  
5 g of gelatin was dissolved in 150 mL MilliQ water. The dissolved gelatin was added to the mixture 
and was stirred overnight at room temperature. The mixture was transferred to dialysis tubes with a 
molecular cut-off of 1,000 Da.  
The final product was dialysed against 100 mM NaCl, 25% ethanol, and Milli-Q water for 2 days each 
in sequence, with N2 gas purging the dialysed solutions. The products were then lyophilised. 
Conjugation of 3, 4-dihydroxyhydrocinnamic acid to gelatin was confirmed by 1H NMR (D2O). In 
brief, the conjugation of DHHA on gelatin was assessed in D2O using an NMR operating at 300 MHz 
(ACF300, Bruker Pty Ltd, Alexandria, NSW, and Australia).  
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The gelation time of Gtn-DHHA was estimated using an inverted tube test method according to Gupta 
et al.[378]. Briefly, laccase at concentrations of 2.27, 4.16 and 5.76 units/mL were added to 2 ml 
microcentrifuge tubes (Axygen Scientific, VWR International Pty Ltd, Murarrie, QLD, Australia) 
containing 5%, 10% and 15% (v/v) Gtn-DHHA in PBS. The mixture was vortexed and mixed with 
the tube reverted every 30 s interval to observe flow. The gelation time was recorded as the time when 
the gel ceased to flow. 
The swelling ratio of the Gtn-DHHA hydrogel was measured using a conventional gravimetric 
method according to Hoo et al. [383].  In brief, sterilised hydrogels were prepared at 5%, 10% and 
15% (v/v) Gtn-DHHA with 2.27 units/mL laccase concentrations. The hydrogels were subsequently 
cut into round disks using a sterile circular mould and were swollen by immersion in sterile PBS for 3 
days at 37ᵒC. Excess liquid was wiped off by gently blotting the hydrogel with laboratory wipes. The 
swelling ratio, SR, of the scaffold was calculated according to the equation below: 
   
     
  
 
where Wh is the weight of the scaffold in the swollen equilibrium and Wd is the weight of the dried 
scaffold. Each sample was measured three times from triplicate specimens and the average value of 
the measurement was taken. Rheological measurements of the hydrogel formation were performed 
using an HR3 
 
Discovery Hybrid stress-controlled rheometer (TA Instruments, USA). The instrument 
was calibrated before the experiments by using Poly Dimethyl Siloxane (PDMS) as a calibration 
standard; cross-over frequency was well within the limits as per standards provided by the instrument 
suppliers. The cone and plate geometry of 50 mm diameter and 0.04ᵒ cone angles used were 
according to Wang et al. [441]. The shear rheological measurements were conducted at room 
temperature in the dynamic oscillatory mode with a constant deformation of 1% and frequency of 1 
Hz.  Laccase was added at different concentrations of an aqueous solution of Gtn-DHHA (5%, 10% 
and 15% in 1 mL of PBS). This solution was vortexed and then immediately applied to the bottom 
plate. The upper cone was then lowered to a measurement gap of the truncated value provided by the 
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instrument supplier).  A layer of silicon oil was carefully applied around the cone to prevent solvent 
evaporation during the experiment.  
A solvent trap was used to cover the rheometer to avoid further change in phase change. The 
measurement parameters were determined to be within the linear viscoelastic region in preliminary 
experiments. A compression test was carried out to assess the mechanical properties of Gtn-DHHA 
scaffolds at different polymer concentrations using a dynamic mechanical analyser (TQ Instruments, 
Q800) at a frequency of 1 Hz and a preload 0.01 N according to [442].  
 
The test was performed at room temperature (22C) and at 298 K. The testing was performed in 
quadruplicate. To measure degradation rate, hydrogels were prepared at 5%, 10% and 15% (w/v) 
polymer concentrations, and the hydrogels were then immersed in 10 mL of PBS containing 0.61 
units/ml of type I collagenase and incubated at 37C in an orbital shaker at 100 rpm. The degradation 
rate of the hydrogels was assessed by measuring the residual hydrogel weight. To measure the 
residual weight, the hydrogels were removed from the solution, blotted dry and weighed at different 
time points [441].  
6.2.2 Cell culture  
 
 
E14TG2A cells were cultured on 0.1% gelatin-coated tissue culture plates in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum-embryonic stem cell-qualified (Gibco), 
1% non-essential amino acids (Gibco), 1% L-glutamine (Gibco), 0.1 mM 2-mercaptoethanol, 1% 
penicillin-streptomycin and 1000 U mL
-1
 murine leukemia inhibitory factor (mLIF, Chemicon, 
Australia). Cells were maintained in a humidified atmosphere of 5% CO2/95% air at 37ᵒC. 
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6.2.3 Cell viability  
 
 
ESCs were immobilized in the enzymatically cross-linked hydrogels in 24-well plates. Cells cultured 
on 0.1% gelatin-coated tissue culture plates served as controls. After 24 hours, a live/dead cytotoxicity 
kit (Life tTechnologies) containing calcein-AM and propidium iodide were used to evaluate viability 
of pluripotent embryonic stem cells [327].  
Confocal laser scanning microscopy was used to visualize the live (green) and dead (red) cells, dead 
cells were imaged by the inclusion of the propidium iodide fluorophore in the medium and then 
visualised by laser confocal fluorescence microscopy (Nikon A1R equipped with a Nikon Eclipse Ti 
Fluorescence Microscope). 
6.2.4 Cell proliferation assay 
 
 
Cells were immobilized in the enzymatically cross-linked hydrogels in 24-well plates and compared 
with those cultured on 0.1 gelatin-coated plates as control.  For the control, mESCs at a cell density of 
1×10
5
 cells/ml were seeded in 6-well coated plates and maintained in culture medium while 3D cell 
cultures in hydrogel mESCs were mixed with 1 mL of Gtn-DHHA solution (10% w/w) in 6-well 
plates at a final concentration of 1×10
5
cells/ml. To initiate gel formation, 2.27 units/mL of laccase 
(Sigma Aldrich, Australia) was added to the solution. The hydrogels were allowed to set for 2 hours 
before the addition of culture medium. For both 2D and 3D studies, the culture medium was changed 
every day. 
The total number of cells within Gtn-DHHA hydrogel was quantified using a Quant-iT™ PicoGreen® 
dsDNA Assay Kit by measuring the DNA content, as DNA is the cellular component that most 
precisely reflects cell number [443]. PicoGreen assay was performed according to the manufacturer’s 
instructions (Life Technologies). Fluorescence of the samples was measured using a plate reader and 
compared with that of a lambda DNA standard, provided with the kit.  
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In brief, the cells were trypsinised from the substrate and centrifuged for 5 min at 140×g. The cell 
pellet was washed with cold PBS twice, each followed by centrifugation for 5 min at 140×g. The 
resulting cell pellet was collected by discarding the supernatant. The cells were lysed using 100 µL of 
NP40 cell lysis buffer (Life Technologies, Australia) for 30 min on ice and vortexed at 10 min 
intervals. The extract was transferred to microcentrifuge tubes and centrifuged at 13000 rpm for 10 
min at 4°C.  
The clear lysate was aliquoted to clean microcentrifuge tube, 100 μL of PicoGreen reagent was added 
and allowed to incubate for 5 min at room temperature in the dark. The final solution was transferred 
into a 96-well plate, and the fluorescence was read using a fluorescence plate reader (FLUOstar 
Omega microplate reader, BMG Labtech Pty, Ltd, Australia) at standard fluorescein wavelengths 
(excitation~ 480 nm, emission ~ 520 nm). The unknown DNA results were compared with that of a 
DNA standard curve. 
6.2.5 Differentiation of embryonic stem cells into lung epithelial cells  
 
 
To investigate the ability of embryonic stem cells to differentiate into definitive endoderm and further 
into lung epithelial cells, the cells were trypsinised with TrypLE™ Express Enzyme (1X) (Life 
Technologies, Australia), and then seeded at a cell density 1×10
5
 cells/mL in maintaining medium 
composed of DMEM and 10% fetal bovine serum, 1% non-essential amino acid, 1% L-glutamine,  
0.1 mM 2-mercaptoethanol and 1% penicillin-streptomycin in 24-well plates without leukaemia 
inhibitor factor (LIF) in the presence or absence of growth factors in an air-liquid interface and 
submerged medium for immunofluorescence and qPCR analysis.  
 
After 1 day of culture, the spent medium was changed with a differentiation medium containing 75% 
(v/v) Iscove’s Modified Dulbecco’s Medium (Life Technologies, Australia), and 25% (v/v) Ham’s 
F12 Medium (Life Technologies, Australia), 1% FBS (Life Technologies, Australia) supplemented 
with 0.5 x B27,    50% U/mL penicillin, 50% µg/mL streptomycin, 0.05% BSA, 2 mM glutamine 
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(Life Technologies, Australia), 0.5 mM ascorbic acid, 4.5 x 10
-4
 M 1-thioglycerol (Sigma Aldrich, 
Australia), 20 ng/ml Activin; also 1 ng/ml Wnt3a (Bio-Scientific, Australia) was added to the 
differentiation medium. Cells were allowed to grow for 7 and 14 days in the differentiation medium 
for 2D and 3D culture respectively. Medium exchange was carried out every 2 days.  
To better mimic the lung microenvironment, cells were maintained in Gtn-DHHA hydrogel under air-
liquid interface (ALI) culture conditions, spent medium was removed after 7 days and 14 days for 2D 
and 3D culture, respectively.  Fresh differentiation medium supplemented with 1 µg/mL heparin 
sulphate salt and   500 ng/mL FGF2 (F0291, Sigma Aldrich, Australia) replaced the spent medium 
and cells were incubated for a further 14 and 30 days for the control and hydrogel samples 
respectively.  
6.2.6 Immunofluorescence assays  
 
A. Immunofluorescence assays for endoderm markers 
 
Endoderm markers were evaluated for both control and 3D cells in the presence of growth factors 
after 7 and 14 days respectively. For immunofluorescence assay, control cells (2D) and cells in 3D 
scaffolds were fixed in 4% paraformaldehyde for 10 min and 30 min respectively and washed 3 times 
with PBS. Cells were blocked with 1% BSA (bovine serum albumin) for 30 and 60 min respectively.       
E-Cadherin and Foxa2 primary antibodies (Santa Cruz Biotechnology, USA) were added to cells 
(1:100) and incubated for 1 hour and 48 hours (to allow for antibodies to penetrate within the 
hydrogel) respectively. Cells were then washed three times with PBS for 5 minutes each for the 
control and 15 min each for the 3D scaffold cells. Goat anti-rabbit secondary antibody (Sapphire 
Bioscience, Australia) and Donkey anti goat antibody (Life Technologies, Australia) were added to 
cells (1:1000) and then incubated for 30 min and 4 hours for control and 3D scaffold cells 
respectively. Cells were rinsed 3 times with PBS for 5 min and 15 min respectively. Then 4', 6-
diamidino-2-phenylindole (DAPI) 1:2000 was added to the cells and incubated for 3 min and 20 min 
for control and 3D scaffold cells respectively at terminal stages of the technique.  
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Prior to determining endoderm markers, cells were immersed in 300 µL of PBS to prevent cell drying.  
Images of cells were acquired by laser confocal fluorescence microscopy (Nikon A1R with a Nikon 
Eclipse Ti Fluorescence Microscope).  
B. Immunofluorescence assays for lung cell markers 
 
 
Control cells and 3D cells were fixed in 4% paraformaldehyde for 10 and 30 min respectively and 
rinsed three times with 1X PBS. Cells were blocked with 1% BSA (bovine serum albumin) for 30 min 
and 60 min respectively. Pep2 and Sema4f primary antibodies (Santa Cruz Biotechnology, USA) were 
added to cells (1:100) and incubated for 1 hour and 48 hours respectively. Cells were rinsed three 
times with PBS for 5 min and 15 min for control and 3D cultures respectively. Goat anti-rabbit 
secondary antibody (Sapphire Bioscience, Australia) was added to cells (1:1000) and cells incubated 
for 30 min and 4 hours for control and 3D cultures respectively. Cells were rinsed 3 times with PBS 
for 5 min and 15 min, respectively and then 4', 6-diamidino-2-phenylindole (DAPI) (1:2000) was 
added to cells and incubated for 3 min and 20 min respectively at terminal stages of the technique. 
Prior to determining lung epithelial cells, cells were immersed in 300 µL of PBS to prevent cell 
drying.  Images of cells were acquired by laser confocal fluorescence microscopy (Nikon A1R with a 
Nikon Eclipse Ti Fluorescence Microscope). 
6.2.7 TaqMan quantitative PCR  
 
 
The gene expression of Sox17, Fox2a for endoderm markers and Ttf1, Unc5b, Pept2 and Sema4f for 
lung markers in 2D control and 3D scaffolds were quantified using qPCR. Pou5f1 and GAPDH were 
used as negative and positive controls respectively. Ribonucleic acid (RNA) was isolated from cells 
using an RNAeasy Mini Kit (Qiagen, Australia) according to the manufacturer’s instructions. The 
RNA quality and concentration were examined using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Thermofisher, Australia). To eliminate any contaminating genomic DNA, the isolated 
RNA was treated with a DNA-free kit according to the manufacturer’s instructions. 
Complementary DNA (cDNA) was generated using QuantiTect Reverse Transcription kit (Qiagen, 
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Australia) according to the manufacturer’s instructions. The cDNA samples were subjected to PCR 
amplification using probes obtained from Applied Biosystems (Australia). The qPCR analysis was 
performed using a Rotor-Gene Q (Qiagen, Australia) with a TaqMan transcription kit (Life 
Technologies, Australia) using TaqMan assays, Sox17 (Mu00488363_m1), Foxa2 
(Mm01976556_s1) and Pou5f1 (Mm03053917_g1), and Ttf1 (Mm00657018_m1), 
Unc5bMm00504054_m1), Pept2(Mm00451610_m1) and Sema4f(Mm01181883_m1). All 
gene expressions were normalised to GAPDH (Mm99999915_g1) as a reference in 
corresponding samples. After 10 min of denaturation at 95C, 40 PCR cycles were carried out 
at 95C for 15 s, 60C for 30 s, and 72C for 15 s. The relative mRNA levels were calculated 
using the CT method [332]. The results were reported as fold change values compared to 
2D monolayer cells. 
 
6.2.8 Statistical analysis 
 
 
All experiments were performed with at least 3 replicates and results were reported as the average 
value ± standard deviation. Multiple groups of data were compared using One Way Analysis of 
Variance (ANOVA).  Two groups of data were compared using Student’s t-test. Differences between 
groups of data were considered statistically significant when p < 0.05. 
 
 
 
 
 
 
Design and Development of miRNA and stem cell based micro/nano systems as lung disease therapy            L Alhasan 
 
138 
 
6.3 Results and Discussion 
 
 
This study attempted to examine the proliferation and differentiation potential of murine embryonic 
stem cells in Gtn-DHHA scaffold hydrogels via an in vitro experiment in the presence and absence 
growth factors and with or without provision of air-liquid interface. The ability of mESCs to 
differentiate into endoderm and subsequently lung epithelial cells was evaluated.  
    
6.3.1 Gtn-DHHA characterisation and hydrogel preparation 
 
 
DHHA conjugate was synthesized according to the scheme illustrated in Figure 6.1; the conjugation 
was confirmed using 
1
H NMR spectroscopy as shown in Figure 6.2. 
1
H NMR spectra of Gtn-DHHA 
were compared with DHHA and gelatin as controls to determine if there was a change. The 
1
H NMR 
spectra showed that the difference between the DHHA control spectrum (Figure 6.2A) and gelatin as 
controls (data not shown), and the Gtn-DHHA conjugate spectrum (Figure 6.2B); original peaks 
appearing in the control either changed or disappeared from the conjugate spectrum. All four peaks 
present in the DHHA control spectra were no longer present, or had changed in the conjugate spectra.  
Figure 6.2B shows a typical spectrum of Gtn-DHHA; the cluster peaks at  = 7.2 and 7.5 confirmed 
the conjugation of DHHA with Gtn.  The Gtn-DHHA conjugate with 5%, 10% and 15% at various 
concentrations of laccase was used to determine optimum gel precursor/cross-linker ratio. This test 
found that all concentrations could be crosslinked by laccase, with gelation time decreasing as gel 
Gtn-DHHA concentration increased, and the gelation time decreased with increased availability of O2 
by purging O2 in the hydrogel liquid with air (Figure 6.3).  
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Figure 6.1: Synthesis scheme for (A) 3,4-dihydroxyhydrocinnamic acid, and (B) gelatin-3,4-
dihydroxyhydrocinnamic hydrogel crosslinking. 
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Figure 6.2: 
1
H NMR spectrum of (a) 3, 4-Dihydroxyhydrocinnamic acid, b. gelatin-3,4-
dihydroxyhydrocinnamic acid conjugate. 
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Figure 6.3: Images of Gln-DHHA hydrogel gelation at various concentrations of laccase  
(2.27, 4.16, and 5.76 units/ml). 
 
6.3.2 Swelling ratio and mechanical properties 
 
 
Figure 6.4A summarises the swelling ratios of different concentrations of Gtn-DHHA hydrogel cross-
linked by a fixed amount of laccase at 2.27 U/ml. The swelling ratio is a measure of the material 
wettability; hydrogels with high swelling ratios are highly hydrophilic and highly permeable, which 
facilitates the transport of water-soluble molecules, oxygen, nutrients and the exchange of metabolites 
within the hydrogel [441]. As expected, the swelling ratios decreased with increasing polymer 
concentration (p < 0.05, n = 3), and were 36.03% ± 4.30, 25.16 ± 3.25 and 18.7 ± 3.5 for 5%, 10% 
and 15% Gtn-DHHA hydrogels respectively. From rheological measurement, the crossover of G" and 
G', also known as gel point, occurred within 533.76 s for 5% Gtn-DHHA hydrogel cross-linked by 
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2.27 U/ml of laccase (Table 6.1). The gel point is known as the transition point from the liquid state 
to the solid state [444]. The effects of various concentration of polymer on gel point were also studied; 
the time required to reach gel point decreased as polymer concentrations increased while keeping 
laccase concentration constant. The gel points were 248.52 s and 121.54 s for 10% and 15% Gtn-
DHHA respectively, indicating that the gel point was dependent on polymer concentration. These 
results are in good agreement with previous reports on the independent tuning of hydrogel mechanical 
properties and gelation rates [441, 445-447].  For tissue regeneration to be successful, it was expected 
that the mechanical properties of the scaffold had to be similar to those of in vivo tissue in order to 
provide cells with an instructive microenvironment. The storage modulus values of 5%, 10% and 15% 
Gtn-DHHA were 1.29 ± 0.14, 3.43 ± 0.18 and 10.17 ± 0.62 kPa respectively. 
As predicted, the storage moduli increased as Gtn-DHHA polymer precursor concentration increased 
(p < 0.05, n=4), as shown in Figure 6.4B. It is well known that the hydrogels with greater precursor 
masses display stronger mechanical properties. The storage moduli of the Gtn-DHHA hydrogels were 
comparable to those of soft tissues and organs, for example thyroid, fibrotic liver, breast and kidney 
[448]. These results demonstrate that the swelling ratio and the mechanical strength of the hydrogel 
could be modulated by changing the hydrogel concentration. 
Table 6.1: Gelation time for 3D hydrogel by rheology testing. 
 
 
Gln-DHHA concentration (w/v) Laccase concentration (U/mL) Gelation time (s) 
5% 2.27 533.76 
10% 2.27 248.52 
15% 2.27 121.54 
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Figure 6.4:  Swelling ratio (A) and storage modulus (KPa) (B) of Gln-DHHA-5 wt%, 10 wt% and   
15 wt% at 2.27 unit/ml laccase. The data are represented as mean values with standard deviation as 
error bars in the form of mean value ± standard deviation. 
 
6.3.3 Degradation rate 
 
 
Figure 6.5 shows that the rate of hydrogel degradation decreased with increased hydrogel 
concentration due to the lower water accessibility (therefore slower degradation rate) and this result 
demonstrated that the enzymatic degradability of Gtn-DHHA hydrogels could be modulated by 
varying polymer concentration. 
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Figure 6.5: Degradation rate of swelling ratio of scaffold hydrogels prepared at 5%, 10% and         
15% (w/v). The data are shown as mean values ± standard deviation. 
 
6.3.4 Cell viability and proliferation 
 
 
The viability of ESCs was around 90% as measured by counting the number of Calcein AM-stained 
cells. At 24 hours after immobilisation, cells encapsulated within the hydrogels displayed a rounded 
morphology; cells need to degrade the hydrogel by secreting proteinase such as MMP prior to 
spreading out (Figure 6.6).  
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Figure 6.6: The effect of scaffold hydrogel on embryonic stem cell viability (E14TG2A). Cells were 
embedded in scaffold hydrogel. Cells were stained with Calcein-AM and propidium iodide. Viable 
cells stained with Calcein at 24 hours after culturing are shown.  Scale bars represent 100 µm. 
 
The cell DNA content was no significantly increased over a 7-day period; the cell number in scaffolds 
changed more slowly than those in the controls at day 7, probably because cells in hydrogel need to 
secret proteinase to degrade the 3D hydrogel before they can propagate, which takes longer than 
propagation on a 2D surface (Figure 6.7). Nonetheless, these results indicate that the Gtn-DHHA 
encapsulated cells remained viable and possibly capable of proliferation, and confirmed that Gtn-
DHHA hydrogel was suitable for tissue engineering applications.  
 
Design and Development of miRNA and stem cell based micro/nano systems as lung disease therapy            L Alhasan 
 
146 
 
 
Figure 6.7: Cell proliferation of embryonic stem cells (E14TG2A) in coated well plates and scaffold 
hydrogels. Data are represented as mean (n = 3) ± standard error of the mean and were compared by 
Student t-test with control cells.  
  
 6.3.5 Gene expression and immunostaining profile for endoderm markers 
 
 
Various factors should be considered in attempt to develop lung distal airways cells as the presence of 
biomolecules may direct the differentiation of ES cells into lung epithelium, for example molecular 
signalling associated with fibroblast growth factor (FGF2), B-27 without retinoic acid, Activin, 
WNT3 signalling, heparin salts, bovine serum albumin and ascorbic acid [449, 450].  
Figure 6.8 shows a schematic of the protocol used to differentiate mESCs into cells with phenotypic 
characteristics of alveolar epithelial cells, in which fibroblast growth factor (FGF-2) was added to 
drive the differentiation of mESCs into lung epithelial cells. 
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Figure 6.8: Schematic of protocol utilised to differentiate murine embryonic stem cells (E14tg2a) into 
cells with phenotypic characteristics of lung epithelial cells.  A. Control, B. Immobilised cells at air-
liquid interface medium, C. immobilised with submerged medium in the presence and absence of 
growth factors. 
 
Lung cells are differentiated from endoderm. Definitive endoderm was first produced from mESCs by 
adding growth factors Activin A and WNT3 [451]. In the study in this thesis, over periods of 7 days 
and 14 days, the endoderm transcription factors Foxa2 and Sox17 of 3D culture cells exhibited greater 
expression than 2D monolayer cells, in particular for those cells that were embedded in 3D hydrogel 
in an air-liquid interface (8.46±1.10, 4.73± 0.85) fold change respectively, compared with submerged 
medium (6.40 ± 0.72, 5.90 ± 0.91) fold change respectively, and control cells (3.40 ± 0.75,            
3.16 ± 0.30) fold change respectively in the presence of growth factors (Figure 6.9A). These results 
support prior investigations, which suggested that Sox17 and Foxa2 expression initially was increased 
with Activin A treatment [451]. A lesser expression was shown in the absence of growth factors       
(Figure 6.9B). 
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Figure 6.9: Fold change of gene expression of differentiated embryonic stem cells into endoderm 
relative to undifferentiated ESCs in the presence (A) and (B) absence of growth factors compared 
with their controls. Cells were assessed after 7 days and 14 days for control and embedded scaffolds 
respectively. Data are represented as mean (n = 3) ± standard error of the mean and were compared by 
Student t-test to control cells. Differences were considered significant at p<0.05.  
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Differentiated cells were analysed by immunostaining using confocal microscopy for all tested 
conditions to assess if the up regulation of E-caderin and Fox2a was correlated with Gtn-DHHA 
scaffolds. The immunostaining pattern of E-cadherin and Fox2a showed that there was a difference in 
protein distribution between 2D and 3D culture cells; the expression of E-cadherin and Fox2a of 3D 
cells appeared brighter and more uniformly distributed in cells exposed to air-liquid interfaces 
compared with those in submerged scaffold. E-cadherin is a glycoprotein and cell adhesion molecule 
that plays a role in the process of cell-to-cell adhesion; Fox2a and E-cadherin are also good indicators 
for definitive endoderm [452], as shown in Figure 6.10 A, B.  
 
Figure 6.10A:  Immunofluorescence analysis of endoderm expression (E-Cadherin). These images 
were taken for cells embedded in scaffolds in the presence of growth factor compared with the 
control. Nucleated cells are in Blue (DAPI). The E-cadherin marker is shown by a green colour and is 
an indicator for endoderm. Expression for this marker was brighter in cells embedded in scaffolds and 
control. Scale bar represents 100 µm.  
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Figure 6.10B: Immunofluorescence analysis of endoderm expression (Fox2a). These images were 
taken for cells embedded in scaffolds in the presence of growth factors compared with controls (cells 
were cultured on gelatin-coated plates). Nucleated cells are in Blue (DAPI). The Fox2a marker is 
shown by a green colour and is an indicator for endoderm. Expression for this marker was brighter in 
cells embedded in scaffolds than in the control. Scale bar represents 100 µm.  
 
  
 6.3.6 Gene expression and immunostaining profile for lung epithelial markers 
 
 
Relative to control and submerged cells, cells incubated in an air-liquid interface for 30 days showed 
evidence of differentiation, with greater Pept2, Sema4f, Unc5b and Ttf-1 gene expression             
(8.70 ± 1.80, 5.90 ± 0.52, 6.43 ± 0.35, 3.80 ± 1.38)-fold changes compared with cells grown in 
submerged medium (4.43 ± 0.68, 2.93 ± 0.49, 2.53 ± 0.45, 1.36 ± 0.251)-fold changes, and control 
cells (1.83 ± 0.709, 3.36 ± 1.70, 3.20 ± 0.55, 3.13 ± 0.95)-fold changes respectively, in the absence of 
growth factors (Figure 6.11A). By contrast, in the presence of growth factors, there was significantly 
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greater Pep2, Sema4f, Unc5b and Ttf-1 gene expression for 3D cells in an air-liquid interface      
(12.03 ± 1.95, 5.83 ± 1.64, 6.03 ± 0.30, 4.03 ± 0.85)-fold changes than in 3D cells in submerged 
medium (6.90 ± 1.56, 4.00  ± 1.30, 2.73 ± 0.50, 1.96 ± 0.15)-fold changes, and in control cells      
(6.20 ± 0.36, 3.76 ± 0.90, 3.24 ± 1.05, 2.90 ± 1.73)-fold changes, as shown in Figure 6.11B. 
These differences may be because the scaffold cells are grown in an environment similar to the in vivo 
airway epithelia, both grown in ALI (air-liquid interface) conditions [453, 454]. Ttf-1 is the earliest 
marker known for lung expression and was more greatly expressed in scaffold cells exposed to ALI 
conditions than in those not so exposed, probably because the combination of both 3D and ALI 
provide a suitable extracellular matrix environment that mimics that in vivo, and such conditions are 
not present in monolayer cultures.  Pep2 plays an important role in nitric oxide precursor uptake and 
is localised in alveolar type II cells and highly expressed in lung epithelial cells [455-457].  There was 
up-regulation of Pept2 after 30 days of culture on scaffolds, under ALI culture. Semaphorin 4F has 
been identified as a cell surface marker specific for lung bud [458]. Similarly, the present study 
demonstrated that Semaphorin 4F exhibited greater expression in immobilised cells with growth 
factor and in the presence of ALI than the control, as shown by qPCR results. 
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Figure 6.11: Fold change in gene expression during differentiation of embryonic stem cells into lung 
epithelial cells relative to undifferentiated ESCs in the absence (A) and presence (B) of growth factors 
compared with their controls. Cells were assessed after 14 days and 30 days for control and embedded 
scaffolds respectively. Data are represented as mean (n = 3) ± standard error of the mean and were 
compared by Student t-test with control cells. Differences were considered significant at p<0.05.  
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Protein expression, anti Pept2 and Sema4f antibodies were used to detect the expression of their 
corresponding lung epithelial markers using immunostaining at selected times. There was greater 
Pept2 and Sema4f protein expression in scaffold cells at 30 days following exposure to an air-liquid 
interface than in submerged and control cells (Figure 6.12 A and B). This study demonstrated that the 
use of a 3-dimensional (3D) scaffold was advantageous compared with 2-dimensional (2D) 
monolayer culture in terms of generating lung epithelial cells, since 3D systems closely mimic the  
in-vivo microenvironment, especially in an air-liquid interface [440].  As predicted, the embryonic 
stem cells maintained their viability and further differentiated in Gtn-DHHA hydrogel; therefore, this 
hydrogel is a suitable and promising scaffold candidate for use in lung tissue regeneration. 
 
Figure 6.12A: Immunofluorescence analysis of lung epithelial cells (Pept2). These images were taken 
of cells embedded in scaffolds in the presence of growth factors compared with the control. Nucleated 
cells are in blue (DAPI). Pep2 marker staining (green colour) is an indicator for lung epithelium cells. 
Expression for this marker was greater in cells embedded in scaffolds in air-liquid medium compared 
with that in submerged and control cells. Scale bar represents 100 µm.  
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Figure 6.12B: Immunofluorescence analysis of lung epithelial cells (Sema4f). These images were 
taken of cells embedded in scaffolds in the presence of growth factors. Nucleated cells are in blue 
(DAPI). Sema4f marker (green colour) is an indicator for lung epithelium cells. Expression for this 
marker was greater in cells embedded in scaffolds compared with that in submerged and control cells. 
Scale bar represents 100 µm.  
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6.4 Conclusions  
 
 
In the current study, a novel injectable biodegradable hydrogel composed of Gtn and DHHA cross-
linked by laccase was designed for lung tissue engineering. Gtn-DHHA hydrogel displayed a high 
swelling ratio, biodegradability, high biocompatibility and mechanical integrity. Gtn-DHHA hydrogel 
enhanced ESCs proliferation and differentiation toward lung epithelial cells in both the presence and 
absence of growth factors. Gene expression and immunostaining results suggested that Gtn-DHHA 
hydrogel supported stem cell differentiation and allowed growth factors to diffuse within the scaffold 
to reach cells, in particular under air-liquid interface (ALI) culture compared with submerged and 
control cells. This study suggests that Gtn-DHHA hydrogel is suitable for lung tissue repair and 
regenerative medicine for lung regeneration and may be applicable to other tissue regeneration uses.  
The combination of Gtn-DHHA hydrogel and air-liquid (ALI) culture provided a useful tool for the 
in-vitro differentiation of murine embryonic cells and provided structural support for lung epithelial 
cell survival and growth. 
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CHAPTER SEVEN 
7. General Discussion, Conclusion and Future Directions  
7.1 General Discussion 
 
 
There are many different types of lung disease that currently have no effective cure. This study 
attempted to develop novel tools with the ultimate goal of treating lung disease. For lung cancer, 
liquid marble (LM) and SAW microcentrifugation methods were developed to generate a valid 
tumour model to enhance miRNA transfection. 
 
Lung spheroids generated from the LM method had a spherical shape while spheroids generated from 
the liquid monolayer (LS) method exhibited more irregular shapes. This observation is consistent with 
previous studies [153]. In both LM- and LS- generated spheroids, the periphery was populated with 
viable cells, as tested by vital staining with Calcein AM and propidium iodide (PI). There was an 
absence of colour in the spheroid core, possibly because the core was populated with dead cells or 
because the stains did not penetrate through the tightly knit peripheral cells. PI is impermeable to live 
cells but can penetrate through a dead cell’s leaky membrane and stain the nuclei [333]. PEI and 
lipofectamine as delivery vehicles both protected miRNA against degradation by nucleases in serum.  
 
A major objective of the first approach was to evaluate miR-126 expression in both monolayer 
cultures and spheroids. miR-126 was highly expressed in spheroids generated using LM, especially in 
spheroids transfected inside LM. Spheroids are often more resistant to chemotherapeutic drug uptake 
than monolayer cells, due to a variety of reasons, including differences in: cell-cell communication, 
cell shape and/or the ability to repair damage [337]. More miRNA-Dy547 internalised into LM-
generated spheroids than into LS-generated spheroids. However, the internalised miRNA-Dy547 was 
localised at the only the periphery of the spheroid. The high transfection rate in LM-generated 
spheroids may be due to a more regular shape and greater viability than that of LS-generated 
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spheroids. However, following transfection in ultra-low attachment plates, miRNA-Dy547 was 
localised at the periphery as well as penetrating deeply into the core of the LM-generated and 
transfected spheroids. These results suggested that the high miR-126 expression found in LM-
generated and transfected spheroids was due to high miRNA uptake. The greatest miRNA uptake was 
observed in LM-transfected spheroids but not in ultra-low attachment plates, suggesting that LM as a 
transfection vessel also played a key role in transfection. PTFE, which makes up the LM, resists 
protein adhesion due to its ultra-low surface free energy and high hydrophobicity with a water contact 
angle of 108[343, 344]. The anti-adhesive LM shell inhibits non-specific absorption of miRNA to the 
shell and therefore reduces loss of miRNA by adsorption. The level of VEGF-A reduced in A549 
cells, regardless of whether cells were cultured in monolayers or in spheroids. These results agree 
with previous results by others that miR-126 transfection leads to down-regulation of VEGF-A in 
A549 [349]. Overall, this study demonstrated that LM could serve not only as a platform that 
produces tumour-like spheroids, but also as an efficient microbioreactor vessel that enhances miRNA 
transfection and outperforms conventional transfection vessels. 
 
Most cells found on the periphery of the spheroids generated by SAW microcentrifugation remained 
viable and formed a shell around an unstained, possibly necrotic core. Necrotic cores are common in 
spheroids, especially in older and larger spheroids, where the cells in the centre of the spheroid are 
deprived of oxygen and nutrients due to limitations in diffusion [11, 334].  The spheroids produced 
via liquid overlay (LO) and SAW microcentrifugation methods also exhibited heterogeneous cell 
subpopulations that contained viable cells at their periphery and possibly inviable cells in their core.  
The SAW device also had the advantage of being able to handle larger fluid volumes than the 
conventional hanging drop method [459]. The cell concentration process was rapid, requiring only a 
minute, compared with other conventional methods such as liquid overlay, which require at least a 
day. The resulting spheroid displayed the concentric heterogeneous cell population arrangement and 
the tight cell-to-cell interfaces characteristically observed in solid tumors in vivo. This demonstrated 
the usefulness of the platform for improving cancer biology and drug screening investigations. 
Design and Development of miRNA and stem cell based micro/nano systems as lung disease therapy            L Alhasan 
 
158 
 
Spheroids generated using both liquid marble and SAW microcentrifugation methods in Chapter 3 
and 4 could be used as an effective tumour model to study miRNA transfection. 
 
A study in Chapter 5 attempted to spray stem cells into a model of small lung damage. A 
preliminary study optimised the SAW nebulisation for the retention of cell viability post-
nebulisation. The proportion of viable cells decreased as power applied increased, probably 
due to the increase in stresses to which the cells were subjected, with increasing levels of 
acoustic radiation. This observation is consistent with a previous study on using SAW 
radiation to drive osteoblast perfusion into tissue scaffolds, in which cell viability decreased 
with increasing applied power [372]. RT-PCR analysis of both control and nebulised MSCs 
expressed CD29, CD44 and CD106 markers at both 24 and 72 hours. These suggested that the 
nebulised cells were phenotypically similar to the control cells. The nebulised MSCs 
continued to express similar levels of these markers to controls after 24 hours, suggesting that 
SAW nebulisation did not alter these genes’ expression in the MSCs. Similarly, tests of 
protein expression in whole cells showed that nebulised MSCs and controls had similar CD29, 
CD44 and CD106 positive cell counts after 24 hours. This suggests that nebulised cells 
functioned in the same manner as cells held in culture without exposure to SAW. Given the novelty of 
inhaled stem cell therapy, comparisons with other delivery methods is difficult, although more 
benchmarking data are anticipated in the future due to the increasing interest in stem cell therapy 
because of the absence of viable current alternative treatments for respiratory ailments. However, 
these results provide evidence that the SAW nebulisation platform, with its inherent benefits of low 
cost and portability, constitutes an attractive tool for the delivery of stem cells via inhalation for the 
treatment and repair of lung function, and can be a novel inhaled stem cell therapy for lung ailments.  
 
For lung tissues damaged by accident, the study in Chapter 6 attempted to create large lung tissue 
scaffolds as replacements. Embryonic stem cells (ESCs) survived in a 10% Gtn-DHHA hydrogel 
cross-linked with 2.27 unit/mL of laccase, as ESC viability was about 90% as measured by counting 
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Calcein AM stained cells. Cell DNA content did not change over a 7 day period in hydrogel. This 
suggests that the cell number in hydrogel scaffolds grew more slowly than in the control, possibly 
because the cells needed to secret proteinase to degrade the 3-dimensional (3D) 3D hydrogel before 
they could propagate, unlike growth on two-dimensional (2D) surfaces. These results suggested that 
the Gtn-DHHA encapsulated cells were viable and capable of proliferation, and that Gtn-DHHA 
hydrogel is suitable for tissue engineering applications. 
 
The formation of definitive endoderm was assessed by qPCR and immunostaining assays. Over 
periods of 7 and 14 days, the endoderm transcription factors Foxa2 and Sox17 exhibited higher 
expression in 3D culture cells in the hydrogel scaffolds than in the 2D monolayer cells, in particular in 
cells embedded in 3D hydrogel in an air-liquid interface compared with submerged and control cells. 
These results support prior investigations, which suggested that Sox17 and Foxa2 expression initially 
increased on Activin A treatment [451]. Qualitative and quantitative assays were performed to 
evaluate the differentiation of stem cells into lung epithelial cells. Relative to control and submerged 
cells, cells incubated in the air-liquid interface for 30 days showed evidence of differentiation, as 
judged by their greater Pept2, Sema4f, Unc5b and Ttf-1 gene expression. This was as expected, 
because the scaffold cells are grown in air-liquid interface (ALI) conditions similar to those of in-vivo 
airway epithelia [453, 454]. 
 
These results were confirmed by evaluation of the expression of lung epithelial markers. There was 
greater expression of Pept2 and Sema4f in cells in scaffolds at 30 days following their exposure in the 
air-liquid interface than in submerged and control cells. This study demonstrated that a 3D scaffold 
was advantageous over a 2D monolayer culture for generating lung epithelial cells, since 3D systems 
more closely mimicked the in-vivo microenvironment, especially in forming an air-liquid interface 
[440]. Gtn-DHHA hydrogel and air-liquid interface (ALI) culture thus provides a useful tool for the in 
vitro study of embryonic cells, by increasing their differentiation and the formation of cells 
resembling lung epithelial cells both structurally and functionally.  
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The experimental evidence suggests that both liquid marble and SAW microcentrifugation enhanced 
spheroid formation and miRNA transfection, and that cells grown in 3D scaffolds and delivered by 
SAW nebuliser could be used to cure lung ailments.  
7.2 General Conclusion 
 
The four parts of this thesis have improved the knowledge of: gene therapy, microfluidic device 
assisted stem cell delivery and stem-cell-based tissue engineering for lung diseases.  
 
The first part demonstrated the feasibility of a simple, effective and successful strategy called liquid 
marble (LM) to form lung spheroids compared with a conventional method. Liquid marbles made of 
liquid growth medium wrapped by non-adhesive powder particles were presented as efficient 
microbioreactors capable of supplying a convenient medium for cells to grow and aggregate. A549 
lung cancer spheroids were generated in a LM microbioreactor; the spheroids were subjected to miR-
126 transfection inside the LM. The miR-126 expression and the subsequent VEGF-A down-
regulation in LM-transfected spheroids reached a level that could not be achieved in various controls, 
including monolayer cells, spheroids generated using the LS method, and spheroids transfected in 
conventional ultra-low attachment plates.  Overall, this study demonstrated that LM could serve not 
only as a platform that produces tumour-like spheroids, but also as an efficient microbioreactor vessel 
that enhanced miRNA transfection and outperformed conventional transfection vessels. 
The second part of this thesis investigated the feasibility of using surface acoustic waves (SAW) to 
generate multicellular spheroids. The results showed that the surface acoustic device had advantages 
over other microfluidics for the formation of uniform multicellular spheroids by driving cells into a 
tight aggregate. The SAW device also enhanced the production of spheroids in microwells of standard 
tissue culture microplates. Multiple SAW devices could be used in parallel to produce multiple 
spheroids simultaneously. Spheroid size could be controlled by varying the input power of the SAW 
device. This represents a distinct improvement on current methods, since it circumvents the need for 
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the fabrication of multiple devices with various geometric designs. Spheroid generation required only 
one minute, compared with that of the liquid overlay method, which takes at least a day.  
 
The third part of the thesis was concerned with investigating the feasibility of generating MSC-laden 
aerosols via SAW without causing harmful effects on cells. An optimum power level of 1.5 W yielded 
a balance between maximising cell viability at an acceptable level (about 90%). The data 
demonstrated that the SAW nebuliser had no deleterious effects in rat mesenchymal stem cell 
viability, proliferation, or cell surface marker integrity and expression. 
 
The fourth part of this thesis was concerned with developing a novel injectable biodegradable 
hydrogel for lung tissue engineering. Gtn-DHHA displayed a high swelling ratio, biodegradability, 
high biocompatibility and mechanical integrity. Gtn-DHHA enhanced ESC survival and proliferation.  
A comprehensive study investigated the feasibility of lung differentiation in mouse ESCs within 3D 
scaffolds. Gene expression studies suggested the differentiation of the ESCs into cells characteristic of 
lung epithelia. This was demonstrated by the expression of endoderm-specific markers, followed by 
the expression of lung-specific transcription markers and the immunological detection of lung 
markers (Sema4f and Pept2) in cells. This suggests that Gtn-DHHA hydrogel is a suitable tissue-
engineered scaffold that could be used for lung tissue repair and presents a new pathway for 
regeneration of lung as well as possibly other tissue types. 
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7.3 Future Perspectives 
 
Due to the success of this miRNA-based gene therapy, stem-cell delivery and fabrication of Gtn-
DHHA scaffolds for lung regeneration and repair, other applications are now possible. 
 PEI and lipofectamine significantly influenced the delivery of miRNA 126 into spheroids of lung 
cancer cells in the liquid marble method. Microarray devices and cell trapping barriers should be 
developed to make more effective and uniformly sized cellular spheroids to test the delivery of 
miRNA 126 coupled with PEI and lipofectamine [118-120]. 
 
 The most significant properties of liquid marbles are the permeability of the porous shell, which 
allows the possibility of gas exchange between the medium and the surrounding environment, and 
the non-adhesiveness of the hydrophobic powder particles, which encourages cell suspension in 
the medium. A multicellular lung spheroid was successfully formed in Chapter 3. The unique 
properties of liquid marble to form spheroids are applicable to both embryoid bodies and 
multicellular tumour spheroid formation [151, 153]. As a result, liquid marble should be explored 
for lung differentiation from embryonic stem cells, as another important biological application.  
  
 The micro-centrifugation flow by the SAW microfluidic device rapidly enhanced the 
concentration of BT-474 cells into tight aggregates within a minute in Chapter 4. This is 
considerably faster than the conventional liquid overlay method. Therefore, the SAW device 
should be studied for its ability to generate embryoid bodies. This would be another vital area for 
future study. 
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 Liquid marble and SAW microcentrifugation should be used together to form uniform-sized, 
highly-reproducible, massive spheroids by encapsulating different kinds of cancer cells – this 
would compare well with droplet-based microfluidics [460]. 
 
 The concept of using 3D biodegradable scaffolds as alternatives to the extracellular matrix (ECM) 
more closely mimics cells’ native environment and is an interesting area of study in current tissue 
engineering. The fourth section of this thesis (Chapter 6) focused the feasibility of producing 
lung epithelial cells using novel 3D scaffolds. This scaffold was biodegradable and was prepared 
by conjugating gelatin with 3, 4-dihydroxyhydrocinnamic acid. The observation of lung epithelial 
cells inside the hydrogel implied that the murine stem cells survived and proliferated well. Gtn-
DHHA hydrogel allowed the formation of more lung epithelial cells at the ensuing air-liquid 
interface with medium conditions than did submerged and monolayered cultures. The 
biocompatibility, strength and mechanical properties of the Gtn-DHHA hydrogel are comparable 
to those of soft tissues and organs such as the thyroid, liver and breast [448]. Hence, Gtn-DHHA 
hydrogels should be tested as tissue scaffolds that mimic these soft tissues too. 
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                                                                   APPENDICES   
 
Appendix I: Software 
 
 
Software Manufacturer 
Flowing software Flowing Software, Turku Centre for Biotechnology, 
Finland 
ImageJ National Institutes of Health, Bethesda, MD 
GraphPad Prism version 6.01 GraphPad Prism Software Inc.La Jolla,CA, USA 
Microsoft Office 2011 Excel  Microsoft  Corporation, Redmond, Washington, USA 
NIS-Element imaging software Nikon Instruments Inc,, Japan 
Quantity One Analysis 4.3.0 software Bio-Rad Laboratories 
 
 
Appendix II: Chemicals and Reagents 
 
Chemical Manufacturer 
1-thioglycerol Sigma-Aldrich Pty Ltd, Australia 
2-mercaptoethanol  Life Technologies Pty Ltd, Australia 
2% gelatin Sigma-Aldrich Pty Ltd, Australia 
3,4-dihydroxyhydrocinnamic acid Sigma-Aldrich Pty Ltd, Australia 
4’,6-diamidino-2-phenylindole (DAPI) Life technologists Pty Ltd, Australia      
AlamarBlue dye  Life technologists Pty Ltd, Australia      
Ascorbic acid Sigma-Aldrich Pty Ltd, Australia 
Bovine serum albumin (BSA) Sigma-Aldrich Pty Ltd, Australia 
Carboxymethyl cellulose sodium salt Sigma-Aldrich  Pty Ltd, Australia 
Collagenase Type I   Life Technologies Pty Ltd, Australia 
Deuterium oxide (D2O) Sigma-Aldrich Pty Ltd, Australia 
Dialysis tubing (MWCO 124000) Sigma-Aldrich Pty Ltd, Australia 
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Dimethylsulfoxide (DMSO) Sigma-Aldrich Pty Ltd, Australia 
Dimethylformamide (DMF) Sigma-Aldrich Pty Ltd, Australia 
Ethanol  BDH Chemicals, Australia 
Eosin  ProSciTech Pty Ltd, Australia 
Ethidium bromide Roche Applied Sciences, Germany 
Ethylenediamine tetra acetic acid, EDTA BDH Chemicals, Australia 
Fluoro-Gel mounting medium ProSciTech Pty Ltd, Australia 
Fluorescently labelled miRNA (Dharmacon 
Miridian miRNA-Dy547) 
Millennium Science Pty Ltd, Australia 
Gelatin (MW = 80–140 kDa, pI = 5) Novachem Pty Ltd, Australia 
Haematoxylin ProSciTech Pty Ltd, Australia 
Heparin sulphate salt (Sigma H-4784) Sigma-Aldrich Pty. Ltd, Australia 
Horseradish peroxidase (HRP; 100 units/mg) Novachem Pty Ltd, Australia 
Hydrogen peroxide (H2O2) Merck Pty Ltd, Australia 
Isopropanol Ajax Chemicals Pty Ltd, Australia 
Laccase (10 U/mg) Sigma-Aldrich Pty Ltd, Australia 
Lambda DNA (ΛdNA) Life Technologies Pty Ltd, Australia  
Lambda RNA Life Technologies Pty Ltd, Australia  
Lipofectamine®RNAiMAX Transfection Reagent Life Technologies Pty Ltd, Australia  
NP40 Cell Lysis Buffer Life Technologies Pty Ltd, Australia  
N-(3-dimethylaminopropyl)-N-ethylcarbdiimide 
hydrochloride (EDC) 
Sigma-Aldrich Pty Ltd, Australia 
N-hydroxysuccinimide (NHS) Sigma-Aldrich Pty Ltd, Australia 
Orange G Dye  Cell Signalling Pty Ltd , Australia 
Phosphate Buffered Saline, PBS Sigma-Aldrich Pty Ltd, Australia 
Paraformaldehyde ProSciTech Pty Ltd , Australia 
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Protease Inhibitor Cocktails Sigma-Aldrich Pty Ltd, Australia 
Polyethylenimine (MW ~25,000) Sigma-Aldrich Pty Ltd, Australia 
Polytetrafluoroethlene (PTFE) Sigma-Aldrich Pty Ltd, Australia 
Sodium hydroxide (NaOH) BDH Chemicals Pty Ltd, Australia 
Triton-X100 Sigma-Aldrich Pty. Ltd, Australia 
Trypan Blue (Gibco®) Life Technologies Pty Ltd, Australia 
Tyramine hydrochloride (TYR) Sigma-Aldrich Pty. Ltd, Australia 
Tween 20 Sigma-Aldrich Pty. Ltd, Australia 
 
 
Appendix III: Cell lines 
 
 
Cell line Source 
Breast cancer cells (Bt474) School of Medical Sciences, RMIT University, 
Australia 
Lung cancer cells (A549) School of Medical Sciences, RMIT University, 
Australia  
Mouse embryonic stem cells (mESC)  Cell Bank Australia, Australia 
Rat mesenchymal stem cells (rMSC)  Life Technologies Pty Ltd, USA 
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Appendix IV: Tissue Culture Media and Reagents 
 
 
Medium Manufacturers 
Activin A Bio-Scientific Pty Ltd., Australia 
B27 (without retinoic acid) Bio-Scientific Pty Ltd., Australia 
Dulbecco's Modified Eagle's Medium, low Glucose, 
GlutaMAX™ and Pyruvate (Gibco®) 
Life Technologies Pty Ltd., Australia 
Dulbecco's Phosphate-Buffered Saline (DPBS) 
(Gibco®) 
Life Technologies Pty Ltd., Australia 
Fetal bovine serum, FBS Bovogen Serum Biologicals Pty Ltd., Australia 
Fetal bovine serum (Gibco®) Life Technologies Pty Ltd., Australia 
Fetal Bovine Serum-Embryonic Stem Cell-
Qualified (Gibco®) 
Life Technologies Pty Ltd., Australia 
Fibroblast growth factor (F0291) Sigma-Aldrich Pty Ltd., Australia 
Gentamicin reagent solution (Gibco®) Life Technologies Pty Ltd., Australia 
Ham’s F12 Medium (Gibco®) Life Technologies Pty Ltd., Australia 
Iscove’s Modified Dulbecco’s Medium (Gibco®) Life Technologies Pty Ltd., Australia 
L-glutamine (Gibco®) Life Technologies Pty Ltd., Australia 
Murine leukemia inhibitory factor Millipore, Chemicon, Australia 
Non-essential amino acids (Gibco®) Life Technologies (Gibco®) Pty Ltd., Australia 
Opti-MEM® I Reduced Serum Medium (Gibco®) Life Technologies (Gibco®) Pty Ltd., Australia 
Penicillin-Streptomycin (Gibco®) Life Technologies (Gibco®) Pty Ltd., Australia 
RPMI 1640 medium (Gibco®) Life Technologies (Gibco®) Pty Ltd., Australia 
TrypLE™ express solution (Gibco®) Life Technologies (Gibco®) Pty Ltd., Australia 
Trypsin (0.05x) (Gibco®) Life Technologies (Gibco®) Pty Ltd., Australia 
Trypsin (10x) (Gibco®) Life Technologies (Gibco®) Pty Ltd., Australia 
Wtn3a Bio-Scientific Pty Ltd., Australia 
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Appendix V: Commercial Kits 
 
 
Commercial Kit Manufacturer 
Cytoskeleton/Focal Adhesion Staining Kit Merck Pty Ltd., Australia 
LIVE/DEAD@ Cell Viability Life Technologies Pty Ltd., Australia 
QuantiTect Reverse Transcription Kit (50 reactions) Qiagen Pty Ltd., Australia 
QuantiTect SYBR Green RT-PCR Kit Qiagen Pty Ltd., Australia 
Quant-iT™ PicoGreen® dsDNA Assay Kit Life Technologies Pty Ltd., Australia 
RNA Mini Kit Qiagen Pty Ltd., Australia 
miRNeasy Mini Kit Qiagen Pty Ltd., Australia 
TaqMan® Gene Expression Master Mix Life Technologies Pty Ltd., Australia 
TaqMan® MicroRNA Reverse Transcription Kit Life Technologies Pty Ltd., Australia 
TaqMan® Universal Master Mix II, no UNG Life Technologies Pty Ltd., Australia 
Turbo DNA-free TM (Ambion) Life Technologies Pty Ltd., Australia 
 
 
Appendix VI: Antibodies 
 
Antibody Manufacturer 
Alexa Fluor® 488 donkey anti-goat IgG (H+L) 
antibody 
Life Technologies Pty Ltd., Australia 
Anti-CD44 antibody conjugate Merck Millipore Pty Ltd., Australia 
Anti-CD106 antibody conjugate Biolegend, USA 
E-Cadherin  Santa Cruz Biotechnology, USA 
FOX2a Santa Cruz Biotechnology, USA 
Integrate beta anti-CD29 antibody conjugate Life Technologies Pty Ltd., Australia 
Goat anti-mouse secondary antibody Millipore Merck Pty Ltd., Australia 
Goat anti-rabbit secondary antibody Sapphire Pty Ltd., Australia 
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Pep2 primary antibody Santa Cruz Biotechnology, USA 
Sema4f primary antibody Santa Cruz Biotechnology, USA 
Vinculin antibody  Merck Millipore Pty Ltd., Australia 
VEGF Antibody  Santa Cruz Biotechnology, USA 
 
Appendix VII: TaqMan assays 
 
 
Gene Host Assay ID Manufacturer 
Foxa2 Mouse Mm01976556_s1 Applied Biosystems 
GAPDH Human Hs02758991_g1 Applied Biosystems 
GAPDH Mouse Mm99999915_g1 Applied Biosystems 
hsa-miR-126 Human 000451 Applied Biosystems 
RNU44 Human 001094 Applied Biosystems 
Pou5f1 (Oct4) Mouse Mm00504054_m1 Applied Biosystems 
Sema4f Mouse Mm01181883_m1 Applied Biosystems 
Sox17 Mouse Mu00488363_m1 Applied Biosystems 
VEGF-A Human Hs00900055_m1 Applied Biosystems 
Ttf1 Mouse Mm00657018_m1 Applied Biosystems 
Unc5b Mouse Mm00504054_m1 Applied Biosystems 
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Appendix VIII: Equipment and Associated Consumables 
 
Equipment and associated consumables Manufacturer 
Balance (0.1-500 g) U-Lab, Australia 
Centrifuges:   
(i) Microcentrifuge     Zentrifugen, Germany 
(ii) Bench top centrifuge Eppendorf, Australia 
(iii) High-Speed centrifuge Thermofisher, Australia 
(iv) Ultra-Speed centrifuge Beckman, USA 
Biological Safety Cabinet Class II cabinet LAF Technologies, Australia 
Countess® Automated Cell Counter  Invitrogen, USA 
Countess® Automated Cell slides Life Technologies Pty Ltd, Australia 
Confocal Laser Scanning Microscope Nikon Instruments Inc, Japan 
Electrophoresis Mini-gel Bio-Rad Laboratories, USA 
Electrophoresis Power Supply PAC300 Bio-Rad Laboratories, USA 
Gel-Doc System Bio-Rad Laboratories, USA 
HR3 Discovery-Hybrid stress controlled rheometer Cornell Centre for Materials Research, Ithaca, NY, 
USA 
CO2 incubator  SANYO Electric Co. Ltd, Japan 
Light microscope Olympus Optical 
Microcentrifuge Eppendorf, Germany 
NanoDrop Lite Microlitre Spectrophotometer Thermo Fisher Scientific, Australia 
Nuclear magnetic resonance spectroscope ACF300, Bruker Pty Ltd, Alexandria, NSW, 
Australia 
Phase contrast microscope Nikon Kogaku KK, Japan 
pH meter Radiometer, Denmark 
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POLARstar Omega Microplate Reader BMG LABTECH, Australia 
Real-time PCR Rotor-Gene, Qiagen Pty Ltd, Australia 
Disposable folded capillary cells ATC Scientific Pty Ltd, Australia 
Filter (0.2µm)  Millipore, Australia 
Centrifuge tubes: Sarstedt, Germany 
(i) 1.5 mL microcentrifuge tubes Greiner Bio-One, Germany 
(ii) 2 ml microcentrifuge tubes VWR International Pty Ltd, Australia 
(iii) 10 mL centrifuge tubes Greiner Bio-One, Germany 
(iv) 50 mL centrifuge tubes Greiner Bio-One, Germany 
Micropipette plastic tips (blue and yellow) Greiner Bio-One, Germany 
Microtitre Plates:  
(i) Microtitre Plate (96-well, flat bottom) Greiner Bio-One, Germany 
(ii) Microtitre Plate (24-well) Greiner Bio-One, Germany 
(iii) Microtitre Plate (12-well) Greiner Bio-One, Germany 
(iv) Microtitre Plate (6-well) Greiner Bio-One, Germany 
Petri dishes:  
Petri dishes (100 cm
3
)  VWR International Pty Ltd, Australia 
Petri dishes (35 cm
3
) Thermo Fisher Scientific Pty Ltd, Australia 
Strip tubes with caps Qiagen Pty Ltd, Australia 
Syringes (5 mL, 10 mL, 20 mL, 50 mL) Thermo Fisher Scientific Pty Ltd, Australia 
Tissue culture flask (25 cm
3
 and 75 cm
3
) VWR International Pty Ltd, Australia 
 
 
 
 
 
 
 
 
 
 
 
 
Design and Development of miRNA and stem cell based micro/nano systems as lung disease therapy            L Alhasan 
 
 
193 
 
Appendix IX: Agarose gel electrophoresis assay figure 
 
 
 
 
 
 Figure shows Agarose gel electrophoresis assay of PEI/miR-126 Nano-complexes: M. RNA ladder,  
lane 1, miRNA alone, lanes 2 to 6 miRNA complexes N/P ratio 4 , 13 , 19 , 25 and 33. 
